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1CHAPTER 1. GENERAL INTRODUCTION 
STATEMENT OF PROBLEM 
Swine influenza is responsible for significant respiratory disease in the North 
American pig population. Swine influenza is caused by a RNA virus that belongs to the 
influenza A virus genus in the family Orthomyxoviridae. It consists of a segmented genome 
which allows mutation through accumulation of point mutations (antigenic drift) and genetic 
reassortment between different viruses that co-infect the same cell (antigenic shift) [1]. The 
first swine influenza virus (SIV) was isolated in 1930 and was known as the classical swine 
H1N1 (cH1N1) [2,3]. The cH1N1 was the principal etiology of swine influenza in the U.S. 
for almost 70 years [4]. In 1998, a H3N2 subtype virus emerged in to the U.S. swine 
population. The H3N2 virus rapidly evolved from a virus that was initially a double 
reassortant virus consisting of genes of human and swine lineages to a triple reassortant virus 
that contained human, swine and avian gene lineages [5]. Once established the H3N2 viruses 
have undergone further reassortment with the cH1N1 viruses resulting in a new H1N2 
subtype virus [6]. The appearance of the H3N2 viruses into the North American swine 
population initiated a shift of virus that significantly changed the epidemiology of SIV.  At 
present, all three subtypes, H1N1, H3N2 and H1N2 are well established in the U.S. swine 
population and evidence show that the multiple lineages with increased diversity of both 
genetic and antigenic make-up continue to evolve making control of swine influenza virus 
increasingly difficult [6-9].   
Swine influenza infected pigs exhibit clinical disease consisting of high fever, cough, 
labored breathing, anorexia, inactivity and an obvious sign of weight loss [10]. Although 
recovery from SIV infection is generally within 5-7 days, the resulting reduction in weight 
gain often causes a negative economic impact due to stunned growth and increased numbers 
of days to reach market weight [10]. A reduction in the number of pigs born alive and 
abortion in late pregnancy has been reported following outbreaks of swine influenza in naïve 
sow herds [11-13].  Swine influenza is an important viral component to the porcine 
respiratory disease complex (PRDC) when combined with porcine reproductive and 
respiratory syndrome virus (PRRSV), porcine circovirus type 2, and/or Mycoplasma 
hyopneumoniae. PRDC typically occurs in pigs at 14 to 20 week of age and causes a 
2significant source of economic loss to swine producers worldwide [14]. In the U.S. alone 
annual loss due to PRDC was estimated to exceed $210 million in the year 2002 [15] 
Vaccination is the most common strategy used to control SIV-induced disease [1]. 
Sow herd immunization is a common practice. Vaccinating the sow herd against swine 
influenza can induce and maintain sufficient immunity in sows and produce passive 
immunity that is transferred to young pigs during nursing [16-19]. Another approach to SIV 
control is piglet immunization in the nursery or finisher to provide protection through the 
finishing period. This strategy helps control SIV-induced disease in growing pigs and will 
contribute to reducing its impact in PRDC.  
Current commercial SIV vaccines consist of inactivated viruses combined with 
adjuvant preparations. The efficacy of these vaccines is primarily through antibody 
production induced by the vaccine strains whose antigenic make-up is representative of the 
circulating field strains [20].  Most SIV vaccines are labeled for use in pigs at 3 weeks of age 
or older and usually require two intra-muscular administrations. Many factors can affect the 
SIV vaccine efficacy when administered to young pigs such as strain variation. Two common 
factors in reduced vaccine efficacy are the presence of other infection such as PRRSV and 
the interference by SIV-specific maternally derived antibodies (MDA). The estimate of 
PRRSV prevalence at a herd level has been described as 60-80% in swine-dense areas [21]. 
Although there are differences in the infection rate within PRRSV infected herds, evidence of 
seroconversion in some littermates has been detected in pigs as early as 6 to 8 weeks of age 
[22]. As a result, there is an increased potential for PRRSV to be circulating in the young 
pigss at the time of SIV vaccination. Studies have reported the negative impact of PRRSV 
infection on the development of an immune response to vaccination against other pathogens 
[23-26] . However, the timing of PRRSV infection was shown to influence the outcome of 
subsequent vaccinations [26,27]. To date, no studies have been conducted to investigate the 
impact PRRSV may have on SIV vaccine efficacy.  
The presence of SIV-specific MDA at the time of SIV vaccination is an important 
factor to consider when administrating SIV vaccines. It has been demonstrated that SIV-
vaccinated sows provide a higher level of passive immunity to young pigs compared to 
nonvaccinated sows [17,28]. The persistence of SIV-specific MDA in young pigs varies 
3according to the initial level of antibodies transferred from the sow. However, studies have 
detected MDA lasting in pigs up to 10- to 12-weeks of age [28,29]. Previous studies have 
found that presence of MDA also suppress the piglet’s antibody response to swine influenza 
infection as measured by the hemagglutinin-inhibition (HI) test [19,30-33]. These findings 
were based on pigs that were experimentally challenged with viruses that were homologous 
to the strains that produced MDA. With the current situation in North American pig 
population where the circulating strains of SIV appear to be continuously evolving, it is 
essential to evaluate the impact of SIV-specific MDA on SIV vaccination with young pigs 
that are infected with virus that is heterologous to the vaccine. At this time, no such studies 
have been conducted.  
In addition to the factors just discussed that may interfere with SIV vaccination in 
young pigs, the nature of influenza viruses also poses a major drawback to vaccination with 
inactivated SIV vaccines. In general, administering inactivated SIV vaccines in seronegative 
pigs is effective in providing protection against homologous infection [34-38]. However 
since the level of protection after vaccination is highly dependent on how closely matched 
the vaccine virus is to the circulating viruses, vaccine failure can also occur through the 
process of viral antigenic drift. Accordingly, human influenza vaccines are annually updated 
in the attempt to ensure the closest possible match between the vaccine strains and the field 
strains. In the swine industry this strategy is difficult to implement due to the lack of active 
surveillance, funding and a laboratory network. Therefore, new novel vaccine strategies to 
improve and broaden the degree of protection against SIV infection with antigenically distant 
isolates are urgently needed. Such strategies are important not only for the control of SIV in 
the swine population but to reduce the risk of potential infection in humans as swine 
influenza is a zoonotic disease as well. 
GENERAL OBJECTIVES AND RESEARCH PLAN 
 The objectives in the studies described here were to first investigate factors that 
impact vaccination strategies using currently available inactivated SIV vaccines. We 
focused on two major factors most likely to interfere with successful SIV vaccination in 
nursery herds. The presence of PRRSV infection at the time of vaccination was the first 
factor studied. The specific aim of this study was to assess the influence of PRRSV infection 
4on inactivated SIV vaccine efficacy using a highly virulent strain of North American 
PRRSV. The PRRSV infection was placed between SIV vaccines based on earlier studies 
with Mycoplasma hyopneumoniae vaccines [26]. The impact of PRRSV infection on SIV 
vaccine efficacy was based on respiratory disease, macroscopic and microscopic lung 
lesions, virus isolation and immunological parameters. The presence of SIV-specific MDA 
at the time of SIV vaccination was the second factor studied. MDAs have been detected in 
young pigs up to 12 weeks of age born from SIV vaccinated sow herds [17,28,29]. Previous 
studies have shown that the presence of MDA suppressed seroconversion to SIV infection as 
measured by the HI test assay [19,33]. In addition, it had been reported that in order for pigs 
to seroconvert to the H1N1 and H3N2 vaccine antigens, respectively, MDA titers of 1:10 or 
less than 1: 80 when receiving the first SIV vaccination were required [39]. The study 
described herein had a specific aim to simulate field conditions where sows and young pigs 
are exposed to multiple SIV strains and vaccines that may differ genetically. An experimental 
challenge study was conducted to determine the effect MDA had on vaccine efficacy in 
young pigs experimentally infected with a heterologous SIV and protection parameters were 
evaluated.  
In addition to addressing the factors that could compromise a successful SIV 
vaccination, our second objective was to investigate a potential strategy to improve currently 
available inactivated SIV vaccines. We proposed to use the matrix 2 (M2) protein, a 
conserved influenza A protein, in combination with a commercial bivalent SIV vaccine to 
induce a broader immune response against different strains of an H1 subtype virus. Our first 
specific aim was to produce a recombinant full-length M2 protein (rM2) in a baculovirus 
expression system for use in immunizing pigs and also to produce a truncated N-terminal 
extracellular region of the M2 protein (M2e) for the development of an indirect ELISA to 
characterize the M2 antibody response in SIV-infected and/or SIV vaccinated pigs and pigs 
with SIV-specific MDA.  The protective efficacy to heterosubtypic influenza A viruses by 
actively induced M2 specific immunity has been demonstrated in mice [40] and other 
laboratory animals that are not natural hosts of influenza viruses [41]. However, one earlier 
study in pigs demonstrated negative findings when pigs vaccinated with M2 were challenged 
in the presence of only the M2 and nucleoprotein specific antibodies [42]. These findings 
5demonstrate that findings in one species may not apply to another and also demonstrate the 
importance of immunity to the two major envelope glycoproteins; the HA and NA. 
Accordingly, our second specific aim was to evaluate the protective efficacy of the SIV 
vaccine when pigs received rM2 protein with the inactivated SIV vaccine.                 
The overall goal of the investigations reported here were to provide updated 
information on successful SIV vaccination using commercially available vaccines and 
implementing new effective vaccine strategies to aid swine practitioners and veterinarians in 
controlling respiratory disease caused by SIV.  
DISSERTATION ORGANIZATION 
 This dissertation is written in the alternative format and is organized into six chapters. 
The first chapter contains a statement of the problem, general objectives and research plan, 
dissertation organization and literature review. Chapters two through five present the author’s 
research in manuscript format prepared for publication. General conclusions and implications 
of this work are provided in the sixth chapter. The citations from the introduction, literature 
review, and general conclusions sections are compiled in the reference list at the end of the 
dissertation. 
LITERATURE REVIEW 
Swine influenza virus (SIV)
Swine influenza virus (SIV) is an Influenza A virus and a member of the family 
Orthomyxoviridae. The genome contains 8 RNA segmented genes that encode 10 viral 
proteins. The virion consists of a membrane envelope and an inner core of ribonucleoprotein 
(RNP) complexes. There are two major envelope glycoproteins, hemagglutinin (HA) and 
neuraminidase (NA), and one minor membrane protein, matrix 2 (M2) [1]. The HA protein is 
a rod-shaped spike homotrimer (Mr~76,000). The HA molecule is produced in a precursor 
form known as HA0 that is postranslationally-cleaved into two subunits, HA1 and HA2. The 
location and specificity of this cleavage site is a viral virulence factor as it is required for the 
fusion process of the virus infection step [43]. The NA protein is a mushroom-shaped 
homotetramer (Mr ~220,000). The NA stalk holds the enzyme active site above the virion 
envelope and the length of the stalk has been  shown to be another virulence factor of the 
virus [44]. The ratio of HA to NA on an average virion varies but usually is 4-5 to 1 [1]. The 
6third viral membrane protein M2, is encoded by spliced mRNA derived from the RNA 
segment 7 [45]. The native form of the M2 protein is a homotetramer of 97 amino acids 
consisting of a subunit made up of 24 N-terminal extracellular residues, a 19-residue 
transmembrane domain and a 54-residue cytoplasmic tail [46]. The M2 protein is abundantly 
expressed on the membrane of influenza virus infected cells but has a low incorporation rate 
in the virion as only 20-60 molecules are detected [47,48].  
The primary responsibility of the HA and NA proteins is for entering and exiting the 
host cell after virus replication, respectively. The HA initiates attachment of the virion to the 
cell by binding to a sialic acid-containing receptor on the surface after which the virus enters 
into the cell through fusion to the endosomal membrane. The NA proteins allow new viral 
progeny to exit the cells by removing the sialic acid from the HA, thus facilitating viral 
transport through mucin layers on the respiratory tracts to find the target epithelial cells [1]. It 
is essential for the virus to have functionally cooperative HA and NA proteins for successful 
infection and incompatibility between HA and NA can limit the virulence of reassortant 
viruses [44]. For example, a virus with an HA that binds tightly to the cell receptor requires 
an active NA to be released from infected cells following replication. On the other hand, a 
virus with a HA that weakly binds the receptor would require relatively low NA activity. It 
has been demonstrated that when both the HA and NA genes of a human H3N2 virus were 
replaced with swine HA and NA genes the ability of the virus to infect and cause disease in 
pigs was significantly enhanced [49].  
The M2 protein has an important role in the virus uncoating process following the 
attachment of virus to the receptor. Hydrogen ions flow through the M2 channel lowering the  
pH which induces the dissociation of the matrix 1 (M1) protein from the virus nucleoproteins 
(vRNP) allowing the entry of vRNPs into the cell nucleus [50]. The M2 protein is susceptible 
to amantadine and rimantadine antiviral drugs. Studies both in vitro and in vivo have 
indicated that drug resistant mutants occur from a single amino acid change within the 
transmembrane domain of the M2 protein [50].  
The vRNP core consists of eight different segmented RNA genomes of negative 
polarity, each complexed with four virally encoded proteins: the nucleoprotein (NP) and 
three polymerase proteins (PB1, PB2 and PA) that mediate viral RNA synthesis. The viral 
7matrix 1 protein (M1) is a structural protein that interacts with both NP and the cytoplasmic 
tails of the HA and NA proteins to provide a structural framework for the virion. There are 
two nonstructural proteins: NS1 and NS2 (previously named nuclear export protein; NEP) 
which together with NP and M1 regulates RNA splicing and nuclear transport of RNA [1].   
Influenza A viruses are further subdivided by the antigenic characterization of the HA 
and NA surface glycoproteins. A total of 16 HA and 9 NA subtypes have been identified, 
with minimal serological cross-reaction between the subtypes [51-53]. The HAs are placed 
into one of the 16 antigenic subtypes based on their ability to react with the subtype-specific 
anti-HA hyperimmune sera [52]. Amino acid sequence comparisons indicate that homology 
within subtypes is approximately 90% or more, with homology of 40-80% between the 
influenza subtypes [54]. New isolates are designated by their serotype/host species/site of 
origin/strain designation/year of origin and (HA [H] and NA [N] subtype) e.g. 
A/swine/Colorado/23619/99 (H3N2) [55]. The virus undergoes two major forms of 
evolution, antigenic shift and antigenic drift, which are the primary causes for influenza 
epidemics and pandemics. Antigenic shift occurs through genetic reassortment of the 
multiple HA and NA subtypes and the eight individual segments of the viral genome. When 
two different subtypes of influenza co-infect the same cell, the RNA segments can be 
interchanged to produce a variety of viral progeny, thereby introducing new subtypes to the 
population. This type of mutation in the past has been the cause of numerous influenza 
outbreaks due to the spread of the newly emerged virus in immunologically naïve 
populations [56]. Antigenic drift refers to an accumulation of point mutations that occur 
during replication due to the lack of proof reading activity by the RNA polymerase complex 
[1]. These mutations occur primarily in the HA and NA proteins resulting in amino acid 
substitutions at antigenic sites. A region closely related to, but not directly in the receptor 
binding site on the HA1 domain of the HA protein [57,58], and the region on the surface loop 
structure surrounding the catalytic sites of the enzyme on the NA globular heads [59] are the 
most common site of antigenic variation. Antigenic drift does not result in the introduction of 
new subtype viruses into the population. However, the substitution of new amino acids on the 
viral membrane can prevent the binding of antibodies induced by previous infections, thus 
enabling the virus to evade the host immune response. The ongoing mutation of the virus 
8provides the rationale for yearly re-evaluation of the human influenza vaccines that 
frequently require replacement of vaccine viruses with more contemporary strains. This 
phenomenon has also been shown to occur with swine influenza viruses [60,61].  
 In contrast to the mutation rate of the HA and NA proteins the M2 protein is highly 
conserved among influenza A viruses. The first nine amino acids on the N-terminal region of 
the M2 protein are conserved between viruses and are shared with the virus structural 
protein, M1 [45].  Previous phylogenetic analysis in 1991 revealed a slow rate of 
evolutionary changes in the M2 sequences compared to the HA gene [62]. Genomic analysis 
of the swine M2 gene showed a mutation rate of only 0.51% [63]. A recent study in 2005 
analyzed the variability of 24 amino acids in the M2 extracellular region (M2e) of 716 
influenza A viruses grouped according to host restriction (human, avian, swine, equine and 
other hosts) and found that 17 of the 24 amino acids were conserved at a rate of over 94% 
[64]. Five amino acids within the region of amino acids 10 to 20 of the M2e protein were 
shown to be host restricted, with the proteins of human influenza viruses being closely 
related to swine viruses. The low degree of variation in the M2 protein as compared to the 
HA and NA protein is clearly attributed to the genetic relation with M1 which is the most 
conserved protein of the virus.    
Epidemiology of SIV in North American swine population
Swine influenza virus (SIV) was first described in the north-central region of the 
United States in late summer of 1918, the same year the most devastating influenza pandemic 
in humans killed over 20 million people around the world [10,65]. It was recognized that 
both the clinical symptoms and pathological findings of influenza disease in humans and in 
swine were similar. However, the pathogenic agent was not identified until almost 20 years 
later when Richard Shope successfully isolated the virus from pigs in 1930 [3]. The virus, 
A/Swine/Iowa/15/1930 (H1N1) was named the ‘classical swine H1N1’ (cH1N1) as the 
genetic makeup consisted of a wholly swine lineage [60]. At present, endemic swine 
influenza viruses occur in three well established subtype combinations: H1N1, H3N2 and 
H1N2 [4,5,60,66]. Until 1998, influenza in swine in North America was primarily caused by 
infection with the cH1N1 virus. In 1997, a H3N2 virus was isolated from a 1-week old piglet 
in Ontario that died of pneumonia [67]. The virus was confined to the one piglet and was 
9identified as a wholly human virus with no genetic reassortment. In the following year, 
another H3N2 virus was isolated from pigs in North Carolina and at the end of the same year 
outbreaks of H3N2 viruses were reported in Minnesota, Iowa and Texas [5]. This time the 
virus was widely spread; affected pigs had high fever with abortion and death occurring in 
sow herds in addition to the typical respiratory disease of finishing pigs [68]. It was identified 
later that the North Carolina isolate was a double reassortant virus that contained gene 
segments from human and swine lineage.  In contrast, the viruses from the midwestern 
outbreaks were triple reassortants consisting of human, swine and avian genes [68]. These 
H3N2 viruses with surface proteins made up from human genes continued to spread through 
the pig population. A study in 2003, classified the triple reassorted H3N2 viruses into 3 
clusters based on their genetic and antigenic properties [8]. Cluster 1 and 3 viruses were 
shown to share common epitopes and cross-react serologically to each other. The cluster 3 
viruses have become widely spread over time while cluster 2 viruses appeared to fade from 
the U.S. swine population. No H3N2 viruses were reported from Canada since the first H3N2 
was isolated in Ontario, despite the close geographical proximity to the U.S. boarder line. 
However, in the beginning of 2005 a triple reassorted H3N2 virus spread across Canada and 
was isolated from swine, turkey and from a farmer in Ontario [9]. A nucleotide phylogram 
was conducted against various H3N2 viruses including the 3 clusters found in the U.S. and 
the Canadian viruses have been proposed to represent a new cluster 4 group. 
A H1N2 virus was isolated in November 1999 from pigs in Indiana with respiratory 
disease consistent with influenza in addition to inducing abortions in sows [13]. Genetic 
analysis found that this virus was derived from the recent triple reassorted H3N2 that had 
incorporated the HA gene from the cH1N1 virus. Similar to the H3N2 viruses, the H1N2 
virus spread across the U.S. pig population but no further reassortment has been identified as 
isolates collected in 2000 and 2001 were genetically similar to the initial isolate isolated in 
1999 [6,69]. A more recent report however, identified a H1N2 virus in swine that contained 
the H1 gene from a human virus [70,71] while in Canada, a H1N2 virus consisting of human 
HA, NA and PB1 genes has also been reported. In addition, a H1N2 virus from wholly 
human genes was isolated indicating the crossover of human influenza viruses into the swine 
population [72].  
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The introduction of the H3N2 virus in the U.S. swine population in the late 1990’s 
not only shifted swine influenza viruses and allowed the establishment of the H1N2 subtype, 
but also created numerous reassorted H1N1 (rH1N1) viruses from the triple reassorted H3N2 
with HA and NA genes from cH1N1 [71,73]. A rH1N1 viruses containing both HA and NA 
genes from human viruses was isolated from pigs in the U.S. in 2005 and appears to have 
replaced the cH1N1. In addition, rH1N1 viruses with all genes from cH1N1 except the PB1 
gene, which is from a human virus have been detected in Ontario Canada in 2005 [72].  
Other subtypes besides H1N1, H3N2 and H1N2 have sporadically been detected in 
the North American swine population. Since the epithelial lining of the respiratory tracts of 
pigs contain both the Q2,3 and Q2,6 sialic receptors [74,75] pigs potentially can be infected 
with both human and avian influenza viruses. A wholly avian H4N6 virus was detected on a 
farm in Ontario in 1999 [76], an example of direct transmission of the virus from avian to 
swine species. This virus was able to spread to other pigs on the same farm but remained 
confined to the farm. In 2001, a wholly avian H3N3 was isolated from the same farm in 
Ontario. More than one pig was infected and it was determined that the viral source was raw 
lake water that had been pumped to the barn from a nearby lake. Two different H3N1 isolates 
with different genetic makeup have also been detected in U.S. swine herds. An outbreak in 
Minnesota in 2004 detected a H3N1 virus with HA gene closely related to the cluster 3 of 
swine H3N2 virus, the NA gene closely related to the cH1N1, the NP, M and NS1 genes of 
swine origin, the PA and PB1 genes of avian origin and the PB2 gene was of human origin. 
The other report of a H3N1 virus consisted of 2 different isolates, one from a pig in southern 
Michigan and another from central Indiana. The HA gene of these viruses was shown to be 
closely related to an H3N2 virus from turkeys, while the NA was related to a human H1N1 
and the remaining genes were swine in origin [77]. Finding these viruses underline the 
potential of direct avian-to-pig transmission of influenza viruses. Although these viruses have 
not become widely spread across the pig population, evidence of pig-to-pig transmission 
within the farm indicates some degree of viral adaptation and is of public health concern. It is 
therefore important for the swine industry including swine veterinarians and diagnostic 
laboratories to be aware of such variant subtypes that may result in potential epidemics in 
either the swine or human populations.   
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Before the appearance of the H3N2 virus in the North American swine population, 
available data showed that swine influenzas did not evolve as quickly as human viruses. 
Earlier studies reported that swine influenzas were antigenically conserved [78]. Mutation 
rates of the HA protein from H1 swine viruses were reported at 0.4 and 0.48% amino acid 
changes per HA1 domain per year from the periods of 1976-1982 and 1982-1988, 
respectively [79]. These rates were much lower when compared to the 1.2% HA variation in 
human H1 subtypes analyzed between 1950 and 1957 [80] and 0.16% - 3.48% of human 
H1N1 strains isolated between 1977 and 1988 [81]. It was hypothesized that influenza 
viruses in swine encountered less immune pressure as the life span of pigs is shorter than 
humans and that the influenza viruses in pigs is maintained by consistent transmission to 
available naïve young pigs [79]. This is in contrast to the human population where the 
probability of  encountering multiple influenza viruses in a person’s lifetime is greatly 
increased in addition to routinely receiving vaccination consisting of different viral isolates. 
However, recently the epidemiology of influenza viruses in pigs has changed as evidenced by 
the antigenic drift detected among the new H3N2 strains (isolated in 2001 and 2002) with 
low serologic cross-reactivity with the index H3N2 strain isolated in 1998 [66]. The same 
study demonstrated low levels of serological cross-reactivity between the newer H1 isolates 
and serum produced from the Iowa 1930 cH1N1 virus and varying degrees of cross-reactivity 
with sera collected from pigs infected with H1N1 viruses in 2002. In support, another study 
evaluated serological cross-reactivity between two H1N2 strains (isolated in 1999 and 2001), 
one rH1N1 (isolated in 1999) and cH1N1 and found low cross-reactivity between the H1N2 
strain isolated in 1999 and the rH1N1 to the cH1N1 [82]. In addition, only a one-way cross-
reactivity was detected between the H1N2 isolates. Another recent study compared 10 
different H1 isolates from 1930 to 2004 designated into 3 groups by genetic analysis of the 
HA1 gene; cH1N1, rH1N1-like and H1N2-like viruses [83]. Newer reassorted H1 viruses 
caused increased pneumonia and pigs shed higher levels of virus compared to the cH1N1. 
Serological cross-reactivity by HI test was lost over time as newer H1 isolates cross-react at 
only a low level with cH1N1. In addition, serological cross-reactivity was inconsistent even 
within viruses from the same phylogenetic groups. Taken together these studies emphasize 
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the fact that influenza viruses in the North American swine population consist of a complex 
of genetically diverse viruses that continues to evolve through antigenic drift.   
The ongoing evolution of influenza viruses in pigs and the diversity of viruses co-
circulating in the field bring the ecology of North American swine influenza viruses closer to 
the European swine population where the 3 subtypes co-evolved more than 20 years ago. The 
H1N1 virus lineage in Europe was derived from an avian-like virus that is antigenically and 
genetically distinct from the classical-swine lineage [84]. The European H3N2 subtype was 
first detected in 1970 in both Europe and Asia [85] and the H1N2 virus, consistent with a 
virus isolated from pigs in Japan [86] and France, [87] has been isolated since 1980s and 
early 1990s respectively. Sequence analysis of HA genes has shown that antigenic drift does 
occur in both European H1N1 and H3N2 swine viruses [88,89]. A study of the European 
swine H1N1 virus [90] demonstrated a marked antigenic difference from the commercial 
vaccine that contains a 1980 H1N1 vaccine isolate. The results of this study indicate that the 
titers against the vaccine strain were six-fold higher than titers against the more recent 1996 
influenza viruses. Although no significant antigenic drift was observed, the changes in the 
antigenic sites of the swine H1N1 were detected in close proximity to variable regions of the 
HA1 domain that are associated with antigenic drift of human H1N1 viruses [80]. A similar 
study with swine H3N2 viruses [88] detected a pronounced antigenic drift in the virus 
leading to the recommendation of replacement of the vaccine virus with a more recent swine 
H3N2 isolate. Other experimental investigations however, have shown clinical cross-
protection provided by vaccination and reduced, but incomplete inhibition of viral shedding 
following homologous [35,91] and a heterologous swine influenza virus challenges [92]. At 
the moment, although there is no vaccine evaluation studies that directly indicate a need to 
update the North American influenza vaccines for swine, serological cross-reactivity studies 
indicate that such requirements are possible in the near future.  It is essential to continue the 
genetic analysis of influenza viruses isolated from swine along with serological surveillance 
to counteract the evolution of the virus from different host species into the swine population 
and also to assist in swine influenza vaccine evaluation.  
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History of swine influenza vaccination in the U.S. 
Respiratory disease caused by swine influenza has been endemic in the U.S. swine 
population since it was first recognized in 1918 [1].  Disease caused by swine influenza has a 
high morbidity, usually near 100%, but the mortality is usually less than 1% unless 
complicated by other pathogens [1]. The primary cost economically is due to reduced weight 
gain resulting in an increased time to market. Prior to 1976, swine veterinarians in the U.S. 
did not recognize swine influenza infection as a major problem as losses were not as 
dramatic as observed with other important diseases of the time such as hog cholera [93]. As a 
result, there was little interest in producing or using swine influenza vaccines in the swine 
industry.   
In January of 1976, a severe respiratory outbreak in soldiers at Fort Dix, New Jersey 
including 1 death was attributed to a swine H1N1 A/New Jersey/8/76 (named Hsw1N1 at the 
time) virus [94]. The finding of human-to-human transmission by a swine virus was 
alarming. Although the disease did not spread beyond the camp at Fort Dix, a massive 
immunization program was launched in the U.S. by the government in order to prevent a 
predicted epidemic that never happened [95]. However, this resulted in the recognition of 
swine influenza virus as a zoonotic disease with potential to cause human epidemics. In 
addition, there was speculation that the vaccine prepared for the immunization program in 
humans might be suitable for use as a vaccine in pigs to prevent epidemics in humans. 
Several investigators evaluated the human influenza vaccine that contained the Hsw1N1 
strain A/New Jersey/76 and reported consensus findings that the vaccine induced poor 
hemagglutination-inhibition (HI) antibody response in swine. Easterday et al (1977) reported 
that the Hsw1N1-based vaccine when administered to pigs at the same dose recommended 
for adult humans (0.5 ml) induced low titers of antibodies and  the vaccine did not reduce 
virus shedding following an intranasal challenge [96]. Woods and Mansfield (1978) reported 
a dose effect with a 2 ml dose intramuascularly injection inducing a better HI antibody 
response than 0.5 ml in vaccinated gilts, although overall the vaccine stimulated low levels of 
antibodies [97]. Pirtle (1977) immunized hysterectomy-derived pigs with the Hsw1N1-based 
vaccine and challenged the young pigs intranasally with a heterologous virus [98]. That study 
reported low levels of antibodies in the young pigs following vaccination, but appeared 
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capable of reducing virus shedding. It was unclear and was not addressed in those studies 
why the human influenza vaccine that contained swine virus was able to induce an excellent 
immune response in humans [99,100] but generated a poor antibody response in pigs. It was 
suggested by data from earlier studies that pigs required a higher amount of influenza antigen 
to induce a proper antibody response. The difference in the route of injection may also play a 
role as human the vaccines are administered through subcutaneous or intradermal sites. 
Taken together the data showed that the use of a vaccine that was produced and tested in one 
species could not be easily transferred to a different species. 
 A limited number of published reports found in the literature reported on the use of 
influenza vaccines by the swine industry prior to 1998. Woods and Mansfield [101] produced 
a vaccine that contained concentrated A/Swine/Illinois/65 virus that had been inactivated 
with formalin and tested the antigenicity of the vaccine in gilts. They reported that two 
subcutaneously injected vaccinations containing 4 ml of vaccine administered 3 weeks apart 
induced a high HI antibody response [102].  The vaccine efficacy was evaluated by 
vaccinating gilts prior to breeding or at 16 to 25 days after breeding and challenging 
intravenously with homologous virus 4 weeks after the second vaccination [103]. They 
reported that gilts vaccinated prior to breeding had higher HI antibody levels at farrowing 
compared to pigs vaccinated at 16-25 days after breeding. The efficacy of the vaccine could 
not be determined as the study was conducted in the field and control pigs became infected 
with SIV during the study. The results of this study suggested that intravenous challenge did 
not induce clinical disease comparable to use of the intranasal challenge route. In 1984, an 
intratracheal challenge model for swine influenza was developed in growing pigs and proved 
to be an experimental infection route that resulted in reproducible clinical disease [104]. 
Since then swine influenza experimental infection studies have used exclusively either the 
intranasal or the intratracheal challenge route.       
The first licensed swine influenza vaccine available for use on U.S. swine farms was 
a monovalent vaccine that contained an unspecified H1N1 inactivated virus (MaxiVac®-
FLU) [105]. The vaccine was developed in 1994 for use in weaned and breeding pigs by 
Syntrovet, Inc. (currently a part of Schering-Plough Animal Health). The introduction of the 
vaccine helped reliably control disease caused by influenza in swine herds. Since the 
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predominant circulating virus in the U.S. swine population at the time consisted of a classical 
swine H1N1 (cH1N1) lineage the control of swine influenza was uncomplicated. 
Immunization of sow herds to generate high levels of maternally derived antibodies (MDA) 
became a common practice. SIV-specific MDA were passively transferred from the sow to 
suckling pigs and appeared to uniformly protect young pigs from disease through the nursery 
phase. The control of swine influenza became complicated with the emergence of a H3N2 
SIV among the large swine-production states in August 1998. The H3N2 virus spread rapidly 
and caused clinical disease that included not only the typical respiratory signs but also 
abortion in sows [68]. It was apparent that the monovalent H1N1 vaccine could not provide 
protection against a H3N2 SIV subtype infection. The option to use the currently available 
human influenza vaccine which contained the ‘prototype’ H3N2 strain A/Port Chalmers/1/73 
was not preferred as most of the isolated swine H3N2 strains in the U.S. were identified to be 
antigenically distinct to the prototype virus. These findings prompted the Diagnostic 
Virology Laboratory of the National Veterinary Services Laboratories in Ames, Iowa to 
provide a more recent H3N2 field isolate that would be a representative strain for biological 
manufacturers. As a result, the first conditionally licensed vaccine contained this recent 
H3N2 virus that had been characterized as a H3N2 cluster 1 virus and the older Port 
Chalmers strain was released January 23, 2000 followed by the release of fully licensed 
bivalent H1N1/H3N2 in May 2, 2001 [106]. Shortly after the emergence of the H3N2 viruses 
in the swine herds, an H1N2 virus  generated from genetic reassortment of the cH1N1 and 
H3N2 emerged resulting in viruses that contained a mix of viruses made up of diverse 
genetic lineages from swine, human and avian species [6,69]. In addition, the presence of 
reassorted H1N1 (rH1N1) viruses with the HA and NA genes of human lineages were 
reported in swine beginning in 2005, indicating an ongoing human-to-swine transmission 
which further complicated the control of swine influenza [70]. In the past few years, 
manufacturers in the U.S. have developed commercial SIV vaccines that contain more than 
one subtype of the virus as inactivated, adjuvanted products to support the needs of the swine 
industry (table 1). However, the control of SIV in swine herds has become more difficult and 
it is not unusual to recover the virus from sick pigs born from sow herds that have been well 
vaccinated [107,108]. 
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Swine influenza inactivated vaccines
An effective vaccine has two important characteristics; immunogenicity and efficacy 
as demonstrated by protection against disease. Immunogenicity refers to “the ability of a 
vaccine to induce an immune response including antibody and/or cell mediated immunity in 
a vaccinated individual” [109]. Parenterally administered swine influenza inactivated 
vaccines primarily target the production of antibodies against the hemagglutinin (HA) and 
neuraminidase (NA) proteins. For human influenza inactivated vaccines, a minimum amount 
of 15 microgram of the HA protein per strain is required for the vaccine to be considered 
efficacious [110]. Serum HI antibodies appear to provide protection in the bronchoalveolar 
(BAL) passages of the lung area [111]. Specifically, the antibodies against the HA protein 
which neutralizes the virus and thus prevents infection are needed to prevent disease [112]. 
Antibodies measured by the HI assay are thought to be correlated with protection against 
influenza infection  [34,37,113-115] and as a result, the HI antibody response following 
immunization has become the most commonly used marker for assessing vaccine efficacy 
[109,116]. Antibodies to NA protein are less effective in providing protection against 
infection. Antibodies to the NA protein do not prevent viral infection but rather are more 
effective in reducing the cell-to-cell spread in the airways and viral production [112].  
Vaccine efficacy in humans is defined as “the percent reduction in attack rates in the 
vaccinated compared to the unvaccinated populations” [109]. The measurement of swine 
vaccine efficacy is more closely defined as the reduction of clinical disease severity and virus 
shedding, which are the primary purpose of using influenza vaccines in swine herds. The 
production of certain cytokines such as interferon-alpha and interleukin (IL)-6 have been 
proposed to be indicators in experimental studies of the vaccine efficacy as these cytokines 
have been shown to be closely correlated with influenza infection and disease both in swine 
[117] and humans [118]. In general, inactivated swine influenza vaccines do not provide 
complete protection from SIV infection, but have been shown to decrease the severity of 
clinical respiratory disease and reduce virus circulation [35,92,119].  
Vaccination of pigs with inactivated influenza vaccines is most commonly performed 
using two intramuscular inoculations. Vaccine efficacy studies are based on experimental 
vaccination-challenge studies conducted in SIV-seronegative pigs. Commercial swine 
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influenza vaccine efficacy information in U.S. is provided by studies conducted by the 
manufacturers. Two studies demonstrated protection provided by commercial vaccines that 
contained the H3N2 cluster 1 vaccine virus against infection with a H3N2 cluster 3 virus, the 
currently predominant virus circulating in the U.S. swine herds [120,121]. A different 
commercial bivalent H1N1/H3N2 vaccine has also been reported to provide protection 
against a H1N2 challenge [122].  Overall, satisfactory protection efficacy based on the 
reduction of clinical severity, lung lesions and viral shedding are provided by the vaccines 
against the viruses used in the experimental models. However, in most cases, minimal 
information about the genetic composition of the strains of viruses included in the 
commercial vaccines is provided by the companies. Such genetic information along with 
continued serological monitoring of herds is necessary for the use to assess antigenic drift 
and the re-evaluations of swine influenza vaccine efficacy.      
Inactivated swine influenza vaccines typically provide effective protection against a 
homologous virus or when the vaccine virus is closely related to the infecting strains [34-37]. 
The protective ability of a vaccine may vary when pigs are challenged with heterologous 
viruses of the same subtype, especially when they are antigenically different as detected 
using serology assays. Increased protection against heterologous strains is correlated to the 
level of subtype-specific immunity which is defined as the immunity among different strains 
of the same subtype. It was suggested that the development of increased levels of HI 
antibody titers induced by the vaccine increases the potential of protection against disease 
caused by a heterologous strain [91]. However, low cross-reactive HI antibody levels against 
a heterologous strain may not always result in vaccine failure as demonstrated in vaccine 
studies where pigs were protected against a heterologous H1 virus [92] or heterologous 
H3N2 virus infection [35]. These results indicate that other immune responses beyond HI 
antibody production are induced by vaccination and can contribute to protection. Such 
immune responses are usually not measured during vaccine evaluation. As an example, the 
antibodies against the NA protein as the tests are difficult to accurately measure and correlate 
to disease protection [123,124]. There is also evidence of other serum antibodies that do not 
prevent viral attachment as observed with the HI antibodies, but neutralize the virus by 
interfering with subsequent stages of virus replication in the endosomal fusion or the 
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uncoating of the viral genome phases [125]. In addition, serum antibodies may not reflect 
local immunity in the lungs. It has been shown that inactivated swine influenza vaccines can 
prime a local antibody response as demonstrated by significantly higher IgG and IgA 
antibody levels detected in the vaccinated-challenged pigs compared to the nonvaccinated-
challenged pigs [38,92].     
Table 1. Commercial inactivated swine influenza vaccines in the United States of America 
Trade name Company Strains Type Recommendations 
FLUSURE™  Pfizer Animal Health H1N1, H3N2  Amphigen®,
oil-in-water  
 3 wks of age or older, revaccinate 
after 3 wks 
MaxiVac Excell 3  Schering-Plough 
Animal Health 
 rH1N1, cH1N1, 
 H3N2 (cluster 1)
Emunade®,  
 oil-in-water 
 5 wks of age or older, revaccinate 
 after 2- 3 wks 
 End-FLUence®2 Intervet Inc  H1N1, H3N2 
 (cluster 1) 
 Microsol 
 Diluvac  
 Forte®, 
 oil-in-water 
 3 wks of age or older, revaccinate 
after 3 wks 
 Suvaxyn® SIV  Fort Dodge Animal 
 Health 
 H1N1, H3N2  Mineral oil- 
 Free 
 9 days of age or older, revaccinate 
 after 2-3 wks  
 PneumoSTAR® SIV    Novartis Animal 
 Health 
 H1N1, H3N2  ImmunSTAR
water-in-oil- 
 in-water 
 One dose at 3 wks of age or older 
Heterosubtypic immunity between different subtypes of the same type of virus was 
evaluated in two different studies. The first study used a U.S. bivalent commercial vaccine 
containing unidentified H1N1 and H3N2 viruses followed by challenge of pigs with a H1N2 
SIV [122]. Vaccinated pigs had average HI titers of 1:35 against the H1N2 virus 2 weeks 
after the second vaccination. It appeared that the vaccine reduced clinical disease, pneumonia 
and the numbers of pigs shedding the H1N2 virus following infection. Another study 
investigated the efficacy of a European licensed bivalent vaccine that contained the H1N1 
strain A/New Jersey/8/76 and a H3N2 A/Port Chalmers/1/73 SIV against infection with a 
H1N2 strain A/Swine/Gent/7625/99 virus [126]. While low levels of cross-reactive HI 
antibodies were induced by vaccination against the H1N2 antigen, only when the HI titer to 
the H1 vaccine virus was > 512 were HI antibodies to H1N2 detected. Thus, suboptimal 
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levels of protection against a heterologous subtype H1N2 infection was demonstrated in this 
study as the vaccine was able to reduce clinical disease but not viral shedding. It has been 
suggested that a H1N2 virus should be incorporated into the vaccine for complete protection 
against all three circulating subtypes in swine. The apparently contradictory findings 
regarding the heterosubtypic immunity induced by vaccination with swine influenza 
inactivated vaccine from both studies indicate the need for further investigation. It should be 
noted that experimental challenge models are often conducted with high health status pigs in 
clean isolated facilities and lack interfering factors such as the presence of MDA. These 
factors are highly variable under farm conditions and may reduce vaccine efficacy when used 
under field conditions.  
 The influence of influenza-specific MDA on neonatal immunization against influenza 
has been well documented in humans [127] and in foals born from equine influenza 
vaccinated mares [128,129]. In one report a tolerance-like phenomenon was developed in 
some MDA positive  foals vaccinated against equine influenza virus [130]. In that study foals 
failed to respond serologically after 5-6 doses of the equine influenza inactivated vaccine. 
Previous data found that the level of protection in young pigs correlated to the MDA level at 
the time of infection [18,19]. A more recent study demonstrated that MDA positive young 
pigs shed more virus following infection with the homologous virus than young pigs without 
MDA [33]. Limited data is available on the influence of MDA on the immune response to 
swine influenza vaccination. Since swine influenza virus-specific MDA can last in young 
pigs until 12 weeks of age or more [17,28,29] the potential for interference with vaccination 
in the nursery and/or growing pigs is increased. In order for pigs to seroconvert to the H1N1 
and H3N2 vaccine antigen, respectively, MDA HI titers should be equal to 10 or less than 80 
when receiving the first swine influenza vaccination [39]. The topic of MDAs in relation to 
swine influenza vaccination is important since swine veterinarians use MDA as a tool to 
prevent disease from swine influenza in young pigss. However few experimental studies to 
validate the strategy have been performed to date. No data describing the role that MDA have 
in protection of young pigs against infection with the newer field strains or MDA 
interference with vaccine efficacy against heterologous virus infection have been reported.  
This raises the question as to whether the presence of MDA that are not completely 
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protective against newer diverse viruses allow increased antigenic drift to take place in swine 
influenza virus-infected MDA positive young pigs? If MDA are ineffective at protecting 
against the new swine influenza strains and are present at the time of vaccination will they 
selectively suppress certain epitopes of the vaccine antigen and result in disease enhancement 
when vaccinated young pigs are subsequently infected with swine influenza virus? These are 
just a few of many questions that are waiting to be answered.  
One important change in modern swine production is the decreasing in numbers of 
swine herds but increasing in the size of individual production systems. The goals of these 
large production systems include having high-health status pigs, with centralization of the 
origin of replacement animals resulting in nurseries with pigs from multiple sources. As a 
result, the disease patterns associated with the various pathogens, including timing and onset 
of infection are unique to the individual farm and often discrete from other swine production 
systems even those in the same geographical region [131,132]. The use of autogenous swine 
influenza vaccines for the control of swine influenza within an individual farm has become 
increasingly accepted in many of these swine production system. By definition, autogenous 
biological vaccines are produced from inactivated or are non-toxic pathogens either viruses 
or bacteria that cause disease in a particular livestock operation. The resulting vaccine is 
specific to the pathogenic strain(s) in the herd and must be used under the direction of a 
veterinarian and within a veterinarian-client-patient relationship [133]. In general, 
autogenous vaccines can be an important tool when new disease agents emerge and no 
commercial vaccine is available or when antigenic variation occurs on a herd basis that is 
outside the spectrum of protection provided by commercially available vaccines. It has been 
estimated that in the U.S. approximately $16 million worth of swine autogenous vaccines 
were used between May 1999 and April 2000 [134]. Vaccines against porcine reproductive 
and respiratory syndrome virus (PRRSV) and SIV were responsible for over one-half of the 
autogenous vaccines produced. An example of the use of autogenous swine influenza 
vaccines was documented in two large swine production systems in the Midwest [108] where 
in spite of vaccination of gilts and sow herds with a commercial swine influenza vaccine, 
nursery and finishing pigs had clinical influenza disease. In these herds, two different H3N2 
viruses were isolated from the nursery and the finishing herds. It was determined that these 
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isolates were genetically distinct from the vaccine virus and antibodies from the vaccine 
viruses did not provide cross-protection against either of the new isolates. As a result, two 
autogenous vaccines were produced, based on the isolates from the individual farm and 
vaccination was administered to the sow herds in both swine production systems. Following 
the use of the autogenous vaccines, the MDA positive young pigs born from the vaccinated 
sows appeared to be protected against clinical disease.  
Swine influenza vaccine research
Swine influenza inactivated vaccines are administered via parenteral routes and 
normally induce the production of serum immunoglobulin (Ig) G antibodies.  These vaccines 
are less effective in inducing mucosal and cell-mediated immunity (CMI) [35,126,135]. 
Current vaccine research efforts have been directed primarily towards improving the efficacy 
of the available inactivated vaccines or the development of new types of vaccines.  In 
addition to the antigens, several adjuvants such as virosomes [136], immune stimulating 
complexes (ISCOMs®) [137] and ISCOMATRIX® [138] have been studied in influenza 
vaccines using human and animal models. These studies demonstrated an enhancement of 
CMI and/or mucosal immunity superior to the current oil-in-water adjuvant based vaccines. 
A new carrier delivery system ‘BioMed’ which entraps protein in a biphasic system that 
combines a colloidal phase from a negatively charged oil-in-water emulsion and a positively 
charged Alhydrogel® has also been tested with a swine influenza inactivated vaccine model 
challenged with homologous virus [139].  This study demonstrated that pigs vaccinated with 
the BioMed adjuvant system had significantly higher serum antibody levels and increased 
CMI (measured by the presence of the CD4+CD8+ T lymphocytes) compared to pigs 
vaccinated with an aluminum hydroxide adjuvanted vaccine (Alhydrogel® 1.3%). More than 
half of the pigs vaccinated with the BioMed system were free of macroscopic lesions and 
only one pig had virus in the lungs indicating highly effective protection provided by the 
vaccine.   
Studies in mice have found that mucosal immunity as represented by influenza-
specific secretory IgA antibodies, but not serum IgG antibodies, have an essential role in 
providing cross-protection against infection with viruses that have undergone antigenic drift 
[140,141]. A study evaluated the protective efficacy of an inactivated influenza virus vaccine 
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in pigs by immunizing via an intransal route [142]. Pigs were vaccinated 4 times and then 
challenged with swine influenza virus intranasally. After challenge, no serum antibodies 
were detected against the challenge virus and virus was negative in nasal swabs from 
vaccinated pigs indicating complete inhibition of virus replication. Heterosubtypic (Het-I) 
and subtype-specific immunity was not evaluated since the pigs were challenged with 
homologous virus. However, Het-I was demonstrated in a study in mice when an inactivated 
adjuvanted H3N2 virus was administered intranasally 3 times followed by challenge with a 
H5N1 highly pathogenic human virus [143]. This vaccine induced significantly higher 
mucosal IgG and IgA levels and provided effective protection in the vaccinated mice as virus 
levels in the lungs were significantly reduced compared to mice vaccinated with the same 
vaccine through a subcutaneous route. Both of these studies demonstrate the importance of 
the vaccine administration route in activating the different compartments of the immune 
response. These studies appeared to be effective in providing protection against influenza 
infection especially against heterologous virus however the requirement for multiple doses of 
vaccination may not be practical and cost-effective for use in animal production systems.  
The use of adenovirus vectored vaccines has been proposed for use in pigs. An 
advantage of this type of vaccine compared to commercial inactivated vaccines is the lack of  
pre-existing MDA to adenoviruses that will interfere with vaccination efficacy in young pigs 
[144].  Two human adenovirus 5 recombinant viruses expressing the HA and the 
nucleoproteins (NP) of a H3N2 swine influenza virus were tested in weaned pigs.  Influenza 
virus seronegative pigs were vaccinated once intramuscularly with the recombinant 
adenovirus vaccine expressing either the HA or NP protein alone or in combination. Pigs 
were challenged intranasally 5 weeks later with a heterologous strain of H3N2. Pigs 
vaccinated with the combination of both the recombinant HA and NP proteins were 
completely protected against infection as demonstrated by no virus shedding from the nasal 
cavities and no lung lesions at 7 days post infection.  In addition to the advantage of lack of 
reduction in vaccine efficacy due to MDA as observed with conventional swine influenza 
inactivated vaccines, the adenovirus recombinant vaccine infects the muscles and other cell 
types, mimicking the presentation of the HA and NP proteins to the immune sytem inducing 
both antibody and CMI. The study reported here did not evaluate the CMI response, although 
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the HI antibody response was high. One limitation of the adenovirus vector vaccine is that 
the vaccine can not be administered in a booster response as it has been demonstrated in 
mice, rats and rhesus monkey that neutralizing antibodies to the fiber and hexon proteins of 
the adenovirus are produced and will prevent reinfection of the virus [145].   
 Use of DNA vaccines was introduced over 10 years ago when it was demonstrated 
that a protein could be expressed in a cell when a plasmid DNA encoding gene is injected 
into muscle tissue [146]. Several advantages of DNA immunization exist, one includes the 
fact that this process mimics live attenuated vaccination without the undesirable side effects 
such as reactions from the culture system agents. A second advantage is that the CMI 
response is enhanced as the encoded proteins are presented in the context of the host’s major 
histocompatibility class (MHC) I [147]. DNA-based influenza virus vaccines have been 
studied since 1993 in many animal models including mice, chickens, ferrets and non-human 
primates. Several recombinant plasmid DNA constructs including HA, NP, NA and/or matrix 
(M) genes have been tested by intravenous, intransal, or intramuscular routes and also by 
intradermal injection with gene gun [148-151]. The first influenza DNA-based vaccine tested 
in pigs was a NP gene construct generated from the human influenza H1N1 virus, A/PR8/34, 
delivered through the epidermis (at least 3 different sites) and was ineffective in protecting 
against the challenge virus [152]. A different construct containing the HA gene from a swine 
virus H1N1 strain, A/Swine/Indiana/1726/88 (Sw/IN), was tested using two different routes 
of administration including the epidermis and the tongue. Vaccination using the two routes 
was able to induce a swine influenza-specific antibody response measured by HI test and 
ELISA and significantly reduced viral shedding. Interestingly, pigs vaccinated on the tongue 
shed significantly lower levels of virus compared to pigs vaccinated in the skin. Another 
study found enhanced protective efficacy of the Sw/IN-DNA vaccine described above by 
priming pigs with the DNA vaccine and boostering pigs with a conventional whole-virus 
inactivated vaccine [153]. This study demonstrated that the alternative route vaccine regime 
resulted in improved protection compared to injecting 2 doses of the DNA vaccine. However, 
the findings were similar to injecting pigs with 2 doses of the conventional vaccine and 
minimal levels of swine influenza-specific IgA antibodies were detected in the nasal wash 
solution from pigs prior to challenge. The same research group further evaluated the Sw/IN-
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DNA vaccine by assessing the effect of dose, route of vaccination (intradermal vs. ventral 
surface of tongue) and the co-administration of porcine IL-6 as an adjuvant [154]. 
Administration of IL-6 was based on the fact that IL-6 helps promote the production of IgA-
antibody secreting cells (ASC) [155] and reduced HA-specific IgA ASCs were found in IL-6 
knockout mice [156]. The study found that a higher dose of vaccine antigen, but not the 
addition of IL-6 correlated with an increase in a serum swine influenza-specific antibody 
response. Pigs vaccinated on the tongue shed virus one day less than when vaccinated 
intradermally. The Sw/IN-DNA vaccine did not provide steriliziing protection nor did it 
induce detectable mucosal SIV-specific antibody response prior to challenge although the 
levels were increased following infection.    
An earlier European study determined that conventional bivalent swine influenza 
inactivated vaccines containing the H1N1 and H3N2 subtypes did not protect against 
infection with a European H1N2 subtype [126]. In contrast, H1N1 or H3N2 infection-
induced immunity provided partial protection against H1N2 virus, while pigs infected with 
both the H1N1 and the H3N2 viruses were completely protected against the H1N2 virus with 
undetectable clinical disease and undetectable or remarkably reduced virus replication [157]. 
The three viruses did not cross-react serologically in HI assays suggesting that cross-
protection was mainly provided by the induction of CMI response since all three had 
identical internal proteins, differing only by the HA and NP antigens. Accordingly, a swine 
influenza NS1 truncated modified live-virus vaccine was developed recently with the 
hypothesis that infection provides a more protective immune response than the inactivated 
vaccines [158]. The NS1 deletion in influenza virus was shown to attenuate the virus and 
reduce virus replication in cells expressing interferon (IFN) type I [159,160]. In a study, pigs 
were vaccinated using an intratracheal route and infected with a homologous H3N2 virus or a 
heterologous H1N1 virus. Complete protection against disease was demonstrated in the NS1 
truncated modified live-virus vaccinated pigs infected with homologous H3N2 virus while 
partial protection was found in pigs infected with the H1N1 virus with macroscopic lesions 
and shedding of a low amount of virus. The results of this study parallels the findings in an 
earlier experimental infection study where pigs were shown to be completely protected 
against re-infection with the same virus but partial  protection was found against a different 
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subtype virus infection [161]. These results suggest that the NS1 truncated modified live-
virus vaccine induces an innate immune response to type I IFN that confer protection. In 
addition, vaccinated pigs in the study produced low levels of NS1 antibodies and which 
could possibly be used as a diagnostic differentiating based test. However, future studies 
need to investigate improving the heterosubtypic immunity studies and should include using 
different routes of vaccination since intratracheal route is not practical in the field.          
Overall the different types of vaccines discussed in this review still face one evitable 
problem, which is the fact that there are different swine influenza subtypes that do not cross-
react serologically and the major antigenic determinant of these viruses constantly drifts 
allowing the virus to escape the immune response. In humans, the problem is partially solved 
by continual updating of the vaccine viruses. Since 1948, the World Health Organization 
(WHO) has been responsible for providing annual recommendations on the composition of 
human influenza vaccines. The data is based upon in-depth analysis of the antigenic and 
genetic characteristics of the major strains of influenza that had are dominate around the 
world. The results of laboratory and clinical studies are reviewed yearly by WHO in 
consultation with the Centers for Disease Control (CDC) and key personnel of national 
representative laboratories to make the recommendation in February for the Northern 
Hemisphere and in September for the Southern Hemisphere [162].  Similar surveillance 
measures are not currently available to the swine industry.  
 The extracellular domain of the integral transmembrane M2 (M2e) protein which 
consist of 24 amino acids, is nearly invariant in all influenza A strains [163,164]. A region 
within amino acid 10 -20 of the M2e protein was found to be host restricted between human, 
avian and swine with only 2 amino acids differing between human and swine and 3 amino 
acids differing between avian and swine species[64]. Because of its highly conserved 
character, the M2e is considered a strong candidate protein for a universal influenza A based 
vaccine [165,166]. It was demonstrated in mice that vaccination with the M2 protein 
provided protection and enhanced viral clearance in conjunction with challenge with 
homologous and heterologous influenza A viruses. Many M2 vaccination strategies have 
been tested in mice and ferret models including the use of M2-expressing recombinant 
viruses, M2 recombinant proteins, and the use of synthetic M2e peptides that were 
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chemically linked to carrier proteins such as keyhole limpet hemocyanin or N. meningitides 
outer membrane protein [41,163,166-169]. Recently, a novel vaccine technology that fuses a 
target antigen to a proprietary hydrophobic protein domain (HD) was used to fuse 3 M2e 
proteins representative of  potential pandemic influenza strains into a liposomal M2 vaccine 
[170]. The efficacy of this vaccine was evaluated in mice and shown to induce an immune 
response and provided protection against challenge with H1N1, H5N1, H6N2 and H9N2 
strains of influenza virus. In pigs, only a DNA vaccine strategy was evaluated [42]. Two 
different types of constructs were tested, a DNA construct expressing the M2e and 
nucleoprotein (M2eNP) and the M2e fused with a hepatitis B core protein (M2eHBc). Pigs 
were vaccinated 3 times at 3 week intervals and challenged with a H1N1 field strain 
A/Swine/Best/96. All vaccinated pigs had an antibody response to the M2e protein and the 
M2eNP vaccinates demonstrated significant virus-specific lymphoproliferation compared to 
non-vaccinated pigs. No protection was observed following infection and unexpectedly the 
M2eNP vaccinated pigs exhibited severe clinical signs and half of the challenged pigs died at 
1 and 2 days post infection. It was suggested that, since M2e antibodies do not prevent the 
initial infection, there is a possibility that they are most effective in the early stages of 
infection especially when CMI responses are induced and no neutralizing antibodies are 
present. These findings demonstrate that the induction of a broad spectrum immunity by 
other ways may be safer than using only the M2e and/or NP. It should be noted that this was 
the first study using a M2e-based vaccine that was evaluated in an influenza natural host. 
More studies should be conducted to confirm the findings of this study to determine if they 
are reproducible. However, currently the data from these studies serves as a reminder that the 
immune response works in a balance of complex networks and more importantly, data 
observed from infection studies from one species may not apply to another. 
 Many problems regarding the development of new generations of vaccines for the 
control of swine influenza virus still remain unaddressed. It appears that each vaccine 
strategy has problems and that one vaccine will not solve all problems. Swine influenza 
control strategies based on vaccination in the future may require the use of a combination of 
more than one type vaccine and may use different strategies in the sow herd versus grow-
finishing pigs.    
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The responses of the host following swine influenza virus infection
Innate immune response 
 Early in the influenza infection process, the nonspecific immune system plays an 
important role in preventing the establishment of viral infection. Influenza viruses infect the 
epithelial lining of the respiratory tract by the binding of the viral hemagglutinin (HA) 
protein to the sialic acid (SA) receptors on the host cells surface [1]. In swine and other 
natural influenza hosts, the surfactant proteins A (SP-A) and D (SP-D), present in large 
amounts in the alveolar lining fluids or serum, make up one of the first lines of defense [171]. 
The SP-A is sialyted with both Q(2,3)- and Q(2,6)-linked SA while SP-D is exclusively 
sialyted with Q(2,6)-linked SA. Studies demonstrated that both SP-A and SP-D can directly 
interact and neutralize influenza A viruses by causing aggregates of the virus [172,173]. 
Furthermore SP-A and SP-D act as opsonins which helps facilitate the clearance by 
macrophages and neutrophils [174]. At this stage of infection, the influenza virus 
neuraminidase (NA) protein has a crucial role in overriding the mock SA receptors by 
cleaving the SA on the surfactants, paving the way for the virus to evade this part of the 
immune system and infect target cells [1].  
All influenza A viruses including swine influenza virus infect epithelial cells resulting 
in cell necrosis [1,111,175]. In addition, the virus can infect pulmonary alveolar macrophages 
(PAMs) perhaps by way of the mannose receptor [176]. Viral proteins are expressed in 
PAMs, however the virus is unable to replicate and produce progeny viruses [177-179]. The 
necrosis of epithelial cells and particularly the activation of PAMs initiates a downstream 
signal transduction pathway that leads to the production of chemotactic (RANTES, MIP-1 
alpha, MCP-1, MCP-3, and IP-10), pro-inflammatory (IL-1 beta, IL-6, IL-18, and TNF-
alpha), and antiviral (IFN-alpha/beta) cytokines [180]. Much of the information on the 
molecular pathways of cytokine production in response to influenza virus infection reported 
here is the result of studies using mouse models. After infection, the accumulation of the 
influenza double stranded (ds) RNA activates the intracellularly-expressed signaling 
receptors, known as Toll like receptor (TLR) 3 in human bronchial and alveolar epithelial 
cells [181] and TLR7 in mouse dendritic cells [182], initiating the signaling events through 
protein kinase R (PKR). The HA, matrix (M) and nucleoprotein (NP) have been identified as 
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the host signal stimulators. Over expression of HA induces activation of NF-XB through an 
endoplasmic reticulum (ER)-dependent mechanism while the M and NP initiates signaling 
through an ER-independent mechanism [180]. A recombinant NA, but not HA protein, was 
shown to induce the production of IL-1 and tumor necrosis factor (TNF)-alpha in mice 
peritoneal macrophages [183]. Production of these cytokines triggers a downstream signaling 
event resulting in the production of the transcription proteins NF-XB, Jun/Fos (AP-1) and/or 
IRF that are important in selectively regulating the expression of the cytokines and 
chemokines described above [181,184,185].  
 A typical influenza A virus results in the appearance of the clinical symptoms starting 
1 to 4 days following infection and persisting for 3 to 5 days. Clinical signs include high 
fever, myalgia, cough, sleepiness and anorexia. In pigs, coughing, sneezing, labored 
abdominal breathing and feed withdrawing are the most common observable clinical signs 
[10,33,92]. Typical macroscopic lesions in the lungs are generally similar between different 
animal species with variation in the severity of pneumonia and the disease onset [111]. The 
lesions are due to the cytopathic effects of the virus on the cells and investigators have 
correlated the proinflammatory cytokines produced early in the course of infection to the 
severity in pathology of the disease [184,186,187]. In horses, IFN type I and IL-6 but not 
TNF-alpha were detected in nasal secretions. The cytokines peaked at 3 days post 
experimental infection with two isolates of the H3N8 virus that differ in their pathogenicity 
based on the severity of clinical disease [188]. The level of IFN type I and IL-6 was more 
pronounced in animals that had been infected with the more pathogenic strain suggesting a 
correlation between the two cytokines and clinical disease. No systemic IFN type I was 
detected following infection confirming that infection was confined to the respiratory area. It 
was speculated that there was a difference in cytokine down-regulation capacity between the 
two strains used since both strains had similar replication efficiency yet the cytokine 
response and clinical outcome presented differed in magnitude. Studies conducted using 
swine influenza infected gnotobotic pigs [189] and a vaccine-challenge study in conventional 
pigs [117] indicated that IFN-alpha TNF-alpha, IL-6 and IL-1 in BAL fluids was correlated 
to disease severity, viral load and neutrophil infiltration in the lungs. Following infection, 
cytokines as well as other parameters such as fever peaked at 18-24 hours and declined by 
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48-72 hours post infection (HPI). In the latter study with conventional pigs, nonvaccinated-
challenged pigs had higher levels of IFN-alpha, TNF-alpha, and IL-6 at 24 HPI and increased 
clinical scores, virus levels in the lungs and neutrophil numbers compared to vaccinated-
challenged pigs which had lower levels of IFN-alpha, TNF-alpha, and IL-6. An increase in 
IL-1 and IL-8 levels were also detected, however the levels had a lower correlation to the 
clinical parameters studied. These findings are in line with a previous investigation in 
humans where IFN-alpha, TNF-alpha and IL-6, but not IL-1 and IL-8 were associated with 
disease and symptoms [118,190]. An in vitro study demonstrated a strong antiviral effect by 
swine TNF-alpha over IFN-alpha or gamma using an established lung epithelium cell line 
originating from healthy pigs [191]. This study showed an inverse correlation of TNF-alpha 
with viral titers and that pre-treating the cells with swine TNF-alpha resulted in markedly 
increased viral replication compared to cells that had been pre-treated with IFN-alpha or 
IFN-gamma. These data suggest that only replicating viruses induce expression of TNF-alpha 
in swine epithelial cells while a previous study had described induction of TNF-alpha in 
macrophages using a recombinant influenza NA protein. These differences are probably a 
reflection of the different properties of the two cell lines as macrophages can phagocytose 
and process foreign antigens leading to cytokine production while cell lines do not have that 
capability. 
 The Mx protein in addition to PKR and 2’,5’-oligoadenylate synthase are cellular 
proteins that are induced by interferon and thought to play a critical role in inducing an 
antiviral state [192]. Mx genes have been identified in many animal species such as humans, 
mice and cattle [193-195]. Mice that lack the Mx gene were shown to be highly susceptible 
to influenza virus infection [195]. The nature and the extent of the anti-influenza virus 
activity differed between species. The Mx protein in mice is expressed in the nucleus which 
inhibits primary virus transcription possibly by interfering with the viral PB2 protein. In 
contrast, humans have two Mx proteins, MxA and MxB. The MxA protein has been shown to 
accumulate in the cytoplasm of influenza virus infected cells and interfere with virus 
replication [193]. The porcine Mx1 gene was identified and shown to encode a 663 amino 
acid protein that is similar to the human MxA protein [196]. Minimal data is available that 
characterizes the role Mx1 protein plays in inducing swine IFN type I production or the 
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correlation with a pig’s susceptibility to swine influenza infection. One study demonstrated 
an up regulation of the mRNA levels of the IFN-alpha and the Mx1 protein in lung tissues of 
pigs experimentally infected with swine influenza virus [197]. The up regulation of IFN-
alpha and increased levels of the Mx1 protein was confined to cells that had hybridization 
signals for swine influenza virus indicating that the event was a direct response to SIV 
infection.  
Natural killer (NK) cells have been shown in previous studies to have a role in 
reducing viral levels including influenza A virus, early in infection prior to the appearance of 
the specific immune response [198];Biron, 1997 #727;Bancroft, 1993 #730}. In volunteers 
that received live influenza A virus intranasally, increased NK cell activity was detected 
within the first 3 days of infection and levels were correlated to recovery [199]. In pigs, an 
increase in the percentage of NK cells in swine influenza infected lungs was detected 2 days 
post infection [161]. In horses, NK-like cytotoxicity cells were detected in the blood 
circulation 4 days after primary infection with equine influenza virus [200]. The major 
glycoproteins, HA and NA have been shown to have an active role in enhancing NK cell 
activity [201]. Virus replication was not necessary for the induction of NK cells as 
inactivated virus or purified HA and/or NA proteins were able to stimulate NK activation 
[201]. Cytokines such as IL-15 [202] and IL-18 [203] from infected epithelial cells and 
activated monocytes/macrophages have been shown to augment the NK cell mediated 
cytotoxicity. Previous findings demonstrated IL-15 activated human NK cells use 
components of the IL-2R and synergize with IL-12 to significantly potentiate NK cell 
production of IFN-gamma [204]. Originally, IL-18 was described as a necessary factor for 
the production of IFN-gamma by T-lymphocytes in the presence of IL-12. Recent studies 
have attributed other activities to IL-18 such as T- lymphocyte and NK cell proliferation, 
stimulation of cytotoxicity and enhancement of an adaptive T helper 1 (Th1) mediated 
immune response [203]. Therefore, both IL-15 and IL-18, and probably IL-12 are essential in 
the early anti-influenza virus response for up regulating NK cell-mediated killing activity of 
the infected cells. The requirement for IL-12 by NK cells was confirmed by blocking IFN-
gamma production when NK cells were treated with neutralizing IL-12 antibody. However, 
as the infection progresses, virus-specific T lymphocytes migrate into the lung areas, perhaps 
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activated by IL-12 and become the major IFN-gamma producers. Therefore, it has been 
suggested that IL-12 is important in inducing IFN-gamma production by NK cells early in 
infection resulting in inhibition of viral replication.  
IFN-gamma has been shown to have a major impact in regulating the immune 
response to intracellular bacteria, certain parasites and virus infections. The biological 
activity of IFN-gamma includes three major effects; inhibiting the ability of the pathogen to 
multiply, activating a CMI response, and stimulating macrophages and NK cells activity 
[205,206]. It has been shown that IFN-gamma directly inhibits influenza A replication by 
inducing nitric oxide synthase and nitric oxide (NO) production [207,208].  
It should be mentioned that influenza A viruses have developed mechanisms to 
suppress the host’s innate immune response. Among the 10-11 proteins that influenza A virus 
encodes, the nonstructural-1 (NS1) protein has been shown to suppress the anti-viral IFN  
type I response [44,209] and possibly other proinflammatory cytokines. Pigs infected with a 
recombinant human H1N1 that carried the NS gene of the H5N1 virus from 1997 were 
shown to have prolonged clinical signs such as fever and weight loss, and shed virus for a 
longer period compared to pigs infected with the wild-type human H1N1 virus [210]. It was 
indicated from that study that a glutamic acid at position 92 of the NS1 protein is involved in 
the viral resistant to both the type I IFN and TNF-alpha and is associated with the high 
virulence of the H5N1 that was able to infect and kill humans in 1997. The development of 
the reverse genetic technology has allowed us to gain more insights on the virulence of the 
1918 influenza A virus that was responsible for at least 50 millions death world wide. Data 
suggested a link between the virulence of the 1918 influenza virus to the overt innate 
immune response resulting in the severe respiratory disease that led to high death rates in 
young adults [211]. In the study, genes of the 1918 virus were constructed using a plasmid-
based reverse genetic method and a conventional human virus A/Kawasaki/173/01 (H1N1) 
virus was used as the control virus [211]. Both viruses were used to infect groups of 
cynomolgus macaques. The monkeys infected with the control virus exhibited clinical signs 
with quick recovery and limited viral replication. The group infected with the 1918 virus in 
contrast had high titers of virus both in the upper and lower respiratory tissues and the 
animals became so ill that they were euthanized at 8 DPI, 13 days earlier than the originally 
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scheduled date. Results showed that animals infected with the 1918 virus had increased 
levels of IL-6 in the lungs and sera from 3 DPI and at 8 DPI had a 5 to 25 fold increased of 
IL-6 over the control group. The IL-6 levels correlated with the presence of fever and viral 
shedding and confirmed the theory that IL-6 has a role in the influenza clinical manifestation. 
Microarray data found a surprisingly low IFN-alpha and undetectable IFN-beta1 mRNA in 
the 1918 virus infected monkeys while normal levels were detected in the control group. The 
mechanisms causing the down regulation of IFN-beta1 is currently under investigation. 
However the researchers believe that similar to the NS1 protein of the H5N1, the NS1 protein 
of the 1918 influenza virus possibly had a role in modulating the IFN-mediated antiviral 
response.        
The NS1 N-terminal RNA-binding domain can bind to dsRNA, thereby preventing 
the activation of PKR and IRF-3 [212]. Through the function of its effector domain, NS1 
protein can interfere with the cellular 3’-end processing and splicing machinery, thus 
inhibiting the maturation process of cellular mRNAs [213]. Lastly, it has been demonstrated 
that the NS1 protein is able to selectively enhance the translation of viral mRNAs over 
cellular mRNA [214]. Recently it was found that NS1 mutant viruses that lack the C-terminal 
domains induced significantly more IL-6, TNF-alpha and CCL3 (MIP-1alpha) in infected 
cells compared to levels in cells infected with the wild type A/PR/8/34 virus. In addition, it 
has been suggested that the NS1 protein, through the function of its N-terminal domain might 
control caspase-1 activation which then suppresses the maturation of pro-IL-1beta and pro-
IL-18 [209]. These findings are currently the basis for the development of a new generation 
of safe and immunogenic modified live influenza A virus vaccines.      
Protective antibody response  
Pigs infected with swine influenza virus develop antibodies to the envelope proteins 
including the HA, NA and M2 as well as to the internal proteins, M1, NP, NS1 and NS2. 
Following a primary infection with swine influenza, HA-specific IgM and IgG antibodies 
could be detected using an indirect enzyme linked immunosorbent assay (ELISA) as early as 
3 days post infection (DPI) although a substantial increase in IgM and IgG levels were not 
observed until 5 and 7 DPI, respectively [215]. Western blot analysis detected both IgM and 
IgG antibodies specific for the NP, NS1 and NS2 proteins by 7 DPI while only IgG specific 
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to the NA and M1 proteins were detected at 14 DPI [216]. A separate study evaluated serum 
NP-specific antibodies using a NP-specific ELISA and detected a sharp rise of NP-specific 
IgM from no antibodies at 3 DPI to a maximum level at 7 DPI while NP-specific IgG was 
first detected at 10 DPI [35].  Antibodies to the conserved NP and M1 proteins fail to protect 
against influenza virus infection as passive transfer of monoclonal anti-NP and -M1 
antibodies were insufficient to protect mice from challenge with wild-type influenza A 
viruses [217]. Both the NA- and M2-specific antibodies do not have viral-neutralizing 
capability but instead contribute to reducing virus yield and cell-to-cell spread of the virus 
[41,164,217-219]. Since the two antibodies are not directly correlated to protection against 
disease, the assay to detect NA-specific antibodies, known as neuraminidase-inhibition test 
(NI), is tedious [124] and no commercial serological test is currently available to detect M2-
specific antibodies, so assays for these antibodies are not currently performed. As a result, 
minimal information on the production of antibodies against the NA and M2 proteins is 
available using natural host models for influenza virus infection in comparison to data 
obtained using ferrets and mice, common laboratory animal models for influenza A studies. 
Antibodies to the NA protein have not been widely evaluated in swine influenza viruses and 
their role in protection against disease is unknown. The M2-specific antibody response in 
both mice [167,220] and convalescent human sera [168,169,220] has been reported to be low 
and inconsistently detectable. Consistent with these data, a study in pigs showed a low M2-
specific antibody response to primary swine influenza infection but an increase in antibody 
levels following a heterosubtypic infection was onserved [161]. Both M2- [221], and NA-
specific antibodies [222] can inhibit influenza A virus spread by antibody-dependent cell 
cytotoxicity (ADCC) through NK cell killing of infected cells. A study in mice, demonstrated 
that the M2 antibody-dependent NK cell activity could be induced through vaccination with a 
M2e protein conjugated to hepatitis B core vaccine and that the dominant isotype was IgG2b 
with some IgG2a. These 2 antibody isotypes have been shown to be important mediators of 
ADCC in mice [205,223]. However, the level of M2e antibodies induced by M2e-based 
vaccine were inferior compared to a UV-inactivated influenza virus vaccine against a lethal 
dose virus infection, indicating that HA antibodies are far more effective in protecting against 
disease than M2 antibodies [221]. A previous study demonstrated the presence of antibodies 
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associated with ADCC in 5 out of 10 volunteers that were vaccinated with experimental lots 
of a monovalent A/USSR/77 (H1N1) and trivalent A/ USSR/77 (H1N1), A/Texas/77 
(H3N2), and B/Hong Kong whole virus vaccines [224]. The antibodies were detected early at 
3-10 days after their initial vaccination and the response was found in individuals that had 
been previously primed with the A/USSR/77 (H1N1) viral antigen and those that were not 
primed. A separate study observed antibody reactive ADCC in human sera from young 
children following infection and after vaccination with inactivated and live attenuated 
influenza vaccines [222]. The study indicated that antibodies associated with ADCC induced 
by vaccines were detected earlier than HI antibodies and that the primary response to human 
influenza virus infection induced subtype-specific ADCC antibodies which recognized the 
HA and NA proteins but were not directed towards the internal proteins. The role of HA and 
NA proteins on subtype-specific ADCC antibodies was confirmed with combinations of 
recombinant equine influenza viruses, H1Neq1 (human HA1 with equine NA1), Heq1N1 
(equine HA1 and human NA1) and Heq1Neq1 (equine HA1 and equine NA1). Sera from 
children infected with a H1N1 virus or vaccinated with live attenuated H1N1 vaccine reacted 
to H3N1, H1Neq1, and Heq1N1 (to a lower level) but not to Heq1Neq1 virus. Reinfection 
with a heterologous subtype induced a marked rise of ADCC antibodies to the primary virus 
subtype. This is contrast to the HI antibody response where less than a two-fold change was 
detected in the HI titer against the original subtype when children were infected with a new 
subtype. In summary, these observations suggest that ADCC has an important role in the 
initial stage of influenza infection by reducing viral load and contributes to prevention of 
reinfection possibly with heterologous strains of viruses.         
Of the antibodies produced in response to influenza infection, the antibodies to the 
HA protein are considered the most important as they are primarily responsible for virus 
neutralization [112]. Protective antibodies against infection with swine influenza virus are 
based on both quality and quantity of the antibodies produced. Findings in human, mice and 
ferrets suggests that serum anti-HA antibodies (sIgG) transudates into the bronchoalveolar 
passages and prevents the lower respiratory tract from influenza infection [111,225]. Clinical 
protection against experimentally challenged swine influenza virus induced disease seems to 
correlate with the serum HI titer of the individual pig due to priming of the HA and inducing 
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HI antibodies that are antigenically similar or closely related to the infecting strain [34-37]. 
The mechanism of neutralization by HA antibodies appear to be dependent on the 
concentration and the specific antibody isotype involved [125]. Regardless of isotype and 
virus, direct binding by the antibody to the attachment site of the viral envelope protein 
prevents attachment of virus to the host cell receptor. However, if the antibody binds near the 
attachment site, inhibition of attachment will depend upon the molecular conformation and 
properties such as rotational radius of the antibody isotype. Larger polymeric 
immunoglobulin such as IgM and IgA are thus better able to block influenza virus attachment 
compared to IgG. It has been documented that in addition to blocking virus attachment, 
influenza specific-IgG is able to neutralize the internalized virus by preventing viral fusion 
and thus trapping the virus in the cellular endosomal compartment [226]. Moreover, it has 
been suggested that antibodies that are produced to the virus non-attachment sites such as the 
stalk of HA protein, may play an important role in vivo by fixing complement or mediating 
the lysis of infected cells through ADCC [125,224,227].    
In terms of quantifying HA antibodies, the HI test is the gold standard for measuring 
antibody to influenza virus [34]. In general, HI antibodies are believed to be proportionally 
correlated with the serum neutralization (SN) antibodies and broader antibody-antigen 
reaction patterns to heterologous strains have been observed by HI assay compared to the SN 
assay [228]. However, sera with high SN titers to avian influenza viruses and low or no HI 
activity have been reported [229,230]. The protective level of serum HI antibodies has been 
well defined in human medicine and used extensively for evaluation of clinical trials of 
influenza vaccines. It has been agreed that a serum HI antibody titer of 40 is associated with 
50% of the risk of contracting an influenza infection, also defined as the “50% protective HI 
antibody titer” [231]. In equine practice, HI antibody titers of > 32 for H7N7 and of > 16 for 
H3N8 were estimated to protect against field infection [129]. In swine practice, HI titers are 
normally used for the evaluation of a serological status of the herd for the purpose of vaccine 
evaluation or determination of virus exposure. There is no consensus regarding the cutoff 
value of positive HI antibody levels to swine influenza. At Iowa State University’s 
Veterinary Diagnostic Laboratory (ISU-VDL), a pig with no MDA is considered positive 
with a HI titer of > 40 and HI titers of 10-20 are considered suspicious and may be true 
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positives but may also be due to nonspecific reactions [232,233]. Other researcher’s consider 
positive antibody levels when the reciprocal titers are > 80 [234,235]. An inverse correlation 
between HI antibody titer and the susceptibility to influenza A virus infection has been well 
documented by many experimental models [112,161,235] and therefore are frequently used 
as a marker to indicate exposure to the virus or to assess vaccine efficacy [91,110,112]. 
However, no such agreement exists about the levels of HI antibodies protective against 
clinical disease, particularly against subtype-specific strains of swine influenza viruses.  
Following a primary infection of 2×105 egg infectious dose (EID)50 of a H1N1 
influenza strain, A/Swine/Indiana/1726/88 virus, the HI antibody levels peaked 2-3 weeks 
following infection with a mean titer of ~ 640 and IgG being the dominant virus-specific 
isotype in the serum [235,236]. While virus-specific serum IgA was also detected, the levels 
were approximately 2-4 times lower than IgG titers [235]. A separate study demonstrated a 
quick increase in HI antibodies to a maximum level at 7 DPI following infection with 2×108
tissue culture infectious dose (TCID)50 of H3N2 strain A/Swine/Neth/St.Oedenrode/96 virus 
[234]. The HI antibody levels remained the same until the end of the study at 45 DPI. In this 
study, influenza specific IgA antibodies were first detected at 7 DPI and reached maximum 
titers at 15 DPI. Antibody titers remained high for several weeks and then declined for 3-6 
months after infection. Low levels of antibody could be detected for 1-2 years, unless further 
antigenic stimulation occurred (Collins J, Gramer M, Rossow K, unpublished data). HI 
antibody responses following inactivated virus vaccination differ from those occurring 
following infection. As discussed earlier in the SIV vaccination review section, it takes 2 
vaccinations at 2-3 week intervals to induce a maximum HI antibody response against the 
vaccine virus. In one study, geometric mean titers of HI antibodies to H1N1 and H3N2 
vaccine viruses were < 10 at 2.5 months following the second vaccination [237]. Heinen et al 
(2001), compared the duration and level of the HI antibody response following infection with 
H3N2 strain A/Swine/Oedenrode/96 to the response following the intramuscular 
administration of an inactivated virus vaccine produced from a heterologous H3N2 strain 
A/Port Chalmers/1/73 virus [35].  They detected maximum HI titers in the infected pigs at 7 
DPI compared to the vaccinated pigs where antibodies occurred at 10 days after the second 
vaccine. The HI antibody levels in the infected pigs were approximately 3-fold lower than 
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the antibody levels produced from vaccination however protection conferred by vaccination 
was suboptimal compared to protection from infection-meditated immune pigs.     
The HI antibody response following a secondary infection with a homologous virus, 
consists primarily of an IgG  response and varies from no response to a prominent increase. 
Pigs infected with a dose of 2×105 EID50 virus and rechallenged with the same virus and dose 
did not produce a substantially increased HI antibody response in the serum suggesting that 
there was no stimulation from the viral antigen during reinfection. These results were further 
confirmed by the undetectable virus shedding from any of the rechallenged pigs [235]. A 
different study infected pigs with a 1×106 TCID50 dose virus and rechallenged pigs 28 days 
later with a 2-fold increased homologous virus detected a minimum of a 2-fold rise in the HI 
antibody titer [82]. These findings suggest that an anamnestic HI antibody response occurred 
with homologous virus infection that appears to vary according to differences in challenge 
dose and the level of antibody produced from previous infection.  
It was shown previously that HI antibodies induced from swine influenza inactivated 
vaccines induced a broader antibody specificity than when the HI antibodies were induced 
through infection [35]. It has been reported in humans that vaccination induced cross-reactive 
antibodies were higher compared to those observed with infection [238]. It has been 
demonstrated in a vesicular stomatitis virus model that live virus but not UV-inactivated 
virus induced dendritic cells to transport and release the live virus in the secondary lymphoid 
tissue for the induction of optimal viral-neutralizing B lymphocyte responses [239]. 
Therefore, since the virus vaccine is nonreplicative it may lack the stimulating signals in all 
the necessary cells required for affinity maturation and would explain why inactivated virus 
vaccine induced IgG antibodies have a lower specificity and affinity which possibly can 
result in reduced capability to effectively bind and neutralize the viral pathogen. 
There is only limited data regarding cross-protection by HI antibodies between 
different influenza subtypes in pigs. In general, the H1N1, H3N2 and H1N2 viruses do not 
cross-react in HI antibody assays [240-242]. Therefore separate protocols have been 
established and performed with at least one strain of each subtype for serological diagnosis of 
influenza. A previous study in pigs infected with a H1N1 virus and subsequently challenged 
with a H3N2 virus demonstrated partial protection against secondary infection based on 
38
clinical disease and reduced levels of virus shedding to contact pigs, indicating the induction 
of Het-I [161]. Pigs produced HI antibodies to the H1N1 virus after the primary infection and 
showed a slight increase in HI titers to the H1N1 virus following the secondary infection 
with H3N2 virus indicating production of some cross-reactive HI antibodies. However, 
enhanced M2 antibody responses were detected in pigs challenged with the heterologous 
virus. These findings suggest that externally conserved epitopes also play an important role 
in Het-I. A separate study evaluated cross-protection against a swine H1N2 virus in pigs 
previously infected with either the H1N1 and/or H3N2 viruses using serological assays, virus 
isolation and clinical observations [157]. This study demonstrated that pigs immunized 
previously with both the H1N1 and the H3N2 virus were protected against infection with a 
H1N2 virus as no disease or significantly reduced virus was detected in infected pigs. 
However, it was found that prior to challenge with the H1N2 virus, all pigs that had 
previously been infected with either the H1N1 or H3N2 viruses or a combination of both 
viruses, had no HI cross-reactive antibodies to H1N2 virus. When pigs were subsequently 
challenged with the H1N2 virus they all seroconverted to the H1N2 virus at 14 DPI. The 
study detected an increase in NI antibodies against all viruses suggesting that these 
antibodies are important, but not the sole contributor to Het-I and serum HI antibody 
responses had a minor role. The minor role of serum HI antibodies in Het-I was confirmed in 
a subsequent study where pigs immunized with H1N1 and H3N2 inactivated virus vaccines 
were challenged with a H1N2 virus [243]. While the vaccine induced HI antibodies to both 
subtypes by vaccination and 11 of 35 pigs had HI cross-reactive antibodies to H1N2, pigs 
were not protected against H1N2-induced disease by the bivalent vaccine.  
These data demonstrate that HI antibodies induced by swine influenza infection are 
detected faster than antibodies induced by immunization with inactivated virus vaccines. The 
serum HI antibodies play a major role in protection against infection with homologous 
viruses or a heterologous strain that is antigenically similar to the virus inducing earlier 
infection. The serum HI antibody responses that are induced following infection are specific 
to the homologous virus while the HI antibodies induced through parenteral inactivated 
vaccination have a broader cross-reactive specificity against heterologous strain virus. In 
terms of cross protection against heterosubtypic viruses or Het-I, the serum HI antibody 
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response induced from inactivated virus vaccination provides limited protection against a 
heterosubtypic challenge. Infection appears to provide a better protection to a subsequent 
heterosubtypic infection compared to inactivated virus vaccination, and the serum HI 
antibody has not been shown to be essential in providing Het-I protection.     
Mucosal immune response 
Secretory (s) IgA is an important component of the mucosal immune system. Thus, 
sIgA are locally produced and then selectively secreted onto mucosal surfaces as mediated by 
the polyimmunoglobulin receptor (PIgR) and an active transport mechanism [244]. The PIgR 
are expressed on the basolateral surface of epithelial cells lining the secretory mucosa. The 
majority of the plasma cells in the lamina propria beneath the epithelial surface are 
committed to IgA production [245]. Secretory IgA (sIgA) in the mucosa has an essential role 
in preventing the invasion of mucosal areas by pathogens by either blocking organism 
attachment or neutralizing the pathogen and down-regulating the systemic immune response 
[246,247]. This type of immune response is typically observed with viruses such as 
coronaviruses and influenza viruses, since the presence of sIgA have been strongly correlated 
with resistance to infection [140,248]. A study in the early 90s showed that the level of virus 
neutralization depends on the level of IgA, as high concentrations of influenza anti-HA IgA 
antibodies inhibited viral attachment to tracheal epithelial monolayers while lower 
concentrations of antibodies reduced the neutralization efficacy. Neutralization by sIgA was 
previously thought to result from binding of antibody to the viral receptor-binding proteins 
extracellularly in the lumen, thereby preventing adherence to epithelial cells. Additional 
findings in influenza viruses have demonstrated that IgA, when actively transported through 
epithelial cells by PIgR, can encounter and bind intracellularly synthesized influenza proteins 
and thus prevent viral assembly [245]. The process begins when the PIgA-IgA complex is 
delivered to basolateral endosomes and then routed to apical recycling endosomes in which 
the newly synthesized viral glycoproteins are transported to the apical surface. The 
intracellular mechanism of IgA in reducing viral replication allows elimination of the 
intracellular pathogen while preserving the epithelium.  
Using a swine model, studies have been conducted to investigate the mucosal 
immune response of both the upper and lower airways. Following infection, SIV-specific 
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antibody secreting cells for both IgG and IgA were detected in the nasal mucosa indicating 
that both SIV-specific isotypes can be produced locally in addition to SIV-specific IgG 
transudated from serum [235]. SIV-specific antibodies in the nasal wash fluids (NW) and 
BAL fluids were detected as early as 4-5 days post primary SIV exposure [215,235]. The 
predominant SIV-specific antibody isotype found in both mucosal areas following primary 
infection was IgA, as oppose to IgG, which was the highest isotype detected in serum 
[35,92,234]. The level of IgA peaked at 14 DPI and was over 100-fold higher than IgG in 
NW. The level of local IgA increased following a secondary infection with homologous virus 
infection and is responsible for the lack of anamnestic response of serum antibodies 
presumably due to the lack of stimulation of the systemic immune response by infection 
since IgA readily neutralizes the virus [35,235]. It should be noted that the local antibody 
produced following experimental infection depends largely upon the inoculation route as an 
intracheal challenge was shown to induce high SIV-specific antibodies in BAL but minimal 
levels in NW [92] while a intransal challenge route demonstrated higher levels of SIV-
specific antibodies in NW [235].   
The production of a vaccine that is capable of inducing an effective mucosal immune 
response for influenza virus protection is one of the ultimate goals for protection against 
disease in the field. Vaccination with SIV inactivated vaccines has demonstrated variable 
levels of IgA detected in the mucosal areas. There is agreement that inactivated virus 
vaccines alone without infection produces a disappointing IgA level at the mucosal level 
[35,92,249]. Vaccination followed by influenza virus infection demonstrated conflicting 
results. A trivalent inactivated intranasal anti-influenza A virus vaccine was found to elicit 
mucosal sIgA antibodies in children, adults and elderly [250,251]. Studies in swine indicated 
that an inactivated virus vaccine was able to prime the local immune response as pigs 
vaccinated followed by viral challenge had higher levels of IgA in BAL fluids compared to 
nonvaccinated-challenged pigs [38,92]. In contrast, earlier studies showed no impact by the 
inactivated virus vaccine on the IgA levels following infection [35,234].     
Following influenza A virus infection, the serum IgG- influenza antibodies become 
highly specific while local sIgA have been found to have a broader spectrum of activity 
[249,252].  Thus, cross-protection in mice was shown to correlate with the pre-existing 
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mucosal IgA rather than serum IgG antibody levels [140,141,253]. The kinetics of the 
heterosubtypic cross-protection in the early phases of influenza infection (0-3 DPI) was 
studied by measuring the influenza viral-Ig complex following infection [135] and found to 
be correlated to the efficiency of viral elimination. When entering the second phase of 
infection at 3 DPI and later, the challenge virus that was not eliminated by the formation of 
immune complexes was then eliminated by secondary CD8+ cytotoxic T cells. A recent 
study evaluated cross-protection between a H1N1 and H1N2 viruses that contained HA genes 
that were genetically distinct and had no serological cross-reactivity by HI test [254]. This 
study demonstrated that SIV-specific IgA was important in protection against heterosubtypic 
infection. Both H1N1 and H1N2 viruses were used for the preparation of inactivated vaccine 
and used as challenge viruses in conventional pigs. Pigs were primed with the inactivated 
vaccines and challenged with both the homologous and heterologous viruses. Both vaccines 
demonstrated excellent protection against homosubtypic challenge. It was demonstrated that 
the inactivated vaccine induced no serum HI cross-reactive antibodies with the 
heterosubtypic virus and thus pigs vaccinated with the H1N1 vaccine failed to protect against 
the H1N2 infection. Interestingly, 3 out of 9 pigs in that group had a significantly higher 
percentage of pneumonia determined by macroscopic lung lesions compared to the non-
vaccinated H1N2 challenged control pigs. Mucosal IgG levels were also increased, but IgA 
levels detected in the lungs of the 3 pigs with increased pneumonia were low, while increased 
IgA levels were detected in the other 6 pigs that did not have enhanced lung lesions. These 
results suggest that the lung lesion potentiation may have been caused by immune mediation 
presumably through high levels of H1N1-specific IgG that were incapable of neutralizing the 
H1N2 virus in the lung tissues. It was suggested in the study that non-neutralizing antibodies 
active in ADCC and/or antibody dependent enhancement (ADE) may play a role as ADCC 
was demonstrated through influenza vaccination and influenza A infection was demonstrated 
in a mice model [255]. The true mechanism of the lung lesion potentiation is unknown. 
However, the finding demonstrates the importance of a balanced immune response 
particularly in the mucosal area between the quality and quantity of the antibodies in 
controlling influenza virus infection.  
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Cellular mediated immune response 
 Cellular immune responses are mediated by both cluster of differentiation (CD) 4+ 
and CD8+ T cells. CD8+ T cells recognize short (~8-10 amino acids) peptides presented by 
MHC class I molecules while CD4+ T cells recognize longer (~13-17 amino acids) peptides 
presented by MHC class II molecules. The effector mechanism of CD8+ and CD4+ T cells 
are cytotoxicity and helping provide antibody responses, respectively. Both CD8+ and CD4+ 
are capable of secreting cytokines and chemokines that have antiviral activity and help 
mediate the antiviral affects [205]. Swine T lymphocytes have been defined into four major 
subpopulations including, CD4+CD8-, CD4-CD8+, CD4+CD8+ and CD4-CD8- [256-260]. 
One unique character of the pig’s T lymphocytes is that they have significant amount of 
extra-thymic CD4+CD8+ T cells that appears to increase with age [258,261]. It has been 
suggested that these CD4+CD8+ T cells have a role as memory cells as demonstrated by the 
ability of these cells to respond to recall antigens [261]. Another unique character of the CMI 
in pigs is that they have higher proportion of CD4-CD8- T cells compared to human and 
rodents [257]. This population of cells expresses the gamma-delta T cell receptor and are 
known as gamma-delta T lymphocytes [262,263]. It appears that gamma-delta T cells do not 
require antigen processing and presentation of peptide epitopes antigen in the context of the 
major histocompatibility complex (MHC) [205]. However, the function and role of gamma-
delta T lymphocytes in the immune response to viruses is poorly understood and requires 
further investigation.    
 In general, the primary CMI response to respiratory viral infection leads to activation 
of lung-resident dendritic cells which subsequently traffic to the local draining lymph nodes. 
The dendritic cells then display the antigen, activate and induce proliferation of the naïve T 
cells [264] that will acquire their effector function and migrate to the site of infection. Mature 
dendritic cells which have processed the influenza virus are required for activation of 
influenza A virus-specific T cells following primary infection [265]. Studies in mice show 
that cytotoxic CD8+ T cells are first detectable at day 7 and peak 9-10 days following 
infection in the lung. The cytotoxic CD8+ T cells play a major role in the clearance of 
influenza A virus through direct cytolytic effect on virally infected cells involving perforin 
and/or Fas [266,267]. The memory CD8+ T cells to influenza viruses have been shown to 
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correlate with clearance of the virus from the respiratory tract, but have not been correlated 
with susceptibility to infection in humans [268]. In pigs, a massive infiltration of cytotoxic 
CD8+ T cells was found at 8 DPI with a decrease in the percentage of NK cells in BAL 
fluids that had infiltrated in the early phases of infection [161]. The primary CD4+ T cells 
response peaked in the lung and BAL fluids at 6-7 DPI in mice [269] and between 4-11 DPI 
in pigs [161]. The Th1 cytokine profile including IL-2, IFN-gamma and TNF-alpha is also 
present at that time point.  In contrast to CD8+ T cells, the role of CD4+ T cells involves 
maintaining memory CD8+ T and B cell responses rather than having a direct role in viral 
clearance [270,271]. Previous reports have shown that the generation of neutralizing 
antibodies is dependent on CD4+ T cell help [272]. The variable HA and NA surface 
glycoproteins are processed and presented via the MHC class II and recognized by the CD4+ 
T cells. These CD4+ T cells stimulate the production of specific antibodies against the HA 
and NA molecules which play a major role in protecting against secondary infection to 
homologous viruses. In addition, it has been shown in CD8 deficient mice that a primary 
CD4+ T cell response can not promote recovery from infection in the absence of B cells 
[273]. This was in spite of evidence that passive transfer of large numbers of influenza A 
vius-specific CD4+ T cells into either immune competent or nude mice resulted in reduced 
viral load in the lungs and enhanced survival rate following challenge with a lethal dose of 
influenza A virus [274]. Thus, protection was not due to the accelerated induction of specific 
antibody production and it has been postulated that it is mediated by the release of Th1 
cytokines (IFN-gamma and TNF-alpha). These contradictious findings in mice are still 
subject to debate and it is hard to summarize which response is of most clinical importance. 
However, all CD4+, CD8+ and B cells appear to contribute to the control of influenza virus 
replication and respiratory disease.  
The cytokine, IFN-gamma, exerts multiple effects including directly inhibiting virus 
replication, promoting apoptosis of infected cells, and up regulating antigen processing and 
presentation via the context of MHC. The result of these stimulation actions is of a CMI 
response that includes T cells, macrophages and NK cells [205]. A study in mice revealed 
that IFN-gamma has a protective role during the recall response to different influenza A 
isolates of differing subtypes [275]. A study detected a strong IFN-gamma response to a 
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H1N1 SIV in experimentally infected pigs in cells of the tracheal bronchial lymph nodes and 
spleen at 21 DPI [235]. The IFN-gamma levels were lower in the respiratory mucosal areas, 
but levels increased following a secondary infection with the homologous virus. A different 
study reported that a recombinant M1 protein stimulated the production of IFN-gamma in 
CD4+CD8- T cells in the peripheral blood mononuclear cells from pigs previously infected 
with either a H3N2 SIV or a combination of both H1N1 and H3N2 viruses [276]. Other 
internally conserved antigens are the targets for CD8+ T cells, but the NP has been shown to 
be the strongest candidate of those antigens [277]. Studies in mice demonstrated the role of T 
cell immunity in protecting against heterologous challenge with strains of influenza viruses 
of different subtypes [275]. Cross-protection between subtypes has been reported in the 
absence of antibodies and has been correlated with a secondary CD8+ cytotoxic T cell 
response [278]. Support of this data has been that mice previously infected with an H1N1 
virus were cross-protected against subsequent challenge with an H3N2 virus and it has been 
shown that both CD8+ and CD4+ T cells were involved in the nasal regions whereas in the 
trachea and lung only CD8+ T cells were involved [279]. It was evident in Ig and B cell 
knockout mice that heterosubtypic protection mediated by the CD8+ and CD4+ T cells was 
efficient in regard to virus reduction and when these T cells were depleted the cross-
protection was eliminated [280]. Following secondary influenza virus infection in pigs, an 
increase in cytotoxic CD8+ T cells was observed when pigs that were infected with a 
heterosubtypic virus, but not homosubtypic virus, implying that these cells are involved in 
Het-I response [161].  
In summary, it appears that CMI plays an important role in the clearance of the virus 
following an influenza virus infection. In addition CMI is believed to be an essential 
component of Het-I as demonstrated by the reponse following secondary infection with a 
heterologous subtype. It is generally agreed that inactivated influenza vaccines primarily 
induce virus-specific serum IgG responses, but poor CMI responses [20,35,135]. Thus, 
inactivated vaccines are relatively ineffective in providing protection against both subtype-
specific strain variations and heterosubtypic viruses. In this case, the use of modified live 
virus for immunization by a mucosal route may increase the protective efficacy of vaccine 
through CMI enhancement.  
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Abstract 
The objective of this study was to assess the effect of concurrent infection with 
porcine reproductive and respiratory syndrome virus (PRRSV) on the efficacy of an 
inactivated swine influenza virus (SIV) vaccine.  Eight groups of pigs were used in the study. 
One group was infected with a virulent PRRSV isolate between the two SIV vaccines or at 
the time of SIV challenge.  Control groups included SIV vaccination without PRRSV and 
pigs infected with SIV and/or PRRSV.  Pigs infected with PRRSV during vaccination 
showed increased levels of macroscopic and microscopic lesions compared to pigs 
vaccinated against and challenged with only SIV. The presence of PRRSV decreased SIV 
vaccine efficacy as measured by increased clinical disease and levels of SIV shedding at the 
acute phase of infection. No alterations in systemic and local antibody response to either SIV 
vaccination or challenge were observed. These findings demonstrate the impact that PRRSV 
infection has on SIV vaccine efficacy is important for disease control.  
Keywords: Influenza; SIV; PRRSV; vaccine 
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1. Introduction 
Porcine respiratory disease complex (PRDC), characterized by pneumonia and 
reduced growth performance, is an economically significant respiratory disorder of nursery 
and finishing pigs and remains a challenge to the swine industry worldwide.  Multiple agents 
have been reported to be associated with PRDC including porcine reproductive and 
respiratory syndrome virus (PRRSV), Mycoplasma hyopneumoniae (MHYO), swine 
influenza virus (SIV), Pasturella multocida and porcine circovirus type 2 (PCV2) [1]. 
However, a previous study indicated SIV and PRRSV to be the primary etiological agents 
associated with respiratory disease of pigs in the mid-western region of the U.S. [2]. 
 In general, SIV-specific passive immunity from vaccinated sows persists up to 8 to 12 
weeks of age [3]. Therefore, SIV typically infects pigs in the late nursery and early finishing 
stages as SIV-specific passive immunity wanes [4].  To protect pigs from SIV-induced 
disease, active immunity is induced through the use of SIV vaccination strategies. Current 
SIV vaccines in the U.S. are inactivated vaccines that are approved for use in pigs 3 weeks of 
age or older and require a second injection administer 2-3 weeks following the first 
vaccination. With the exception of mismatching between the vaccine and challenge strains, 
SIV vaccination in seronegative pigs appears to be effective in experimental studies [5,6]. 
However, failure of SIV vaccine efficacy in the field has been reported with SIV disease 
outbreaks occurring in vaccinated farms. PRRSV, as opposed to SIV, can be transmitted 
transplacentally during gestation in addition to direct physical contact after birth [7,8]. 
Accordingly, young, nursery age pigs from PRRSV-infected sows can readily be infected 
from their dams or littermates, potentially becoming a source of infection to pigs in 
subsequent production stages. Since PRRSV infection often occurs as SIV maternal 
immunity wanes, pigs can be infected with PRRSV at the time of SIV vaccination making 
the influence of PRRSV infection on SIV vaccine efficacy a concern to swine producers and 
veterinarians.  However, data of the impact of PRRSV infection on SIV vaccination efficacy 
is minimal.  
PRRSV and SIV co-infection studies have yielded conflicting results with regard to 
clinical disease interactions, ranging from enhancement [9] to minimal disease overall [10]. 
Perhaps more importantly, PRRSV impact on swine vaccines indicates that the timing of 
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PRRSV infection may influence vaccination outcome. A study performed in our lab found 
that the presence of PRRSV either from a MLV vaccine or infection during or within 2 
weeks of inactivated MHYO vaccination significantly decreased the ability of the MHYO 
vaccine to reduce the percentage of MHYO associated lung pneumonia [11]. In contrast, 
another study demonstrated that administration of an MLV PRRSV vaccine to MHYO-free 
pigs at 7 days prior to vaccination with MHYO inactivated vaccine did not interfere with the 
MHYO vaccine efficacy or immune response to MHYO infection [12]. Two additional 
studies have also documented the negative impact of PRRSV infection 2 days [13] or 7 days 
prior administration of a MLV classical swine fever vaccine [14]. However, no studies have 
been conducted to investigate the impact of PRRSV infection on SIV vaccine efficacy. 
Therefore, the objective of the study reported here was to investigate the influence of PRRSV 
infection on inactivated SIV vaccine efficacy using a North American high virulent strain of 
PRRSV. The impact of the PRRSV infection on SIV vaccine efficacy was evaluated using 
clinical disease symptoms, macroscopic and microscopic lung lesions, virus isolation and 
immunological parameters. The PRRSV infection was placed between SIV vaccines based 
on the earlier studies using MHYO vaccines [11]. In addition, the impact of PRRSV infection 
2 weeks following SIV vaccination was also assessed to provide increased understanding of 
the temporal relationship between PRRSV infection and SIV vaccine efficacy. 
Understanding the impact of PRRSV infection on SIV vaccines provides important 
information regarding both the immunology of PRRSV infection and the development of 
successful intervention strategies to control important respiratory pathogen such as influenza 
in pigs.  
2. Materials and methods 
2.1. Experimental design   
2.1.1 Animals 
Ninety-six 8- to 12-day-old crossbred pigs, obtained from a commercial herd 
serologically negative for PRRSV, MHYO and SIV, were used in the study. Pigs were 
assigned to groups with stratification by arrival weight to 8 groups of 12 pigs. Throughout 
the study, pigs were housed in identical isolation rooms based on their challenge status. Pigs 
were provided feed and water ad libitum throughout the trials. The experimental design is 
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summarized in Table 1. All study procedures and animal care activities were conducted in 
accordance with the guidelines and under the supervision of the Iowa State University (ISU) 
Institutional Committee on Animal Care and Use.  
 
Table 1 
Experimental design.  
 Challenged with: No. of pigs necrosied at: 
Groups SIV Vaccinea SIV PRRSV  7 DPIb 28 DPI 
NEG   No No   No            6           6 
VS[7]   Yes Yes (7)c No            6           6 
S[7]   No Yes (7)   No            6           6 
VS[7]P[4]   Yes Yes (7)   Yes (4)            6           6 
V Yes No   No            6           6 
VS[7]P[7]   Yes Yes (7)   Yes (7)            6           6 
S[7]P[7]   No Yes (7)   Yes (7)            6           6 
P[7]   No No   Yes (7)            6           6 
a Pigs received SIV vaccination at 3 and 5 weeks of age. 
b DPI = days post infection. 
c Weeks of age that the pigs were challenged with SIV or PRRSV. 
 
2.1.2 Vaccine and challenge inocula 
Pigs were vaccinated with a commercial bivalent SIV vaccine (End-FLUence®-2, 
Intervet Inc., Millsboro, DE, USA) containing a newer classic H1N1 and a clade I H3N2 [15] 
according to label directions at 3 and 5 weeks of age. A North American virulent strain of 
PRRSV, VR-2385, was administered intranasally (1 ml/nostril) to pigs in the appropriate 
groups at a dose of 105.6 TCID50/ml, at either 4 or 7 weeks of age, as previously described 
[16]. A virulent classic H1N1 strain (A/Swine/IA/40776/92) was administered intratracheally 
to pigs of the appropriate groups at a dose of 105.5 TCID50/ml (4 ml) at 7 weeks of age [17]. 
PRRSV and SIV were propagated and titrated in MARC-145 and Madin-darby canine kidney 
(MDCK) cells, respectively. Viruses used for challenge and for serological tests were below 
the 5th cell culture passage. The day of SIV inoculation was designated as 0 days post 
infection (DPI).  
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2.2 Laboratory investigations 
2.2.1 Clinical evaluation and production parameters 
Clinical signs including cough, respiratory rate and rectal temperature were evaluated 
daily from 1 day prior to challenge until 7 DPI. Each pig was assigned a daily respiratory 
score (0-3) for respiratory distress associated with SIV. Scoring:  0 = normal; 1 = mild 
dyspnea at rest; 2 = moderate dypsnea and/or tachypnea at rest; 3 = severe dyspnea and 
tachypnea with distinct abdominal breathing. Pigs with rectal temperatures ] 40 0C were 
considered to be febrile. Pigs were weighed upon arrival, prior to challenge, and at necropsy 
to evaluate weight gain.    
2.2.2 Macroscopic and microscopic lesions 
One-half of the pigs in each group were necropsied at 7 DPI and the remaining pigs 
were necropsied at 28 DPI. Lesions consistent with SIV pneumonia (dark red-to-purple 
lobular consolidation) were sketched onto a standard diagram and assessed for percentage of 
lung surface exhibiting lesions as determined from a diagram using a Zeiss SEM-IPS image 
analysis system as previously described [17]. PRRSV lesions were scored as a percentage of 
affected lungs as previously described [16]. Bronchial swabs were obtained from each pig 
and cultured for swine respiratory bacteria using standard microbiologic procedures.  
Tissue samples were collected from each lung lobe, fixed in 10% neutral buffered 
formalin, processed and embedded in paraffin using an automated tissue processor. SIV-
induced lesions were examined only from affected lobes. Lung sections were examined 
microscopically and given a score (0-3) SIV-associated lesions of bronchiolar epithelial 
necrosis based on disruption or attenuation of the epithelial lining of the bronchi and 
epithelial cell proliferation. PRRSV-induced pneumonia lesions were scored (0-3) based on 
the severity of interstitial pneumonia. Lung sections cut from one paraffin-embedded lung 
tissue block, which included 2 pieces (1 by 2 cm) of lung were used to detect SIV-specific 
antigen [18] and PRRSV-specific antigen [19] according to previously described 
immunohistochemistry (IHC) staining protocols.  
2.2.3 SIV isolation  
Nasal swabs were collected and placed in infecting medium on days -1, 2, 5, 7 and 12 
DPI to evaluate the level of SIV shedding. Virus isolation was performed followed by SIV 
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detection using immunocytochemistry (ICC) staining as previously described [6]. Briefly, 
ten-fold serial dilutions of the swab samples were prepared in infecting medium and 
inoculated onto Madin-Darby Canine Kidney (MDCK) cells in a 96-well tissue culture plate 
and incubated at 37 0C with 5% CO2 for 48 hours. Cells were fixed with 4% phosphate-
buffered formalin and washed with 0.5% Tween-20 in phosphate buffered saline (PBS). An 
anti-influenza A nucleoprotein monoclonal antibody (clone HB-65, ATCC, Rockville, 
Maryland) was used as the primary antibody followed by rabbit anti-mouse IgG conjugated 
horseradish peroxidase (Dako Cytomation, Carpinteria, California) as the secondary 
antibody. The color was developed using the chromogen aminoethyl carbazole substrate 
(Sigma, St. Louis, Missouri). Each assay included mock-infected negative control cells and 
positive control cells infected with SIV with a known titer. The viral titer in each nasal swab 
was expressed as log 10 TCID50 per milliliter.     
2.2.4 Serology 
Serum samples were collected prior to each vaccination (-28 and -14 DPI), prior to 
challenge (-1 DPI) and at 6 and 27 DPI. Sera were tested for SIV antibodies by 
hemagglutination-inhibition (HI) assay. The HI assay was performed according to the 
standard protocol routinely performed at ISU-Veterinary Diagnostic Laboratory [20] using 
0.5% rooster erythrocytes for hemagglutination and 8 hemagglutination (HA) units per 50 µl
of the challenge virus strain A/Swine/IA/40776/92 (H1N1). Antibodies against PRRSV were 
measured prior to the first vaccination and at 6 and 27 DPI by a commercially available 
enzyme-linked immunosorbant assay (ELISA) (HerdChek: PRRS; IDEXX Laboratories, 
Inc., Westbrook, Maine) according to the manufacturer’s protocol. Samples were considered 
positive for PRRSV if the calculated sample to positive control (S/P) ratio equal to or greater 
than 0.4. 
2.2.5 SIV-specific antibodies in lower airways 
 Bronchoalveolar lavage (BAL) fluids were collected at each necropsy. To collect 
BAL, the lungs were lavaged with 50 ml of collecting solution (sterile PBS with 1% BSA, 
300 U/ml penicillin and 300 mg/ml streptomycin). Samples were stored at –20 0C prior to 
testing. The BAL fluids were incubated at 37 0C for 1 hr with an equal amount of 10 mM 
dithiothreitol (DTT) to disrupt mucus present in the fluids. ELISA assays for SIV-specific 
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antibodies in the lower respiratory tract was performed as previously described [6]. In brief, 
inactivated challenge virus was diluted to a hemagglutination (HA) concentration of 100 HA 
units/50 µl. Immulon-2HB 96-well plates (Dynex, Chantilly, VA) were coated with 100 µl of
SIV antigen and incubated at room temperature overnight. Plates were blocked for 1 hr with 
100 µl of 10% BSA in PBS and washed 3 times with 0.05% Tween 20 in PBS (PBS-T). The 
assay was performed on each BAL sample in triplicate. Negative controls (DTT with equal 
amount of PBS solution) were included on each plate.  Plates were incubated at room 
temperature for 1 hr, washed 3 times with PBS-T, then incubated with peroxidase-labeled 
goat anti-swine IgG (Kirkegaard and Perry, Gaithersburg, MD) or peroxidase-labeled goat 
anti-swine IgA (Bethyl, TX) at 37 0C for 1 hr. ABTS/peroxidase was added as the substrate 
(Kirkegaard and Perry, Gaithersburg, MD). Antibody levels were reported as the mean 
optical density (OD) and the mean OD of each treatment group was compared. 
2.3 Statistical Analysis 
Data were subjected to analysis of variance and pairwise comparisons between the 
different treatment groups were performed by least significant difference using Statistix for 
Windows Version 7 (Analytical Software, Tallahassee, FL). For all analysis, statistical 
differences between groups were considered when p < 0.05.   
3. Results 
3.1 Clinical disease 
SIV vaccination did not prevent SIV-induced clinical disease as all SIV challenged 
groups had increased rectal temperatures at 1 DPI. Pigs vaccinated in the absence of PRRSV 
(group VS[7]) had fever for only one day post SIV inoculation while pigs that received the 
SIV vaccine and were infected with PRRSV, group VP[4]S[7] were febrile for several 
additional days.  Non-vaccinated PRRSV and SIV co-infected pigs (group S[7]P[7]) had 
mean rectal temperatures of 40.8 0C at 1 DPI and remained febrile throughout the 6 days that 
rectal temperatures were measured. Fever induced by PRRSV infection appeared at 2 DPI 
and persisted longer than fever induced by SIV alone (Table 2).  Pigs in the non-challenged 
groups (NEG and V) had normal rectal temperatures throughout the study.   
Weight gain was assessed from one day prior to infection until 28 DPI. SIV 
vaccination did not affect weight gain as group V had a similar weight gain as compared to 
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the nonvaccinated, nonchallenged controls (group NEG). Single infection with SIV or 
PRRSV at 7 weeks of age also did not significantly reduce weight gain when compared to 
group NEG.  In contrast, all groups infected with both pathogens (despite vaccination status) 
had significantly reduced weight gain. The SIV vaccinated pigs that were challenged with 
PRRSV between vaccines (VS[7]P[4]) had the lowest rate of gain, although it was not 
significantly different than the other groups infected with both pathogens. 
Coughing was minimal throughout the trial period, but was observed in 2 pigs from each of 
groups S[7], VP[4]S[7] and VS[7]P[7] and 1 pig from group P[7]. The average daily 
respiratory scores from 1-7 DPI were significantly higher in co-infected groups, independent 
of SIV vaccination status compared to all other groups. Based on clinical signs, pigs infected 
with both SIV and PRRSV at 7 weeks of age with or without SIV vaccination exhibited the 
most clinical disease. 
 
Table 2  
Summary of clinical observations following infection with SIV and/or PRRSV. Data 
expressed as group average of original data ± SEMa
Groups No. of pigs cough Respiratory Scoreb Days Febrilec Gain per dayd
NEG 0/12 0.0 ± 0.0 a 0.2 ± 0.4 a 674 ± 26 c
VS[7] 0/12 0.0 ± 0.0 a 1.0 ± 0.2 a,b 642 ± 16 b,c 
S[7] 2/12 0.3 ± 0.1 b 1.6 ± 0.2 b 629 ± 18 b,c 
VS[7]P[4] 2/12 0.2 ± 0.1 a,b 1.6 ± 0.5 b 551 ± 37 a
V 0/12 0.0 ± 0.0 a 0.4 ± 0.2 a 669 ± 38 c
VS[7]P[7] 2/12 1.8 ± 0.1 d 3.4 ± 0.6 c 571 ± 23 a,b 
S[7]P[7] 0/12 1.9 ± 0.2 d 4.4 ± 0.5 c 577 ± 19 a,b 
P[7] 1/12 1.3 ± 0.1 c 4.2 ± 0.5 c 631 ± 22 b,c 
a Within each column, values with different bold superscripts are significantly different by 
least significant difference (p < 0.05). 
b Average daily score from 1 to 7 days post SIV and/or PRRSV infection. 
c Proportion of days (out of 7 total) that each pig’s rectal temperature was > 104oF. 
d Daily weight gain (grams) from -1 to 28 days post SIV and/or PRRSV infection. 
 
3.2 Macroscopic and microscopic lesions 
The estimated percentage of lung tissue with visible SIV and/or PRRSV-induced 
pneumonia (macroscopic lesions) is summarized in Table 3. At 7 DPI, pigs co-infected with 
PRRSV and SIV demonstrated the highest percentage of SIV-induced pneumonia. However, 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PRRSV infection (group VP[4]S[7]) did not differ from groups VS[7]P[7] and S[7].  Pigs 
vaccinated for SIV in the absence of PRRSV (groups VS[7]), and VS[7]P[7] had SIV lung 
lesions similar to NEG pigs, indicating effective vaccine protection against SIV if pigs 
become infected with PRRSV following SIV-vaccination. By 28 DPI, there were no 
differences in the percentage of pneumonia consistent with SIV in any of the SIV infected 
groups, independent of PRRSV infection or vaccination status.  
Only groups that were challenged with PRRSV at 7 weeks of age had significant 
PRRSV-induced lesions at either necropsy (Table 3). Interestingly, at 28 DPI the severity of 
PRRSV-associated lesions was significantly higher in the unvaccinated dual infected pigs 
and pigs vaccinated for SIV in the face of PRRSV challenge (Groups S[7]P[7] and 
VP[4]S[7]) compared to the VS[7]P[7] group. 
Microscopic lesions (Table 3) consistent with SIV infection at 7 DPI were prominent 
in groups S[7], VP[4]S[7], and S[7]P[7] and the IHC test confirmed the presence of SIV-
antigen.  Pigs in groups VS[7] and VS[7]P[7], had similar microscopic lesion scores to 
groups SIV and the NEG. By 28 DPI, the lesions associated with SIV infection had resolved 
in all groups. Interstitial pneumonia associated with PRRSV infection at 7 DPI was 
significantly greater in pigs co-infected at 7 weeks of age independent of their vaccination 
status (groups VS[7]P[7] and S[7]P[7]) compared to the NEG group. Viral antigen detection 
by IHC confirmed the presence of PRRSV antigen only in pigs challenged with PRRSV. At 
28 DPI, microscopic lesion associated with PRRSV in group S[7]P[7] remained significantly 
greater than the NEG control group while the lesions in SIV vaccinated group (VS[7[P[7]) 
and PRRSV infected group (P[7]) had resolved.  
3.3 SIV isolation 
Isolation of SIV was performed using nasal swabs to evaluate virus excretion 
shedding in relation to SIV vaccination (Fig. 1). Group S[7] shed significantly more virus at 
both 2 and 5 DPI than any other group. Infection with PRRSV in addition to SIV (group 
S[7]P[7]) did not prolong SIV shedding, although the levels of virus were greater at 5 DPI 
than either VS[7] and VS[7]P[7]. At 2 DPI, group VP[4]S[7] shed significantly higher levels 
of virus compared to the other SIV-vaccinated groups, VS[7] and VS[7]P[7].  In addition, 
pigs in group VP[4]S[7] shed virus for a longer period compared to all other groups, as at 7  
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Fig. 1. SIV titers in nasal swabs collected at 2, 5 and 7 days post infection (DPI) from 
vaccinated, SIV-challenged at 7 weeks of age (wks) pigs (VS[7]), nonvaccinated, SIV-
challenged at 7 wks pigs (S[7]), vaccinated, SIV-challenged at 7 wks, PRRSV-challenged at 
4 wks pigs (VS[7]P[4]), vaccinated, SIV-challenged at 7 wks, PRRSV-challenged at 7 wks 
pigs (VS[7]P[7]) and nonvaccinated, SIV and PRRSV-challenged at 7 wks pigs (S[7]P[7]). 
Data expressed as group average ± SEM with different letters (a, b, c) were statistically 
different within the same dpi (p ` 0.0001). The results of non SIV-challenged groups are not 
included.  
 
Fig. 2. Average serum hemagglutinin-inhibition (HI) antibody titers to the SIV challenge 
isolate from pigs prior to the first vaccination (-28 days post infection; DPI), prior to second 
vaccination (-14 DPI), prior to SIV and/or PRRSV infection at 7 weeks of age (-1 DPI) and 
prior to both necropsy dates (6 and 27 DPI). The nonvaccinated, nonchallenged group (NEG) 
and the nonvaccinated, PRRSV infected group (P[7]) are not shown. Different letters (a, b, c, 
d) within each time point were significantly different (p<0.0001).   









































































DPI a low amount of virus was detected while other groups were virus negative. No virus 
was isolated from nasal swabs collected from non-SIV infected groups at any time 
throughout the trial.  By 12 DPI, all groups were negative for virus (data not shown). 
3.4 Serology 
Two weeks following the first vaccination all SIV vaccinated pigs had low HI titers 
while all other groups remained seronegative (Fig. 2). At 2 weeks after the second 
vaccination and prior to challenge with SIV and/or PRRSV (at 7 weeks of age), all SIV-
vaccinated pigs had mean HI antibody titers ranged from 40-160. However, it should be 
noticed that group [7]P[4] which was infected with PRRSV at 4 weeks of age had the lowest 
level of HI antibody and was significantly lower than group VS[7] that was vaccinated with 
out the presence of PRRSV. Following SIV challenge, all vaccinated groups had similar HI 
antibody levels and the levels were significantly greater than any of the non-vaccinated pigs, 
independent of challenge status. The pigs in the NEG and PRRSV infected (group P[7]) 
remained HI-antibody negative for SIV throughout the trial (data not shown). Overall, 
vaccination in the face of PRRSV or PRRSV co-infected with SIV did not impact the serum 
HI antibody response to SIV vaccination or infection. Serum samples collected prior to 
vaccination were negative for both PRRSV and SIV antibodies. At 6 DPI, less than 50% of 
pigs infected with PRRSV at 7 weeks of age seroconverted (S/P ratio > 0.4) while group 
VS[7]P[4] which was infected with PRRSV at 4 weeks of age had over 50% seroconversion 
(Table 4) . However, by 27 DPI all pigs infected with PRRSV were antibody positive 
confirming PRRSV infection in all PRRSV challenged pigs. The NEG and non PRRSV 
infected groups remained seronegative to PRRSV throughout the study. 
An ELISA was used to measure the antibody response to the SIV challenge antigen in 
BAL fluids. IgA was the dominant SIV-specific antibody at both 7 and 28 DPI in the BAL 
fluids (Fig. 3).  At 7 DPI, the level of IgA antibodies specific to the SIV challenge antigen 
was significantly higher (p < 0.0001) in all the vaccinated, SIV-challenged groups 
independent of PRRSV infection compared to the non-vaccinated, SIV-challenged groups. At 
28 DPI, all SIV-challenged pigs, independent of vaccination status, had significantly higher 
levels of SIV-specific IgA antibodies in the BAL compared to nonchallenged pigs or pigs 






























7 DPI 28 DPI
Table 4 
Anti-PRRSV antibody responses and percent PRRSV-seropositive pig during the experiment 
 
Bold figure represents data with S/P ratio > 0.4. 
a Cut-off value for PRRSV-seropositive when S/P ratio > 0.4 (IDEXX® ELISA kit). 
3.5 SIV-specific antibodies in lower airways 
Fig. 3. SIV-specific IgA antibodies in bronchoalveolar lavage fluid from pigs collected at 7 
and 28 days post infection (DPI).  Data are group average of O.D. value ± SEM with 
different letters (a, b) being statistically different (p ` 0.0001).  
 
4. Discussion 
The goal of this study was to assess the impact of PRRSV infection on SIV vaccine 
efficacy. Pigs were vaccinated at 3 and 5 weeks of age with a commercial bivalent SIV 
vaccine containing antigen from newer classic H1N1 and a clade I H3N2 viruses.  The effect 
of PRRSV virus on vaccine efficacy was evaluated by infecting pigs with a virulent isolate of 
 Groups  Mean S/P ratioa (% pig positive) 
- 28 DPI 6 DPI 27 DPI 
NEG  0.023  (0) 0.016  (0) 0.020  (0) 
VS[7]  0.034  (0) 0.032  (0) 0.058  (0) 
 S[7]  0.044  (0) 0.011  (0) 0.033  (0) 
 VS[7]P[4]  0.033  (0) 0.603 (72.72) 1.452 (100) 
 V  0.039  (0) 0.005  (0) 0.075  (0) 
 VS[7]P[7]  0.037  (0) 0.560 (33.33) 1.602 (100) 
 S[7]P[7]  0.025  (0) 0.465 (25) 1.378 (100) 
 P[7]  0.040  (0) 0.384  (41.67)  1.397 (100) 
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PRRSV (North American strain, VR-2385) either between the SIV vaccinations (at 4 weeks 
of age) at 7 weeks of age with or without concurrent of challenge with a virulent classic 
H1N1 strain A/Swine/IA/40776/92. Control groups were included to monitor SIV vaccine 
efficacy in the absence of PRRSV as well as positive control groups consisting of SIV and/or 
PRRSV challenged groups to assess clinical disease severity.  
Similar to our previous SIV-inactivated vaccine study [6] we found that SIV 
vaccination did not prevent SIV-induced clinical disease as all SIV challenged pigs were 
febrile 24 hours following infection. PRRSV infection between SIV vaccines resulted in a 
slight prolongation of fever, coughing and clinical signs similar to the non-vaccinated pigs 
challenged only with SIV. Vaccination did not reduce weight gain while pigs infected with 
SIV and PRRSV, independent of vaccination status, had reduced weight gains, similar to 
earlier findings [21,22] and mimicking what might occur in field situations where co-
infections frequently occur.  
Reduced macroscopic and microscopic lesions consistent with SIV infection are one 
of the parameters indicative of SIV vaccine efficiency. Here we demonstrated that infection 
with PRRSV at the time of SIV vaccination reduced vaccine efficacy based on the 
macroscopic and microscopic lesions associated with SIV (at 7 DPI) as well as presence of 
virus antigen detected by IHC, compared to vaccinated pigs infected only with SIV. Of the 
vaccinated groups, only the pigs boosted in the presence of PRRSV were IHC positive for 
SIV. However, the macroscopic lesions were not significantly different from vaccinated pigs 
infected with both SIV and PRRSV. The combined effect of dual infection with SIV and 
PRRSV appeared to enhance the severity, but did not prolong the SIV-induced pneumonia 
compared to pigs infected with only SIV. A role for SIV in PRRSV lung lesion severity was 
demonstrated, as pigs co-infected with PRRSV and SIV appeared to have prolonged PRRSV-
induced pneumonia based on the macroscopic and microscopic lesions at 28 DPI. In addition, 
pigs vaccinated for SIV in the presence of PRRSV infection had PRRSV-associated lesions 
similar to the non- vaccinated co-infected pigs at 28 DPI.  In contrast, SIV vaccination in the 
absence of PRRSV resulted in comparably lower levels of PRRSV-associated lesions that 
were similar to the negative control group at 28 DPI, demonstrating the importance of 
effective SIV vaccination in reducing disease induced by coinfections of PRRSV and SIV. A 
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potential mechanism for the disease enhancement of PRRSV when coinfected with SIV is 
through the pathobiology and resultant cell signaling induced by SIV infection. SIV 
primarily infects airway epithelial cells resulting in epithelial cell necrosis, infiltration of 
phagocytic cells and production of inflammatory mediators [23,24]. These phagocytic cells 
include pulmonary alveolar macrophages (PAM), which are susceptible to PRRSV infection 
and have been shown to be the primary cell type to support PRRSV replication. [25,26] .  
The level of PRRSV in the respiratory tract was not determined in this study as the primary 
interest of the study was the impact of PRRSV infection on SIV vaccine efficacy.   
The ability to reduce viral shedding is important when evaluating SIV vaccine 
efficacy. In general, SIV clearance is rapid and viral shedding is absent by 7 days following 
experimental SIV infection [27]. In this study, no virus was recovered beyond 5 DPI with the 
exception of one pig that was vaccinated in the presence of PRRSV. Co-infection of pigs 
with SIV and PRRSV at 7 weeks of age did not appear to enhance or extend nasal shedding 
of SIV. However, we found that PRRSV infection at the time of vaccination resulted in 
reduced vaccine efficacy against SIV excretion at the acute stage of SIV infection (2 DPI).  
The increased levels of virus shed in the acute stage of infection from these SIV-vaccinated 
PRRSV-infected pigs may explain the significantly increased severity of the SIV-associated 
macroscopic and microscopic lung lesions at 7 DPI compared to pigs vaccinated in the 
absence of PRRSV.  This is an important finding as reducing the amount of virus shed during 
an SIV outbreak is the ultimate goal of SIV vaccines in addition to decreasing the severity of 
clinical disease at the herd level.  
Previous studies of PRRSV and SIV co-infections have yielded conflicting results on 
the severity of clinical disease, ranging from enhanced disease [9] to minimal disease [10]. 
These studies suggest that disease severity is dependent on the time interval between PRRSV 
and SIV infections [22]. The virulence of the PRRSV isolate may also be an important factor 
in the differences in the studies. Significant differences in clinical respiratory and 
macroscopic lung lesions have been demonstrated between the European (Lelystad virus) and 
the North American isolates (VR-2332) [16,28]. The European isolate and a low-virulence 
U.S. isolate were shown to induce mild fever with macroscopic lung lesion less than 10% 
while several high virulence U.S. isolates induce more severe clinical signs with greater than 
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50% pneumonia [16,29]. In line with these data, Pol et al (1997) found no increase in clinical 
disease in pigs infected with both SIV and the European Lelystad virus.  In earlier studies, 
source and immune status of the pigs was found to affect the clinical outcome of dual 
PRRSV and SIV infection as milder clinical disease was observed in caesarean-derived 
colostrum-deprived pigs compared to conventional pigs that were seronegative to PRRSV 
and SIV [22]. In the study reported here, we demonstrated increased clinical respiratory 
disease in pigs co-infected with SIV-PRRSV at 7 weeks of age independent of their SIV 
vaccination status. One potential explanation for these differences is our use of a highly 
virulent isolate of PRRSV. 
Previous findings [23,24,30] demonstrated increased levels of interferon-alpha (IFN-
Q), tumor necrosis factor-alpha (TNF-Q) and interleukin-6 (IL-6) in the BAL of SIV-infected 
pigs. All 3 cytokines are essential for activating phagocytic cells resulting in the induction of 
a specific adaptive immune response (reviewed in [30]). In addition, they are pyrogenic in 
nature and thus are highly correlated with the clinical signs of fever and fatigue typically 
associated with SIV infection. In contrast, PRRSV infection has been shown to down 
regulate IFN-Q [31] and TNF-Q but prolong production of IL-1. Accordingly, these early 
cytokines produced during the acute phase of SIV and PRRSV co-infection may act in 
synergy to induce lung inflammation and enhance clinical disease. We did not assess these 
cytokines in the study reported here, but their production may be an explanation for the 
results observed in our study and should be studied further.   
While the mechanism by which PRRSV decreases vaccine efficacy is currently not 
known, previous in vitro and in vivo studies have suggested an immunosuppressant effect by 
the virus due to increased IL-10 levels [32,33]. In vivo experiments demonstrated that 
PRRSV infection decreased classical swine fever (CSFV) specific antibodies following 
CSFV vaccination [13] and lymphocyte proliferation following pseudorabies virus 
vaccination [34]. In contrast, antibody levels following MHYO vaccination were increased in 
the face of PRRSV infection [11]. In our study, all SIV vaccinated and challenged groups 
appeared to have serum HI antibody responses, independent of PRRSV infection at the time 
of vaccination. However, at the time point prior to SIV infection the level of mean HI 
antibodies in pigs vaccinated with the presence of PRRSV was lowest compared to all other 
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SIV-vaccinated pigs. The HI antibody levels were significantly lower than the group of pigs 
vaccinated without PRRSV that were subsequently challenged with SIV and was efficiently 
protected against SIV-induced lung pneumonia and shed significantly reduced amount of 
virus. This indicates that the first SIV vaccination, which was free of PRRSV infection in all 
groups, was able to successfully prime an active antibody response to SIV vaccination. The 
difference of mean HI antibody titers observed between groups induced through the second 
vaccination can be accounted in part by the “biological variation”. However, in the particular 
group that elicited the lowest HI antibody level prior to challenge, the presence of PRRSV 
prior to the second vaccination possibly contributed to the low anamnestic HI antibody 
response after the second vaccination, in this case through a transient immunosuppression 
since these pigs exhibited a high HI antibody titer following a subsequent SIV infection.      
PRRSV infection appeared to have little impact on the local antibody response to SIV 
challenge. SIV-specific IgA antibody responses in BAL fluids of SIV vaccinated and 
challenged pigs were significantly higher than the nonvaccinated, challenged pigs 
independent of PRRSV status at either the time of vaccination or at the later challenge date. 
While both PRRSV and SIV replicate in the lung, the difference in cell tropism of the two 
viruses may have minimized the effect on the antibody response to SIV. Although PAMs 
may become infected with SIV, viral replication is restricted [35]. As a result, the series of 
early proinflammatory cytokine production is induced by the SIV-infected PAMs resulting in 
an effective overall immune response and control of SIV-induced disease [35-37].    
In summary, SIV vaccination in the absence of PRRSV provided excellent protection 
against clinical disease and pneumonia following SIV challenge with a heterologous virus of 
the same subtype. The presence of PRRSV between vaccinations, while reducing vaccine 
efficacy, the systemic or local antibody response to either SIV vaccination or challenge was 
generally unaffected.  However, control of SIV at the acute stage of infection appeared to be 
slightly compromised as demonstrated by increased levels of virus. Overall, the results of the 
study described here provide a possible explanation for some of the SIV vaccine failures 
reported in the field. Infection with PRRSV should be considered when implementing 
vaccination strategies for controlling SIV, MHYO and potentially other pathogens.  The 
impact of PRRSV infection on vaccine efficacy would be especially important during gilt 
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acclimatization and in nursery pigs, common times for vaccinating pigs against disease. 
Understanding the impact of PRRSV on vaccine efficacy may provide information on the 
effect of PRRSV on the immune system allowing the development of successful intervention 
strategies against other pathogens in the presence of PRRSV.  
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Abstract 
This study investigated the efficacy of a bivalent swine influenza virus (SIV) vaccine in 
piglets challenged with a heterologous H1N1 SIV isolate. The ability of maternally derived 
antibodies (MDA) to provide protection against a heterologous challenge and the impact 
MDA have on vaccine efficacy were also evaluated. Forty-eight MDA+ pigs and 48 MDA-
pigs were assigned to 8 different groups. Vaccinated pigs received 2 doses of a bivalent SIV 
vaccine at 3 and 5 weeks of age. The infected pigs were challenged at 7 weeks of age with a 
H1N1 SIV strain heterologous to the H1N1 vaccine strain. Clinical signs, rectal temperature, 
macroscopic and microscopic lesions, virus excretion, serum and local antibody responses, 
and influenza-specific T-cell responses were measured. The bivalent SIV vaccine induced a 
high serum hemagglutination-inhibition (HI) antibody titer against the vaccine virus, but 
antibodies cross-reacted at a lower level to the challenge virus. This study determined that 
low serum HI antibodies to a challenge virus induced by vaccination with a  
heterologous virus provided protection demonstrated by clinical protection and reduced 
1 Reprinted with permission of Veterinary Immunology and Immunopathology, 112 (2006) 117-128. 
2 Primary researcher and author. 
3 Author for correspondence. 
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pneumonia and viral excretion. The vaccine was able to prime the local SIV-specific 
antibody response in the lower respiratory tract as well as inducing a systemic SIV-specific 
memory T-cell response. MDA alone were capable of suppressing fever subsequent to 
infection, but other parameters showed reduced protection against infection compared to 
vaccination. The presence of MDA at vaccination negatively impacted vaccine efficacy as 
fever and clinical signs were prolonged, and unexpectedly, SIV-induced pneumonia was 
increased compared to pigs vaccinated in the absence of MDA. MDA also suppressed the 
serum antibody response and the induction of SIV-specific memory T-cells following 
vaccination. The results of this study question the effectiveness of the current practice of 
generating increased MDA levels through sow vaccination in protecting piglets against 
disease.   
 
Keywords: Influenza; Heterologous H1N1; Maternal antibodies; Vaccine; Immune response 
Abbreviations: BAL, bronchoalveolar lavage; CMI, cellular mediated immune; DPI, days 
post infection; HA, hemagglutination; HI, hemagglutination-inhibition; HMI, humoral 
mediated immune; IHC, immunohistochemistry; MDA, maternally derived antibodies; 
MDCK, Madin-Darby Canine Kidney; NW, nasal washes; OD, optical density; PI, post 
infection; SIV, swine influenza virus; SN, serum neutralization; TCID, tissue culture 
infective dose 
1. Introduction 
 The emergence of a H3N2 virus in the late 1990’s has altered the impact of swine 
influenza virus (SIV) infection on the US swine industry the (Karasin et al., 2000b; Olsen, 
2002).  The epidemiology of SIV-induced disease has evolved from a seasonal epidemic 
disease pattern to more of an endemic profile (Choi et al., 2003). Many production systems 
currently face increased respiratory disease due to SIV infection in pigs of all ages including 
nursery and finishing pigs. Vaccination against SIV is a tool used to help prevent and control 
disease in pigs and is most commonly used in sow herds. Sow herd immunization typically 
provides protection against clinical disease associated with SIV infection in the adult sows 
and enhances passive immunity to the piglets as well. The role of maternally derived 
antibodies (MDAs) in protecting the young offspring from clinical disease has been 
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recognized in many viral diseases including SIV (Blaskovic et al., 1970; Renshaw, 1975; 
Puck et al., 1980; Englund et al., 1998; Choi et al., 2004). The use of vaccine-enhanced 
MDA to control SIV-induced clinical disease in nursery pigs was successful in the years 
prior to 1997 when a single H1N1 SIV subtype predominated in the US swine herds. The 
emergence of a new H3N2 subtype in 1997 resulted in the US swine population facing new 
genetically diverse SIV subtypes with genetic materials from multiple origins, including 
avian and human viruses (Karasin et al., 2000b; Webby et al., 2000; Zhou et al., 2000). 
Recently, the H1 viruses in the US herds have evolved to include H1N1 and H1N2 subtypes 
with genomes consisting of avian, swine and human genes that had been acquired from the 
H3N2 subtype (Karasin et al., 2000a; Choi et al., 2002). Current commercial SIV vaccines 
contain one, two or three different SIV isolates. However, swine vaccines are not presently 
updated annually as occurs with human influenza vaccines. The level of cross protection 
between genetically heterologous isolates of the same subtype is unpredictable. Thus, it is 
important to investigate the cross protection of genetically heterologous strains of the same 
subtype.  
 Studies investigating the role of SIV-MDAs have produced differing results. One 
study found that MDA provided complete protection against homologous SIV infection 
(Blaskovic et al., 1970). However, only virus isolation from lung tissue was assayed and 
nasal swabs and viral antigen load in the upper or lower respiratory tract was not assessed. 
Another study concluded that MDA provided no protection against SIV-induced disease 
based on the percentage of lung lesions and viral levels in the lungs (Mensik et al., 1971), 
while Renshaw et al. (Renshaw, 1975) found that the level of protection in piglets correlated 
to the MDA level at the time of infection. A more recent study by Loeffen et al (Loeffen et 
al., 2003) demonstrated incomplete protection against disease by MDA and piglets with 
MDA shed more virus following infection with the homologous virus than piglets without 
MDA. These experiments differed in their experimental design including the level of MDA, 
but all studies were based on homologous virus infection in piglets. In addition, all studies 
demonstrated that MDA, depending on the level present at the time suppress the 
hemagglutinin-inhibition (HI) antibody response by the piglets to SIV infection (Blaskovic et 
al., 1970; Mensik and Pokorny, 1971; Renshaw, 1975; Loeffen et al., 2003). 
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In the present study, we were interested in simulating field conditions where sows and 
piglets are exposed to multiple SIV strains and receive vaccines that may differ genetically. 
The research objectives were three-fold; the first objective was to investigate protection by 
MDA against experimental challenge with a heterologous SIV isolate; the second objective 
assessed vaccine efficacy against a heterologous SIV isolate in the absence of MDA; and the 
third objective examined the effect of MDA on vaccine efficacy in the piglets when 
experimentally challenged with a heterologous SIV.  Cross-protection, vaccine efficacy and 
the immune response induced by vaccination and infection were determined using clinical 
signs, lung lesions, HI antibody titers, virus isolation from nasal swabs, and SIV-specific 
antibodies in the upper and lower airways.  
2. Material and Methods 
2.1 Pigs and experimental design 
All study procedures and animal care activities were conducted in accordance with 
the guidelines and under the approval of the Iowa State University (ISU) Institutional 
Committee on Animal Care and Use.  
 Ninety-six 8- to 12-day-old crossbred pigs were obtained from 2 commercial herds: 
48 pigs with MDA (MDA+) were obtained from a herd with stable SIV status where the sows 
were routinely vaccinated (MaxiVac® Excell™, Schering-Plough Animal Health, Union, New 
Jersey, USA) and 48 pigs without MDA (MDA-) were procured from a herd seronegative for 
SIV, porcine reproductive and respiratory syndrome virus and Mycoplasma  hyopneumoniae. 
The pigs were identified by numbered ear tags and assigned to 8 groups of 12 pigs each 
divided into 2 replicates with stratification by arrival weight. The experimental design is 
summarized in Table 1. Pigs were housed in 2 identical rooms in the Livestock Infectious 
Disease Facility at ISU based on their challenge status. Pigs in the vaccinated groups V, MV, 
VS and MVS were inoculated with a bivalent SIV vaccine containing the H1N1 and H3N2 
subtype (FluSure, Pfizer Animal Health, New York, NY, USA) according to label 
directions at 3 and 5 weeks of age. Pigs’ positive for MDA had HI titers to both the vaccine 
and challenge H1N1 antigens between 1:40-1:80 at the time of the first vaccination. Pigs in 
the infected groups S, VS, MS and MVS were challenged intratracheally at 7 weeks of age (0 
days post infection; DPI) with 10 ml of 105.5 TCID50/ml of H1N1 strain 
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A/Swine/Iowa/40776/92 virus, which demonstrated minimal serum antibody cross-reactivity 
to the vaccine H1N1 strain.  
 
Table 1 
Experimental design-group description, maternal derived antibody (MDA) status, vaccination 
status, SIV infection status and numbers of pigs necropsied on each necropsy days 
 No. of pigs necropsied at:
Group MDA Vaccination Infection 5 DPI a 21 DPI Total No. 
status status   of pigs 
NEG No No No 6 6 12 
V No Yes No 6 6 12 
M Yes b No No 6 6 12 
MV Yes   Yes c No 6 6 12 
S No No   Yes d 6 6 12
VS No Yes Yes 6 6 12 
MS Yes No Yes 6 6 12 
MVS Yes Yes Yes 6 6 12 
a DPI = days post infection 
b Pigs had HI titers between 1:40-1:80 at the time of the first vaccination 
c Pigs were vaccinated at 3 and 5 weeks of age 
d Pigs were infected with H1N1 SIV that was heterologous to the vaccine isolate 
 
2.2 Clinical evaluation 
 Pigs were evaluated for 7 days to assess respiratory disease after SIV infection. The 
pigs were observed and scored (Table 2) at rest followed by rectal temperature measurement. 
Pigs were weighed upon arrival and at -1, 5 and 21 DPI to evaluate production performance. 
 
Table 2  
Clinical sign scores 








 Slightly elevated 
 Moderately elevated, slight abdominal breathing 









All scores per topic are accumulated for a total clinical score. 
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2.3 Necropsy 
 Pigs were euthanized with a pentobarbital-based euthanasia solution (Beuthanasia®, 
Schering-Plough, Kenilworth, NJ, USA) followed by exsanguination. Nasal washes (NW) 
were collected using a previously published methodology (Larsen et al., 2000). Briefly, 10 ml 
of sterile phosphate buffer saline (PBS) with 1% bovine serum albumin (BSA), penicillin 
(300 U/ml) and streptomycin (300 ag/ml) were infused into the nasal passages. The head was 
moved gently and the fluid was allowed to drain into a collection cup. The lungs were 
removed and evaluated for pneumonia. Macroscopic lesions associated with SIV pneumonia, 
consisting of well demarcated dark-purplish areas of lung consolidation, were sketched onto 
a standard lung diagram. The proportion of lung surface with lesions was determined from 
the diagram using a Zeiss SEM-IPS image analyzing system as previously described 
(Thacker et al., 2001). Bronchial swabs were obtained from each pig and cultured for swine 
respiratory bacteria using standard procedures. Bronchoalveolar lavage (BAL) was 
performed as previously described using the same PBS solution as used for the nasal washes 
(Mengeling et al., 1995). A portion of lung tissue was collected from all lung lobes, fixed in 
10% neutral buffered formalin, processed and embedded in paraffin using an automated 
tissue processor. Lung sections were scored for microscopic lung lesions consistent with SIV 
(necrotic bronchiolitis) as previously described (Thacker et al., 2001). 
 The presence of SIV-specific antigen was assessed in the formalin-fixed lung tissues 
using a previously described immunohistochemistry (IHC) staining method (Vincent et al., 
1997). IHC was performed on sections cut from one paraffin-embedded lung tissue block and 
included 3 pieces (1X2 cm) of lung collected at 5 DPI.  
2.4 Virus isolation 
 Following collection at -1, 3, 5, and 7 DPI, nasal swabs were immediately placed in 
infecting medium (MEM with 7% BSA, 300 U/ml penicillin, 300 ag/ml streptomycin and 1 
ag/ml trypsin). Ten-fold serial dilutions of the viral solution were prepared in the infecting 
medium and inoculated onto Madin-Darby Canine Kidney (MDCK) cells prior to incubation 
at 370C with 5% CO2. All of the following steps that required incubation were carried out at 
room temperature. Prior to staining, the cells were fixed with 4% phosphate-buffered 
formalin and washed with 0.5% Tween-20 in PBS (washing solution). Subsequently, the 
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cells were incubated for 1 hour (hr) with anti-influenza A nucleoprotein monoclonal 
antibodies (clone HB-65, ATCC, Rockville, Maryland) diluted 1:650 in the washing solution 
containing 1% BSA (diluting solution). After washing, the cells were incubated 1 hr with the 
rabbit anti-mouse IgG conjugated horseradish peroxidase (Dako Cytomation, Carpinteria, 
California) diluted 1:250 with the diluting solution. The color was developed using a 
chromogen aminoethyl carbazole substrate (Sigma, St. Louis, Missouri). Each procedure 
contained mock-infected negative control cells and positive control cells infected with a virus 
with a known titer. The titer of the virus in each nasal swab was expressed as log 10 TCID50 
per milliliter and calculated by the method of Reed and Muench (Reed and Muench, 1938).     
2.5 Hemagglutination-inhibition (HI) assay 
 Blood was collected at -28, -14, -1, 4 and 20 DPI. Sera was stored at -200C and 
assayed simultaneously following both trials. The HI assays were tested according to the 
standard protocol routinely performed at ISU-Veterinary Diagnostic Laboratory (Yoon et al., 
2004) using 0.5% rooster erythrocytes for hemagglutination. Virus antigens utilized in the HI 
assays included the challenge virus (strain A/Swine/Iowa/40776/92 H1N1) and the H1N1 
vaccine antigen (provided by Pfizer Animal Health, New York, NY, USA).  
2.6 ELISA for local SIV-specific antibody production 
 The NW and BAL fluids were incubated at 370C for 1 hr with an equal amount of 10 
mM dithiothreitol (DTT; Sigma-Aldrich, St. Louis, MO) to disrupt mucus present in the 
fluids. ELISA assays for SIV antibodies in the respiratory tract were performed as previously 
described (Larsen et al., 2000). Briefly, inactivated challenge virus and vaccine antigen were 
diluted to a hemagglutination (HA) concentration of 100 HA units/50 µl. Immulon-2HB 96-
well plates (Dynex, Chantilly, VA) were coated with 100 µl of SIV antigen and incubated at 
room temperature overnight. Plates were blocked for 1 hr with 100 µl of 10% BSA in PBS 
and washed 3 times with 0.05% Tween 20 in PBS (PBS-T). The assay was performed on 
each NW and BAL sample in triplicate. Negative controls (DTT with equal amount of PBS 
solution) were included on each plate.  Plates were incubated at room temperature for 1 hr, 
washed 3 times with PBS-T, then incubated with peroxidase-labeled goat anti-swine IgG 
(Kirkegaard and Perry, Gaithersburg, MD) or peroxidase-labeled goat anti-swine IgA 
(Bethyl, TX) at 370C for 1 hr. The ABTS/peroxidase was added as the substrate (Kirkegaard 
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and Perry, Gaithersburg, MD). Antibody levels were reported as the mean optical density 
(OD) and the mean OD of each treatment group was compared. 
2.7 Flow cytometry analysis 
2.7.1Culture Procedures 
Peripheral blood mononuclear cells (PBMC) were collected in heparinized blood 
collection tubes and isolated by differential centrifugation.  PBMCs were collected one day 
prior to the second vaccination, prior to challenge and prior to each necropsy at 4 and 20 
DPI. The PBMCs were counted prior to staining with PKH67 green fluorescent dye (Sigma-
Aldrich, St. Louis, MO) following a procedure previously described (Dorn et al., 2002). 
Briefly, 2 X 107 PBMCs were centrifuged (400g) for 10 minutes (min), supernatants were 
aspirated, and cells were resuspended in 1 ml of diluent C (Sigma). Cells in diluent C were 
added to 1 ml of PKH67 (2 X 10-6 M) and incubated for 5 min, followed by 2 min incubation 
with fetal bovine serum (FBS) to adsorb the dye and stop the dye uptake. Cells were then 
washed 3 times with RPMI 1640 (Mediatech, Huntingford, VA). Once stained, cells were 
recounted and added to 96-well U-bottomed microtiter plates (Costar, Corning, NY) at a 
density of 5 X 105 cells per well in 100 µl medium (RPMI containing 10% fetal calf serum, 2 
mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin). PBMCs were cultured 
with inactivated challenge and vaccine antigen, 100 HA units/100 µL in duplicate. Positive 
control samples were cultured with 5 µg/ml PHA in duplicate and the culture media was used 
as negative control.  
2.7.2 Cell Surface Marker Staining  
 Cells were centrifuged (300g) for 10 min and the supernatant was discarded. Primary 
antibodies to swine leukocyte surface antigens in PBS containing 1% BSA and 0.1% sodium 
azide (FACS buffer) was added to wells containing cells. Primary antibodies, including 
phycoerythrin (PE)-conjugated anti-CD4 and biotinylated anti-CD8 were added to the 
appropriate wells. After incubating for 20 min, the cells were washed with FACS buffer and 
resuspended in 50 µl of secondary antibody streptavidin-conjugated cychrome dye secondary 
antibody (Pharmingen, BD Bioscience, CA). Cells were incubated, washed, resuspended and 
fixed with 2% formalin in PBS before flow cytometric analysis.  
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The program Modfit Proliferation Wizard (Verity Software House Inc., Topsham, 
Maine) was used to analyze cell proliferation. The results are presented as the mean number 
of proliferating cells + standard error mean per 10,000 PBMCs. The number of cells 
proliferating was calculated by the following formula: (% proliferation to mitogen X number 
of cells in the R1 gate) – (% proliferation with no stimulation X number of cells in the R1 
gate) (Waters et al., 2002). R1 is the region containing live lymphocytes based on forward 
and side light scatter properties of porcine lymphocytes (Dorn et al., 2002).  
2.8 Statistical Analysis 
Comparisons of results between experimental groups were performed using a non-
parametric Wilcoxon / Kruskal-Wallis Test (Rank sum test) from JMP 5.1 Software (SAS 
Institute, Cary, NC). For all analyses, statistically significant difference between groups were 
considered when P < 0.05.  
3. Results 
3.1 Clinical evaluation 
 All pigs inoculated with SIV developed a fever (]104 oF) by 24 hr post infection (PI) 
with the exception of pigs in group MS (nonvaccinated MDA+) which remained normal 
throughout the trial (Figure 1a). The fever resolved by 2 DPI in all SIV infected groups 
except the MDA+-vaccinated, challenged group (group MVS) which remained febrile for 4 
additional days. No fever was detected in the nonchallenged control pigs at any time (data 
not shown).  
 The summary of total accumulated clinical scores is illustrated in Figure 1b. At 24 hr 
PI, all pigs inoculated with SIV had increased clinical scores. Clinical signs consisted of 
increased respiratory rates which decreased over the next few days with the exception of 
group MVS. In all other SIV infected groups, coughing was rare and was detected in only 
one pig from group MS at 24 hr PI. Seven pigs in group MVS continued to cough until 5 DPI 
after which coughing was no longer detected. No coughing was present in any of the 
nonchallenged control pigs (group NEG). Overall, pigs in group MVS showed the most 
clinical disease while pigs that were MDA-, vaccinated and challenged (group VS) 























Fig. 1. Mean rectal temperatures (a) and clinical scores (b) of nonvaccinated, challenged pigs 
( ), MDA- -vaccinated, challenged pigs (   ), MDA+-nonvaccinated, challenged pigs (   ) and 
MDA+-vaccinated, challenged pigs (   ) before (-1 days post infection; DPI) and after (1-7 
DPI) infection with H1N1 SIV at 7 weeks of age. Results of nonchallenged pigs are not 
included. Different letters in the figure are significant difference between values (P<0.05).  
 
3.2 Necropsy 
 Half of the pigs in each group were necropsied at 5 DPI with the remaining pigs 
necropsied at 21 DPI. Macroscopic lung lesions and histopathological findings from both 
necropsies are summarized in Table 3. Pigs in group VS had significantly lower percentages 
of macroscopic lung lesions consistent with SIV (lung consolidation with dark-purplish well 
demarcated areas) than the MDA- - nonvaccinated challenged control group (group S). Pigs 
in group MS had significantly less pneumonia than pigs in group S but the lesion levels were 



















Table 3  
Percentage of lung with visible macroscopic lesions and microscopic lesion scores ± S.E.M 
from pigs infected with H1N1 SIV at both necropsies  
 
Group % of macroscopic lesionse Microscopic lesion scoresf
5 DPI g 21 DPI  5 DPI 21 DPI 
NEG  0.23 ± 0.05a 0.24 ± 0.11a 0 ± 0 a 0
V 0.09 ± 0.06a 0.11 ± 0.04a 0 ± 0 a 0
M 0.12 ± 0.15a 0.44 ± 0.19a,b 0 ± 0 a 0
MV  0.22 ± 0.09a 0.17 ± 0.07a 0 ± 0 a 0
S 10.03 ± 1.71c 1.25 ± 0.09b 2.17 ± 0.31b 0
VS  1.59 ± 0.51a 0.21 ± 0.12a 0.71 ± 0.42a 0
MS  4.46 ± 1.10b 0.48 ± 0.24a 2.14 ± 0.40b 0
MVS  18.33 ± 1.88d 0.85 ± 0.26a,b 2.60 ± 0.40b 0
a, b, c, d Means with different superscripts within a column are statistically different (P < 0.05). 
e As determined by lesion sketches and image analysis. 
f SIV microscopic lesion scores are based on the severity of bronchiolar epithelial damage 
(necrotic bronchiolitis).  
g DPI = days post infection. 
 
in group MVS was significantly increased in severity compared to all other challenged 
groups. No significant lesions consistent with SIV were present in any nonchallenged pigs. 
By 21 DPI, the percentage of pneumonia was minimal in all SIV infected groups and no 
statistical differences were observed. 
In contrast to the SIV-associated macroscopic lung lesions, the microscopic 
difference between the groups was less obvious. However, the trend of the microscopic 
findings supported the macroscopic results. Bronchiolar epithelial damage (necrotic 
bronchiolitis) was considered specific for SIV infection. Scoring focused on airway damage 
and the degree of inflammation surrounding the airways and alveoli. The microscopic score 
was based on the number of airways in the section involved. Pigs in group VS, demonstrated 
less microscopic damage than pigs in any of the other SIV challenged groups. The 
necrotizing bronchiolitis lesion scores decreased at 21 DPI in all SIV infected groups and no 
statistical differences remained. Microscopic lesions consistent with SIV were not detected in 
any nonchallenged pigs.  
 Detection of SIV antigen by IHC was performed on all lungs. SIV antigen was 

























Fig. 2. Virus titers in nasal swabs from nonvaccinated, challenged pigs (S), MDA- -
vaccinated, challenged pigs (VS), MDA+-nonvaccinated, challenged pigs (MS) and MDA+-
vaccinated, challenged pigs (MVS) following H1N1 SIV infection at 7 weeks of age. Results 
are represented as mean log10 TCID50/ml ± S.E.M Different superscription letters within the 
figure are significant difference between the values (P < 0.05). The results of nonchallenged 
pigs are not included.  
 
group VS was positive for SIV antigen by IHC at that time, while SIV antigens were detected 
in all pigs in groups MS, S and MVS. No SIV antigen was detected in the lungs of any of the 
nonchallenged groups.  
3.3 Virus isolation 
 Figure 2 shows the level of virus detected from the nasal swabs from groups that were 
inoculated with SIV. Virus was not detected in the nasal swabs collected from the non-
infected groups or any pigs prior to challenge (data not shown). At 3 DPI, pigs in group VS 
had significantly lower amounts of virus in the nasal swabs compared to all other SIV- 
challenged pigs (groups S, MS and MVS). At 5 DPI, groups S and MS had increased levels 
of virus compared to group VS. Although the virus in group MVS was not significantly 
different from group VS, the level were also similar to groups S and MS. By 7 DPI, virus 
was no longer detected from pigs in groups VS and MS, whereas one pig in group S and one 








3.4 Hemagglutination-inhibition (HI) test 
 Antibodies were measured by HI assays using both the vaccine antigen (Figure 3a) 
and the challenge antigen (Figure 3b). Prior to the first vaccination (-28 DPI) MDA- pigs had 
no HI titers, while pigs that were MDA+ had HI titers that averaged 1:80 (HI score = 4) to 
both antigens. Pigs in nonvaccinated, nonchallenged group M had average HI titers (to both 
antigens) that gradually declined to a titer of less then 1:10 at 21 DPI (~ 10 weeks of age). 
Group NEG remained HI- antibody negative throughout the trial (data not shown). 
 As shown in Figure 3a, pigs that were MDA+ had no increase in HI antibody titers to 
the vaccine antigen at one day prior to the 2nd vaccination (-14 DPI). In contrast, an increase 
in HI titers occurred in groups V and VS indicating an active antibody response to 
vaccination in the absence of MDA. Two weeks after the second vaccination (-1 DPI) 
vaccinated pigs that were MDA- (groups V and VS) demonstrated significantly higher 
(P<0.0317) HI antibody titers than all other vaccinated groups. Pigs in group MV with 
MDA+ demonstrated a slight increase in the HI titer following the second vaccination. 
However, group MVS which also was MDA+ and vaccinated showed no rise in the HI titer 
and had levels that did not differ from the MDA+ - nonvaccinated pigs (groups M and MS) 
 The HI titers to the challenge antigen are shown in Figure 3b. The presence of low 
levels of HI antibodies to the challenge antigen prior to infection (-28, -14 and -1 DPI) 
indicates some cross reactivity between HI antibodies induced by vaccination to the 
challenge antigen (groups V and VS); and the HI MDA induced antibodies (groups M, MV 
and MVS). Two weeks following the first vaccination (-14 DPI), MDA- pigs in groups V and 
VS had no HI antibodies against the challenge antigen. After the second vaccination, pigs in 
groups V and VS developed low levels of HI antibodies to the challenge virus (1:29 ± 1:15 
and 1:20 ± 1:11). MDA+ (groups M, MV and MVS) had HI antibodies to the challenge virus. 
Vaccination of pigs in the presence of MDA+ did not increase the HI antibody levels to the 
challenge virus. The HI antibody levels to the challenge virus decreased a minimum of 1-fold 
every 2 weeks until levels were less than 1:20 on the day prior to challenge in groups MV 
and MVS. However, following challenge all vaccinated pigs independent of MDA status had 



















































Fig. 3. Mean hemagglutinin inhibition (HI) antibody titers against the vaccine antigen (a) and 
challenge antigen (b) from pigs prior to the first vaccination and second vaccination (-28 and 
-14 days post infection; DPI), prior to SIV infection (-1 DPI) and prior to both necropsy dates 
(4 and 20 DPI). The NEG group is not shown. The HI score (n): n = 2n × 5 serum HI 
antibody titer.  
 
3.5 SIV- isotype specific ELISAs 
 An ELISA to measure the local immune antibody response to SIV vaccine antigen 
and challenge antigen was performed on both BAL and NW fluids. Little antibody response 
to either SIV antigen was observed in the NW fluid (data not shown). In BAL fluid, IgA was 
the dominant SIV-specific antibody at both 5 and 21 DPI.  The levels of IgA antibodies in the  
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Table 4 
Lower airway SIV-specific IgA antibody and T-cell proliferation analysis from pigs 
following H1N1 SIV infection at 7 weeks of age 
 
Group SIV-specific IgA antibodies in BALc No. of CD4+/8+ cellsd at 21 DPIe
5 DPI f 21 DPI  Vaccine Ag Challenge Ag 










a, b Means with different superscripts within a column are statistically different   (P < 0.05). 
c Mean O.D of SIV-specific IgA antibodies ± S.E.M against the vaccine antigen from 
bronchoalveolar lavage fluid (BAL) measured by ELISA. Results of nonchallenged pigs are 
not shown. \
d Mean numbers of CD4+/8+ cells ± S.E.M that proliferated to the vaccine and the challenge 
antigen as determined by flow cytometry and cell surface marker staining. Results of 
nonchallenged pigs are not shown.   
e DPI = days post infection.  
 
BAL specific to the vaccine antigen (Table 4) were significantly higher in pigs in groups VS 
and MVS compared to the pigs in groups S and MS at both necropsy dates.  
3.6 Flow Cytometry Analysis 
Table 4 demonstrates that at 21 DPI MDA- pigs in group VS, CD4+/8+ T-cells 
showed significantly increased proliferation when stimulated with either the challenge or 
vaccine antigen. No significant differences were observed between groups in the other 
populations of lymphocytes.   
4. Discussion 
The study reported here had three objectives which included; evaluating the 
protection provided by MDA, evaluating vaccination efficacy against a heterologous SIV 
isolate, and the effect of MDA on vaccine efficacy. Similar to previous findings (Loeffen et 
al., 2003; Choi et al., 2004), MDA were found to be partially protective as at 1 DPI, MDA+-
nonvaccinated, challenged pigs had no fever. However, other clinical symptoms such as 
increased respiratory rates and coughing occurred in the presence of MDA. The MDA alone 
did not protect against SIV infection as virus antigen was detected in the lungs and no 
reduction in virus shedding from the nasal cavity was observed. However, the prolonged 
viral shedding in MDA+ pigs as described in earlier studies was not observed in this study 
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(Renshaw, 1975; Loeffen et al., 2003). MDA--vaccinated pigs were protected against the 
heterologous H1 virus used in this trial. In addition, vaccination significantly reduced the 
level of virus in the lungs and in the upper airways and nasal cavities. The findings in this 
study matched the results from a previous study in Europe that reported cross protection was 
elicited with H1 SIV vaccination followed by a heterologous H1 virus infection (Van Reeth 
et al., 2001).  
 Induction of a local antibody response following SIV infection has been determined 
in previous studies (Larsen et al., 2000; Heinen et al., 2000, 2001). This study confirmed this 
response as vaccination primed the immune system for a local response as vaccine-specific 
IgA antibody levels were increased in the BAL fluid after infection. A minimal antibody 
response to either SIV antigen was observed in the NW fluid.  The lack of a nasal mucosal 
response may be attributed to the fact that the pigs were challenged intratracheally and as a 
result the immune response in the upper airways was reduced. The presence of MDA at the 
time of vaccination did not appear to reduce the local IgA response to the vaccine antigen 
and the presence of vaccine-specific IgA antibodies did not provide protection against the 
heterologous infection. These results bring into question the significance of IgA antibodies in 
providing lower respiratory tract protection against influenza induced disease. 
Previous studies investigated the significance of MDA to homologous SIV infection 
(Blaskovic et al., 1970; Renshaw, 1975; Loeffen et al., 2003) and no enhancement of SIV–
induced disease was observed. No studies have been conducted to study the response to 
heterologous SIV infection which is more likely to occur under field conditions. This study 
suggests that MDA at the time of vaccination may possibly enhance SIV-induced pneumonia 
resulting from heterologous H1 infection. The exact mechanism for this enhancement is 
unknown. It is possible that MDA+ interfered with the cell mediated immune (CMI) response 
to infection by skewing the T-helper 1 (Th1) type of response to a more Th2-like response 
through the formation of antibody-antigen (Ab-Ag) complexes (Casadevall and Pirofski, 
2003). Influenza virus infection normally induces an effective innate immune response and 
the production of proinflammatory cytokines (Van Reeth, 2000; Van Reeth et al., 2002) 
which is responsible for effective adaptive humoral mediated immune (HMI) and CMI 
responses. In mice, clearance of the virus is mediated by T-cells following primary infection 
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and memory T-cells following secondary exposure (Flynn et al., 1998; Woodland et al., 
2001) while protection against infection and clinical disease is mediated by neutralizing 
antibodies directed against the major envelope glycoproteins of the virus (Jakeman et al., 
1989). A recent study by Anderson and Mosser (2002) demonstrated that the innate immune 
system could divert a Th1 to a Th2 adaptive immune response by binding the antigen to the 
IgG Fc portion of the macrophage (FcdR). Typically, activated macrophages acting as 
antigen presenting cells, induce a Th1-like response. However, when the antigen is bound to 
an antibody, the FcdR on the macrophage can be targeted resulting in a more Th2-like 
phenotype. MDA+ at the time of vaccination in the pigs in this study may have resulted in an 
increased Th2-type response due to the presence of Ab-Ag complexes forming from the 
vaccine antigen. Thus following the heterologous H1 infection, MDA+-vaccinated pigs were 
unable to rapidly mount an effective CMI response to clear the virus from the lungs.  
 Our theories are supported by the observed proliferation of CD4+/8+ T-cells 
(memory T-cell) in response to both the vaccine and challenge antigens at 21 DPI in MDA--
vaccinated pigs. In contrast, MDA+-vaccinated pigs had no memory T-cells although high 
levels of HI antibodies to the challenge antigen were present at 21 DPI.  While the MDA--
vaccinated pigs had lower HI antibody levels, significantly higher levels of memory T-cells 
were present which may explain the rapid recovery of MDA--vaccinated pigs following 
infection. In addition, these results confirm previous studies in mice (Flynn et al., 1998; 
Woodland et al., 2001) that demonstrated the importance of memory T-cells in clearing 
influenza virus and controlling clinical disease.  
 This study investigated the efficacy of SIV vaccination against a heterologous 
challenge and the role MDA play in vaccination efficacy for protection against clinical 
disease and pneumonia. We demonstrated that a complete match between the vaccine strains 
to the field strains detected by HI test may not always be required for a successful 
vaccination strategy. Interestingly, at the time of infection no significant differences in the HI 
antibody levels to the challenge antigen were present in vaccinated pigs independent of MDA 
status, yet the outcome following experimental infection differed significantly between the 
groups. Pigs with low levels of HI antibodies to the challenge antigen and high HI antibody 
levels to the vaccine antigen at the time of infection were protected against disease. This is an 
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important finding, since HI antibody levels are commonly thought to correlate with 
protection against clinical disease (de Jong et al., 1999, 2001; Hannoun et al., 2004). The 
results of this study reflect the limited ability of HI antibody levels to be used as tools to 
predict protection; however they can be useful for herd health monitoring or antibody 
surveillance for vaccination.  We also demonstrated that vaccination induced a memory T-
cell response that appears to be important in clearing infection. While the presence of MDA 
decreased clinical disease, they did not reduce the amount of virus present in the respiratory 
tract of infected pigs and their presence suppressed the HI antibody response to vaccination.  
In addition, MDA at the time of vaccination reduced vaccine efficacy and possibly enhanced 
the SIV-induced pneumonia. In this study, it appears that MDA inhibited the production of 
memory T-cells by the vaccine. However, more investigation is required to determine the 
exact mechanism of the MDA-induced disease observed here. The findings in our study 
clearly demonstrated that vaccination provides better protection than MDA against influenza 
and brings into question the common practice of immunizing sows to increase MDA levels 
for piglet protection.   
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Abstract 
The influenza invariant matrix 2 (M2) protein is a potential subunit vaccine candidate 
to induce protective immunity against broader strains of influenza A viruses (IAV). 
Antibodies to M2 protein have not been well characterized in IAV natural hosts. To 
characterize M2-specific antibodies in pigs, an indirect ELISA to the extracellular region of 
the M2 (M2e) protein was developed. Sera from pigs experimentally infected with three 
different swine influenza virus (SIV) subtypes, immunized with an SIV inactivated vaccine, 
or positive for SIV maternally-derived antibodies (MDA) in the absence of SIV infection 
were tested in assay. Confirmation of antibody status of pigs, was determined using a 
hemagglutination-inhibition (HI) test and the presence of antibodies to matrix 1 (M1) protein 
were measured by a recombinant M1 (rM1)-based ELISA.  The antibody titers to the HA and 
M2e proteins but not to the rM1 were directly correlated to the dose of virus used to infect 
the pigs and the level of antibodies detected by the HI assay varied according to SIV subtype. 
Pigs experimentally infected with SIV produced low levels of M2e antibodies compared to 
antibodies detected by the HI and rM1 assays. Vaccination alone followed by infection did 
not increase the levels of M2e antibodies in contrast to HA and rM1 antibodies. Pigs with 
MDA had different levels of HA antibodies and were positive to M2e antibodies, but results 
were not correlated to HA antibodies levels and inconsistently present.  
Keywords: Swine influenza virus; M2 protein; M1 protein; Antibody response 
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1. Introduction 
Swine influenza virus (SIV) infection is a respiratory disease with significantly 
negative economic impact for the swine industry around the world (Choi et al., 2003; 
Maldonado et al., 2006; Song et al., 2003). SIV is an RNA virus that belongs to the genus 
influenza A of the family Orthomyxoviridae (Fields et al., 2001). Since first isolated in 1930 
(Shope, 1931a, b), research has focused on the biology of influenza A virus (IAV) and the 
immune responses induced by infection. The two major viral transmembrane glycoproteins; 
hemagglutinin (HA) and neuraminidase (NA) are used to further subdivide IAV into different 
subtypes and their specific antibodies are known to be highly correlated to protection (Couch, 
2003; Johansson et al., 1989). The HA antibodies are detected using a hemagglutination-
inhibition (HI) test that is modified for each subtype by use of a reference strain capable of 
detecting a wide range of different strains within the corresponding subtype (Long et al., 
2004; Yoon et al., 2004). Current inactivated influenza vaccines target the production of an 
antibody response against the HA proteins. However, point mutations known as antigenic 
drift occur frequently resulting in changes in the proteins that can cause vaccine failure and 
diminishes the accuracy of the HI test (Fields et al., 2001; Skibbe et al., 2004). The third viral 
transmembrane protein, matrix 2 (M2) is a highly conserved protein among IAV. The M2 
protein is expressed in a homotetrameric form with a nonglycosylated extracellular region 
(M2e) of 24 amino acids at the N-terminus (Holsinger and Lamb, 1991; Lamb et al., 1981; 
Zebedee et al., 1985). The highly conserved nature of the M2 protein is due to its genetic 
relatedness to the matrix 1 (M1) structural protein, the two most conserved protein of all IAV 
(Helenius, 1992; Lamb et al., 1981; Pinto et al., 1992). Based on its conserved nature, the M2 
protein has been focused on for use in subunit vaccines that can potentially induce immunity 
to a broad population of IAV strains (De Filette et al., 2005; Neirynck et al., 1999).  The M1 
protein is the most abundant IAV protein and provides the underlining structure for the viral 
envelope (Avalos et al., 1997). The M1 protein has an important role in the nuclear export of 
the viral genome and proteins, and in virus assembly (Bui et al., 2000; Reinhardt and Wolff, 
2000). M1 specific antibodies have been detected in IAV infected animals by both 
immunodiffusion (Webster and Hinshaw, 1977) and western blot assays (Kim et al., 2006; 
Rozek et al., 2003). Although the antibody responses to the M1 protein are incapable of 
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neutralizing the virus (Murphy and Clements, 1989; Webster and Hinshaw, 1977) the 
presence of the antibody response can be used to detect pigs exposed to all SIV independent 
of strains and subtypes.    
While there is interest in using the M2 protein as a subunit vaccine candidate, the 
antibody responses to M2 protein in natural IAV infections have not been well-characterized 
in pigs. There is minimal information in the literature that describes studies assessing M2 
specific antibodies following IAV infection in humans. The first study used a baculovirus 
expressed M2 protein in enzyme link immunosorbent assays (ELISA) and western blot 
analysis to assess M2 antibodies in 17 matched acute- and convalescent-phase sera from 
individuals infected with a human H3N2 virus (Black et al., 1993). The second study used an 
ELISA coated with synthesized M2e peptide to test 66 serum samples from patients with 
confirmed IAV infection and compared them to 43 negative serum samples (Liu et al., 2003). 
The third study utilized a HeLa cell line stably expressing the full length tetrameric form of 
M2 to evaluate 24 paired sera from IAV infected adults (Feng et al., 2006). All three studies 
reported low levels of M2 specific antibodies following infection with IAV in humans. These 
human studies utilized sera from naturally infected patients making the accuracy of the 
antibody response following initial IAV exposure difficult to interpret. To our knowledge, 
only one study on the M2 antibody response to SIV has been reported in experimentally 
infected pigs (Heinen et al., 2001). That study used an ELISA coated with synthetic peptide 
of the M2e protein to test sera from pigs infected with a H3N2 virus and followed by 
infection with either a H1N1 (heterologous challenge) or the H3N2 (homologous challenge) 
viruses. The results of this study indicated that a low M2 antibody response occurred 
following the primary infection. The antibody titers did not increase following homologous 
challenge, but did increase following the heterologous challenge.   
The primary objective of the study was to detect and characterize the M2 specific 
antibody response in sera from conventional pigs with differing SIV exposure histories. This 
study also investigated the antibody response to the M1 protein for the potential use as a 
subtype-unrestricted serological diagnostic assay. Two indirect ELISA assays utilizing the 
M2e protein expressed in an E. coli expression system or a recombinant M1 (rM1) expressed 
in a baculovirus expression system were used. Test samples used to analyze the assays and 
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determine antibody levels were from serum from 3 separate studies of experimentally 
infected and/or vaccinated  pigs, and an additional study of pigs known to be serologically 
positive for SIV maternally-derived antibodies (MDA+). Antibodies to the M1 protein were 
analyzed to compare the findings with the M2e-specific antibodies. Antibodies to the HA 
proteins were evaluated in parallel to confirm the accurate SIV exposure status of the pigs.  
2. Materials and methods 
2.1 Serum samples  
 Three sets of serum samples were included in the study. The first set was from 24 
pigs (4 pigs per group) experimentally infected intratracheally with different SIV strains from 
3 SIV subtypes (Table 1). Groups 1-3 were infected with 5 ml of 106 TCID50/ml of virus (low 
dose) at 5 weeks of age, and challenged a second time with 5 ml of 108 TCID50/ml (high 
dose) of homologous virus at 10 weeks of age.  Groups 4-6 were infected once with the high 
dose of different SIV viruses at 10 weeks of age. Serum collected from 12 pigs prior to 
infection was used for negative control sera. Sera were collected from pigs in groups 1-6 at 7, 
14, 21, 28 days post infection (dpi) and from groups 1-3 at 41 dpi (7 days post second 
infection).  
The second set of sera was from four groups of pigs (10 pigs/group) that had been 
vaccinated and/or experimentally infected with SIV. Group V pigs were vaccinated with a 
commercial inactivated bivalent (H1N1 and H3N2) swine influenza vaccine (End-
FLUence®-2, Intervet Inc., Millsboro, DE, USA) at 3 and 5 weeks of age. Group VC pigs 
were challenged intratracheally with 4 ml of 105.5 TCID50/ml of A/Swine/IA/40776/92 
(H1N1) at 7 weeks of age in addition to vaccination. Group C pigs were not vaccinated but 
were challenged similar to group VC. Group N received no vaccine and no SIV challenge 
and served as negative controls. Sera was collected from all 40 pigs one day prior to 
vaccination (day -1) and at day 21 after the second vaccination which is 7 days after 
challenge.  
The third serum set consisted of matched serum  from 21 pigs at 3 weeks of age that 
were MDA positive for SIV as determined by  the HI assay and 20 age-matched (HI titer < 
10), SIV-seronegative pigs. 
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Table 1  
Virus strains used in serum sample set 1. The low dose of virus was 5 x 106 TCID50 and pigs  
were inoculated at 5 weeks of age. The high dose of virus was 5 x 108 TCID50 and pigs were 
infected at 10 weeks of age. 
 
Group  Virus (Subtype) Virus dose 
1 A/Swine/IA/40776/92 (H1N1) low & high 
2 A/Swine/Wisconsin/R33f/01 (H1N2) low & high 
3 A/Swine/Texas/4199-2/98 (H3N2) low & high 
4 A/Swine/IA/35233/99 (H1N1) high 
5 A/Swine/Indiana/9K035/99 (H1N2) high 
6 A/Swine/Wisconsin/R7c/01 (H3N2) high 
2.2 Hemagglutination-inhibition (HI) test 
The viruses used as test antigens for the serum samples from the first sample set were 
homologous to the viruses used to infect the pigs (Table 1). The A/Swine/IA/40776/92 
(H1N1) virus, which cross-reacted serologically to the H1N1 strain contained in the vaccine 
used in the second and third sample sets, was used as the test antigen for assays of the 
corresponding samples. The HI assay was performed according to the standard protocol 
routinely performed at the Iowa State University-Veterinary Diagnostic Laboratory with HI 
antibody titers > 20 (log2 HI titer > 2) considered as positives (Yoon et al., 2004). The HI 
antibody titer was determined as the reciprocal of the highest serum dilution that fully 
inhibited hemagglutination of 0.5% turkey red blood cells. The log2 HI antibody titers were 
compared between different groups.   
2.3 Development of indirect M2e ELISA 
2.3.1 M2 extracellular domain (M2e) protein production   
2.3.1.1 PCR and plasmid construction 
A truncated form (extracellular N-terminal residues 1-24) of M2 DNA was produced 
by PCR from pENTR/D-TOPO.M2 (Invitrogen, Carlsbad, CA) using specific primers. The 
forward primer (5’-GCCGCGGAATTCCATGAGTCT TCTACTAACCGAGG -3’) was 
specific for the 5’ coding region of the M2 gene (nucleotides 1-19) and began with a 5’ 
EcoR1 restriction endonuclease site. The reverse primer (3’-
CGTTGCTAAGTTCACTAGGAACTCAGCTGCGGCGG-5’) coded for the 3’ 
amplification (nucleotides 985-1004) and began with a 5’ Sal1 restriction endonuclease site. 
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The truncated DNA obtained was cloned into a pGEX-4T3 plasmid (GE Healthcare Bio-
Sciences Corp., Piscataway, NJ) according to the manufacturer’s instructions. The pGEX-
4T3 vector in the pGEX expression system is designed to express under the control of an 
inducible tac promoter, glutathione S-transferase (GST) as a 26-kDa fusion to the N-terminus 
of a subcloned sequence. The integrity of the base sequence of M2e and in-frame status of 
the sequence was verified by sequence analysis. The M2e recombinant pGEX-4T3 (pGEX-
4T3.eM2) plasmid was amplified by transformation into competent TOP10 E.coli cells 
(Invitrogen, Carlsbad, CA) and purified by the QIAGEN Plasmid Midi Kit (QIAGEN Inc., 
Valencia, CA) following the manufacturer’s instructions.   
2.3.1.2 Expression and purification of M2e protein 
To express the M2e protein, pGEX-4T3.eM2 was transformed into competent E. coli 
strain BL21 and recombinant cells were grown overnight in Luria broth (LB) with 100 µg/ml 
ampicillin. The culture was then diluted 1:20 and incubated for 2 hrs at 37oC with vigorous 
shaking. Isopropyl i-D-thiogalactoside (IPTG) was added to a final concentration of 0.1 mM 
and incubated for an additional 2-3 hrs. Cells were then pelleted and M2e protein purification 
was performed using MagneGST purification kit (Promega Corporation, Madison, WI) 
following the manufacturer’s instructions. Western blot analysis was performed as described 
previously (Rozek et al., 2003) using a 15% Tris-glycine gel and transferred onto a 
polyvinylidene difluoride (PVDF) membrane and stained with the monoclonal antibody 
(mAb) anti-influenza A virus M2 clone 14C2 (Affinity BioReagents, Inc., Golden, CO) 
followed by goat anti-mouse IgG horseradish peroxidase conjugate (Dako Cytomation, 
Carpinteria, California) and colors were developed with Opti-4CN substrate kit (Bio-Rad 
Laboratories, Hercules, CA) to confirm the M2e protein expression. The concentration of 
purified eM2 protein was determined by Bicinchoninic Acid (BCA) Protein Assay kit (Pierce 
Biotechnology, Inc., Rockford, IL) and stored at -80oC until use.    
2.3.2 Indirect M2e ELISA 
Immulon 2HB polystyrene microtiter plates (Dynex Technologies Inc., Chantilly, 
VA) were coated with 100 µl of M2e protein at a dilution of 1:300 in carbonate-bicarbonate 
coating buffer, pH 9.5, in a checkerboard pattern as previously described (Nawagitgul et al., 
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2002). The coated plates were incubated at room temperature (RT) overnight and then stored 
at -20oC.  
To test serum samples, M2e plates were thawed and equilibrated to RT and washed 3 
times with 15 second incubations using PBST washing buffer (0.1 M phosphate buffer saline 
(PBS) pH 7.2 with 0.02% Tween 20). The M2e plates were blocked with 100 µl of 5% milk 
diluent (Kirkegaard & Perry Laboratories Inc., Gaithersburg, MD) for 1 hr at RT and washed 
3 times with PBST washing buffer. Serum samples were diluted 1:50 using 5% milk diluent. 
Each diluted sample was run in duplicate using 100 µl of sample per well and incubated for 1 
hr at 37oC. Excess antibodies were removed by washing 3 times with PBST washing buffer 
using a microplate washer (BioTek Instruments, Inc., Winooski, VT). Peroxidase-labeled 
goat anti-swine immunoglobulin G (Sigma-Aldrich, St. Louis, MO) diluted at 1:1000 in 5% 
milk diluent was added at 100 µl per well and incubated for 1 hr at 37oC followed by 3 
washings with PBST washing buffer. A pre-warmed 2,2’-azino-di-(3-ethylbenzthiazoline-6-
sulfonate) (ABTS) substrate freshly prepared according to the manufacturer’s protocol 
(Kirkegaard & Perry Laboratories Inc., Gaithersburg, MD) was added (100 µl) and incubated 
for 30 min at 37oC. The enzyme-substrate reaction was stopped by adding 100 µl of 1% 
sodium dodecyl sulfate (Sigma-Aldrich, St. Louis, MO) in PBS into each well and the optical 
density (OD) was measured at 405 nm. Positive sera samples from rM2-injected pigs were 
run in duplicates with an assay A405 OD = 0.6-0.7 on each plate and the sample diluent was 
included in the blank wells as controls. The M2e specific antibody levels were reported as the 
mean OD of the duplicates and the mean OD of each treatment group including the negative 
controls were then compared. Samples were considered positive was considered when the 
mean ODs of the test samples were significantly different from mean ODs of negative 
control samples. 
2.4 Development of indirect rM1 ELISA 
2.4.1 rM1 protein production   
2.4.1.1 PCR and plasmid construction 
The BaculoDirect® baculovirus expression system (Invitrogen, Carlsbad, CA) was 
used for expression of the full-length M1 protein (252 amino acids) to produce the 
recombinant M1 (rM1) protein. Total cellular RNA was purified from MDCK cells infected 
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with cH1N1 (Table 1). The M1 cDNA was amplified by the SuperScript™ First-Strand 
Synthesis System (Invitrogen, Carlsbad, CA) using the following specific primers: forward 
primer 5'-CACC ATGAGYCTTCTAACC-3' and reverse primer 5’-
AGGATCACTTGAATCGTTGC-3’. The cDNA obtained was inserted into a gateway entry 
vector, pENTR-Directional TOPO (Invitrogen, Carlsbad, CA). The orientation and integrity 
of the base sequence of M1 in the gateway entry vector (pENTR/D-TOPO.M1) was verified 
by sequence analysis. The M1 gene was then inserted into the baculovirus expression vector 
according to the manufacturer’s instructions and expressed in Sf21 cells (Invitrogen, 
Carlsbad, CA) similar to the rM2 protein as described in sections 2.3.1.1.and 2.3.1.2 
respectively.  
2.4.1.2 Expression and purification of rM1protein 
Protein purification was performed with MagneHis purification kit (Promega 
Corporation, Madison, WI) according to the manufacturer’s protocol. Western blot analysis 
was performed as described previously (Rozek et al., 2003) and similar to section 2.3.1.2 and 
stained with monoclonal anti-IAV matrix antibody (ATCC cat# HB-64; American Type 
Culture Collection, Manassas, VA) followed by addition of goat anti-mouse IgG horseradish 
peroxidase conjugate (Dako Cytomation, Carpinteria, California) and color was developed 
with Opti-4CN substrate kit (Bio-Rad Laboratories, Hercules, CA) to verify the rM1 protein 
expression. The concentration of purified rM1 protein was determined by the BCA Protein 
Assay kit (PIERCE, Rockford, IL) and stored at -80oC until use.    
2.4.1 Indirect rM1 ELISA 
The rM1 ELISA plates were prepared and serum samples were assayed using a 
similar protocol as with the indirect M2e ELISA described in section 2.3.2. with two 
modifications. The rM1 plates were blocked with 5% bovine serum albumin (BSA) in PBS 
and serum samples were diluted at 1:50 with 1% BSA in PBS. The rM1 antibody levels were 
reported in the same manner as the M2e antibody levels indicated in section 2.3.2.
2.5 Production of positive control sera for indirect M2e ELISA  
2.5.1. PCR and cloning of M2 cDNA  
To produce positive control sera for indirect M2e ELISA, a full-length recombinant 
M2 (rM2) protein (97 amino acids) was constructed using the BaculoDirect® baculovirus 
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expression system (Invirogen, Carlsbad, CA). Total cellular RNA was purified from Madin-
darby canine kidney (MDCK) cells infected with cH1N1 using Trizol LS (Invitrogen, 
Carlsbad, CA). The M2 cDNA was amplified using SuperScript™ First-Strand Synthesis 
System (Invitrogen, Carlsbad, CA) with the following specific primers: forward primer 5'-
CACCATGAGYCTTCTAACC-3' and reverse primer 5’-AGGATCACTTGAATCGTTGC-
3’. The cDNA obtained was then inserted into a gateway entry vector, pENTR-Directional 
TOPO (pENTR/D-TOPO) (Invitrogen, Carlsbad, CA). The orientation and integrity of the 
base sequence of the M2 sequence in the gateway entry vector (pENTR/D-TOPO.M2) was 
verified by sequence analysis. The M2 gene was then subcloned into the baculovirus 
expression vector according to the manufacturer’s instructions. Briefly, the M2 gene in the 
gateway entry vector was integrated into the BaculoDirect C-Term Linear DNA by site-
specific LR recombination that occurs between specific attachment (att) sites: attL on entry 
the vector and attR on the baculoviral expression vector. The rM2-baculoviral DNA was then 
transfected into Sf9 cells (Invitrogen, Carlsbad, CA) and non-recombinant baculovirus was 
negatively selected by ganciclovir selection. Two additional infection cycles were performed 
on Sf21 cells to obtain higher viral titer for increased rM2 protein expression.  
2.5.2 Expression and purification of rM2 proteins 
The rM2 protein was expressed in Sf21 cells in the presence of amantadine (2 µg/ml) 
and cultured at 270C. Infected Sf21 cells were harvested after 48 hrs of incubation by 
centrifugation. The pellet was washed twice with cold PBS and resuspended in 5 ml of cold 
PBS. Expressed rM2 protein was semi-purified following the method of Schroeder et al. 
(1994) (Schroeder et al., 1994) with modifications. In brief, cells were sonicated 2 times by 
placing the tubes in a container with iced water using a Branson Sonifier at constant power, 
output=8, and continuous sonication for 15 seconds. The remaining cell lysates were 
pelleted, and the supernatant was collected. All solutions in the following steps were 
incorporated with a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). The samples 
were prepared by diluting sucrose in the collected supernatant at 70% (w/v), overlaid with 
HEPES buffered saline (10 mM-HEPES, 150 mM-NaCl pH 7.8) up to the volume of the 
centrifuge tube and centrifuged at 89,454 g in a Beckman SW28 rotor for 12 hrs. The cellular 
membrane fraction at the interface was collected and pelleted at 89,454 g for 1.5 hrs followed 
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by washing once with HEPES buffered saline pH 7.8 and extracted with 1 M-KCl in HEPES 
buffered saline pH 7.8 at 4oC for 1 hr and pelleted. The pellet was washed once with HEPES 
buffered saline pH 7.8 and the transmembrane proteins were extracted with 40 mM-n-octyl 
glucoside (OG; 1-O-n-octyl i-D-glucopyranoside; Sigma-Aldrich, St. Louis, MO) for 1 hr at 
4oC and centrifuged 89,454 g for 1.5 hrs. The semi-purified rM2 protein was dissolved in 3 
ml of 40 mM-OG by passing through a 25-gauge needle and verified by western blot analysis 
as described in section 2.3.1.2 and stored at -80oC until used. 
2.5.3 Production of rM2 specific antibodies 
Pigs 3-5-weeks-of-age received 3 intramuscularly injections at 2 week intervals of 10, 
25 and 50 µg of adjuvanted rM2 protein (Microsol Diluvac Forte®, Intervet Inc., Millsboro, 
DE). Serum samples were collected 2 weeks following the third injection and were 
confirmed to be positive to the M2 protein by western blot analysis and used as positive 
control sera in the indirect M2e ELISA.     
2.6 Statistical analysis 
Analysis of variance was performed to determine group differences for each 
measured parameter. If the P-value for an ANOVA table was less than or equal to 0.05, the 
differences between treatment groups were evaluated using the Tukey-Kramer Honestly 
Significant Difference multiple comparison test. Student’s paired t test was used for analysis 
of paired sera. All data analyses were performed using JMP® statistical software (SAS 
Institute, Cary, NC). 
3. Results  
3.1 Hemagglutination-inhibition (HI) test 
 Sample set 1:  The HI results showed that the infection dose of SIV had an impact on 
the level and time of seroconversion of HI antibody titers produced following infection. At 
all time points except 28 dpi, pigs infected with the higher dose of virus had significantly 
higher HI titers compared to pigs receiving the lower dose of the same subtype virus (Figure 
1A). All pigs infected with the high dose of virus and pigs infected with lower dose of the 
H1N1 virus seroconverted (HI titer > 20 or log2 HI titer > 2) at 7 dpi. Pigs infected with the 
H3N2 subtypes at the low dose seroconverted at 14 dpi while pigs infected with the H1N2 
virus seroconverted at 21 dpi. Strain differences were more evident in the group infected at 
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the lower dose. Within the groups infected at the lower dose, pigs infected with H3N2 
subtype had significantly higher HI titers than did pigs infected with the H1N1 and H1N2 
subtypes at 14 and 21 dpi. Pigs infected at the higher dose of virus had no significant 
differences in HI titers between the subtypes at any time point except at 28 dpi when the titer 
in pigs infected with H1N2 dropped significantly compared to the titers in pigs infected with 
H3N2 (Figure 1A). In the pigs which were first infected with the low dose virus, followed by 
infection with the second higher dose of the same virus, the HI titers increased in all pigs 7 
days following the second infection showing an anamnestic response (Figure 2A). 
Sample set 2: All pigs were seronegative at 1 day prior to vaccination as measured by 
the HI assay and all pigs in group N remained negative throughout the trial (data not shown). 
At 21 days post vaccination (dpv), the HI titers were positive (HI titer > 20) in 9 and 8 out of 
10 pigs in groups V and C, respectively (data not shown). Pigs in group VC had significantly 
higher mean HI titers compared to the other groups (Table 2).  
Sample set 3: The HI titers of the MDA positive pigs were variable. There were 5, 6, 
6 and 4 pigs with HI antibody titers of 80, 160, 320 and 640 respectively (Table 3). 
3.2 Expression of rM2, M2e and rM1 protein 
The purified rM2, M2e and rM1 proteins as determined by immunoblot are shown in 
Figure 3.  
3.3 Indirect M2e ELISA 
Sample set 1: A dose dependent impact on the M2e ELISA OD and timing of 
seroconversion time was observed in SIV infected pigs. Pigs infected with the higher dose of 
virus had significantly higher M2e ELISA OD values compared to pigs infected with the 
lower dose and values were dependent on the SIV subtype (Figure 1B). Subtype had no 
effect on the mean ELISA OD detected after the first infection. Pigs infected with lower dose 
of the H1N1 virus seroconverted at 21 dpi while pigs infected with H3N2 and H1N2 viruses 
seroconverted at 28 dpi. In contrast, all pigs inoculated with the higher dose of all three 
subtypes seroconverted at 7 dpi. The M2e ELISA OD levels peaked at 21 dpi and most 
appeared to begin declining after that time (Figure 1A&B). At 7 days following the second 
inoculation with the homologous virus, an increase in M2e ELISA OD was detected only in 
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pigs infected with the H1N1 virus with a 2-fold increase and levels were significantly higher 
than observed from the other subtypes of virus (Figure 2B).  
 Sample set 2: The M2e ELISA OD values of paired sera from pigs groups V, C and 
VC did not increase significantly compared to the negative control group N following 
vaccination and/or challenge (Table 2).  
 Sample set 3: The M2e ELISA mean OD levels were significantly different in sera 
from the MDA negative pigs was detected only in the MDA+ pigs with HI titers of 80, 320 
and 640. No significant differences were detected between the M2e ELISA OD positive 
groups (Table 3).  
3.4 Indirect rM1 ELISA 
Sample set 1: Neither virus subtype nor infection dose appeared to have much effect 
on the rM1 ELISA OD levels following infection. With the exception of pigs challenged with 
the low dose of H3N2 virus which seroconverted at 7 dpi, all pigs independent of challenge 
dose or subtype seroconverted at 21 dpi. Pigs that received the higher dose of virus 
demonstrated a more rapid decline in the rM1 ELISA OD levels. At 28 dpi, the rM1 ELISA 
OD levels in H3N2 infected pigs that had received the high dose of virus were significantly 
lower than OD levels of the other groups that had received the higher dose of SIV (Figure 
1C).  After secondary challenge, the rM1 ELISA OD levels did not appear to increase 
significantly in any of the SIV challenged pigs (Figure 2C). 
 Sample set 2: The rM1 antibody levels from paired sera from groups V and C did not 
differ significantly from group N. As shown in Table 2, only group VC which was 
vaccinated twice and challenged with SIV, had a significant increase in mean rM1 ELISA 
OD levels compared to the negative control group N. 
 Sample set 3: The only group that had significantly higher rM1 ELISA mean OD 
levels compared to the MDA negative pigs were the MDA positive pigs with HI titers of 640 









Fig. 1. Results from serum sample set 1. Comparison of antibody responses of pigs infected 
with 3 SIV subtypes comparing antibodies produced following either a single low-dose or 
high-dose infection with the same subtype at 4 time points (A) HI antibody levels against 
homologous viruses are expressed as mean Log2 HI titer ± SD (B) M2e ELISA results 
expressed as mean OD ± SD and (C) rM1 ELISA results expressed as mean OD ± SD. a,b 
Values not sharing the same letters are significantly different within the same virus dose and 
dpi. * Significantly higher values at the same dpi of each SIV subtype (P<0.05).  
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Fig. 2. Results from serum sample set 1. Comparison of antibody responses from pigs 
inoculated with a low-dose (5×106 TCID50) of 3 different SIV subtypes followed by a  high-
dose (5×108 TCID50) homologous virus challenge (A) HI antibody levels expressed as mean 
Log2 HI titer ± SD (B) M2e ELISA values expressed as mean OD ± SD and (C) rM1 ELISA 






























































Table 2    
Results from serum sample set 2 demonstrating means±SD of HI titer, M2e ELISA OD and 
rM1 ELISA OD at 21 days after the second vaccination (group V) and 7 days after SIV 
challenge (groups VC and C).  
 
Group HI test  
(mean titer±SD)  
 M2e ELISA 
(mean OD±SD)
rM1 ELISA  
(mean OD±SD) 
V + (80.0±11.5) - (0.225±0.158) - (0.708±0.242)
VC + (343.1±10.0)* - (0.282±0.166) + (0.904±0.504)
C + (56.6±17.4) - (0.173±0.078) - (0.691±0.296)
* Statistically significantly higher mean HI titers (P<0.05) than groups V and C 
 
Table 3 
Results from serum sample set 3 demonstrating the M2e and rM1 ELISA mean OD ± SD at 
different HI titers from MDA+ and MDA- pigs. a,b Values not connected by the same letter 
are significantly different within each ELISA (P<0.05) 
 








MDA – (20)         <10 0.092±0.021a 0.133±0.021a
80 (5) 0.314±0.115b 0.311±0.134a
MDA+ (21)       160 (6) 0.232±0.079a 0.338±0.129a
320 (6)  0.387±0.154a,b 0.524±0.287a










Fig. 3. Immunoperoxidase staining of purified proteins on a polyvinylidene difluoride 
(PVDF) membrane after electrophoresis in a 15% SDS-PAGE under reducing conditions.  
Lane 1: GST-M2e fusion protein (28.9 kD) stained with mAb anti-influenza A virus M2e 
clone 14C2. Lane 2: full length rM2 protein (15 kD) stained with mAb anti-influenza A virus 
matrix clone M2-1C6-4R3. Lane 3: full length rM1 protein (28 kD) stained with anti-IAV 
matrix mAb. The binding of all mAbs was detected using a peroxidase-conjugated goat anti-
mouse IgG and Opti-4CN substrate kit.    
 
4. Discussion 
Antigenic variation of SIV creates a problem in controlling influenza-induced disease 
in the swine industry.  A vaccine that would provide broader protection against antigenic 
variation is needed and the M2 protein appears to be a potential candidate.  However, the 
antibody response to M2 protein following vaccination or infection has not been well studied 
in pigs. While one study detected the presence of M2 antibodies in pigs infected with SIV 
using the extracellular region of the M2 (M2e) synthetic peptide-based ELISA, little else is 
known on the levels of M2 or M1 proteins in pigs (Heinen et al., 2001). This study 
characterized the M2 and M1 antibody responses in pigs with different SIV exposure status 
by using indirect ELISA assays. The tested samples included serum from pigs infected with 
different SIV subtypes, SIV-vaccinated and/or challenged pigs and pigs positive for MDA. 
The presence of HI antibodies was used to confirm the exposure status of each sample set.  
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A recent study suggested that neither western blot analysis nor ELISA could detect all 
antibodies produced against the native tetrameric form of M2 proteins following influenza 
infection (Feng et al., 2006). In the study, a cell-based ELISA generated using a HeLa cell 
line expressing the full-length tetrameric M2 was shown to be more efficient in detecting 
M2e antibodies compared to an immobilized M2e peptide-based ELISA. However, the levels 
of antibodies to all forms of the M2 protein in mice detected by the cell-based ELISA were 
low and only present for a short period of time following infection. The study highlighted the 
importance of choosing the appropriate assay for studying an antibody response, especially 
when the level of antibodies against a native form may be relatively higher than against a 
monomeric form of the same protein. In the case of M2 antibodies, it appears that no matter 
what type of test is utilized for analysis; antibodies were only transiently produced after 
infection. The choice of a serological test to study the M2 antibodies therefore relies on the 
availability and resources of each laboratory. The initial development of a recombinant M2 
protein in either a eukaryotic or prokaryotic system is more economical than the use of 
synthetic peptides. In addition, several studies demonstrated reduced sensitivity of antibody 
detection using synthetic peptides compared to a recombinant protein (Galli et al., 1996; 
Kwang and Torres, 1994).    
The M2e ELISA titers and the timing of seroconversion differed depending on SIV 
exposure. The infection dose had a major effect on when seroconversion occurred and 
antibody level to the HA and M2e proteins but not the rM1 protein. Although the virus titers 
used in the experimental models were much higher than would occur with natural infection in 
humans, which could be estimated at 127–320 TCID50 (Tellier, 2006), only low M2e specific 
antibody responses were detected. However, the positive correlation of the M2e specific 
antibody responses and the infection doses suggests that a higher M2e antigen concentration 
was important to induce a higher level of the M2e immune response to SIV infection. In 
contrast to antibodies measured by the HI assay, differences in subtype did not effect either 
the M2e or rM1 ELISA OD levels. In contrast, HI titers to the H3N2 subtype were 
significantly greater than the titers observed with either H1N1 or H1N2 subtypes. This 
finding is consistent with an earlier study in humans that demonstrate a stronger immune 
response to vaccination with a H3N2 virus compared to a H1N1 virus (Saurwein-Teissl et al., 
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1998). Similarly, several experimental SIV infection studies in pigs have revealed 
comparable results showing that infection with H3N2 viruses induces higher HI titers 
compared to a H1N1 virus (Reeth et al., 2004; Van Reeth et al., 2003; Van Reeth et al., 
2006). The HA protein conformation of the H3 subtype is more easily cleaved into two 
subunits, HA1 and HA2, than the H1 subtype. This has been suggested as reason of the 
higher immunogenicity of H3 viruses compared to the H1 viruses (Treanor et al., 2006; 
Wang et al., 2006).   
The results of this study agreed with the earlier reports in human and mice that low 
levels of M2e specific antibodies were induced in response to IAV infection (Black et al., 
1993; Liu et al., 2003; Mozdzanowska et al., 2003). This study demonstrated similar findings 
in pigs with the induction of low M2e specific antibodies for a short duration following SIV 
infection (Heinen et al., 2001). An earlier study suggested that the number of M2e specific 
antibody producing cells is low in the B cell repertoire and might require multiple 
stimulations for the induction of significant levels of M2e specific antibodies and memory 
cells (Feng et al., 2006). Data in their study found that mice require three consecutive 
infections to significantly increase the level of M2e specific antibodies.  The results from this 
study found a 2-fold increased M2e ELISA OD levels in H1N1 infected pigs that had been 
challenged with the homologous H1N1 which supports this hypothesis. 
Another possible explanation for the low M2e specific antibody response compared 
to the HI titers is the phenomenon known as “intravirionic antigen competition”. An average 
influenza virion expresses these three transmembrane proteins at approximately 14 M2 
tetramers compared to 100 NA tetramers and 400 HA trimers (Zebedee and Lamb, 1988). 
Johannson et al (1987) (Johansson et al., 1987) found that the HA protein is dominate over 
the NA protein in priming both T- and B-lymphocytes, resulting in higher antibody responses 
against the HA protein compared to the NA protein. The intravirionic antigen competition 
could be diminished when both the HA and NA proteins were presented as isolated, 
individual antigens in equal amounts (Johansson and Kilbourne, 1993). In a subsequent 
study, no antigenic competition was observed when mice were immunized with equal levels 
of purified NA, M1 and NP protein (Johansson and Kilbourne, 1996). These findings led 
investigators to determine the optimum quantity of NA protein to be added to inactivated 
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influenza virus vaccines to improve vaccine efficacy (Aymard et al., 2003). For that reason, 
the M2e antibody response after infection or vaccination may compete in a similar manner 
with the NA response. This factor should be considered if the M2 protein is being considered 
as an immunogenic component in a HA- and NA-based vaccine. On the other hand, the M1 
protein is the most abundant and conserved protein on the virion containing at least twice as 
many molecules per virion than does the HA protein (Bucher et al., 1987). Therefore, M1 
antibodies were detected in the vaccinated and challenged pigs.  
 Passive SIV-specific immunity in piglets born from SIV-vaccinated sows contained 
high levels of HA antibodies (Loeffen et al., 2003a; Loeffen et al., 2003b). Sows can be 
exposed to influenza viruses of different strains or subtypes through repeated vaccinations 
and natural infection which could have enhanced the levels of M2e specific antibodies that 
transferred to the piglets. The levels of M2e specific antibodies in pigs that were positive for 
SIV-specific MDA in this study were relatively low and did not appear to be correlated with 
the higher HI antibody titers. Variation in the SIV exposure profile of the sow may have 
accounted for the differences in M2e specific antibody levels of the MDA positive pigs. 
In conclusion, this study found that SIV-vaccinated and/or –infected pigs responded 
with higher levels of M1 specific antibodies compared to the M2e specific antibodies.  
However, the use of M1 antibody as a confirmation for exposure to SIV independent of strain 
and subtype appeared to be discouraging as seroconversion to the M1 protein was not 
uniformed and were detected relatively late in the course of SIV infection. In addition, no 
anamnestic response was detected following secondary infection. Characterizing the antibody 
response to M2 protein in pigs following SIV infection showed that low levels of M2e-
specific antibodies were produced and no further response occurred following vaccination 
with the conventional inactivated SIV vaccine used in this study. Re-infection with 
homologous virus did not appear to significantly enhance the M2e antibody levels and 
seemed to vary by virus subtype. The use of a M2 protein-based vaccine for pigs may induce 
higher levels of M2 specific antibodies that could potentially enhance the protective 
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SUMMARY
The ability of a recombinant matrix 2 (rM2) protein used in combination with a commercial 
vaccine containing H1N1 and H3N2 swine influenza viruses (SIV) to reduce disease 
following experimental challenge was evaluated. Thirty-five pigs were vaccinated with or 
without rM2 protein at 3 and 5 weeks of age and challenged with either a classical swine 
cH1N1 or a H1N2 virus at 7 weeks of age. Non-vaccinated, unchallenged pigs served as 
negative controls and non-vaccinated, challenged pigs were used as positive controls. Pigs 
receiving the rM2 protein with the commercial vaccine had fewer microscopic lung lesions at 
5 days post infection and fewer pigs shed virus compared to either vaccinated pigs that did 
not receive the rM2 or the positive control pigs. Prior to challenge, pigs administered the rM2 
protein had an enhanced CD4+ T cell proliferative response to the cH1N1 antigen compared 
to pigs receiving only the commercial vaccine. Vaccination alone was able to significantly 
reduce pneumonia and decrease virus shedding after infection. Thus, the effect of including 
the rM2 protein with the conventional vaccine could not be conclusively determined. 
However, these results suggest that the rM2 protein may enhance the immune response 




COMMERCIAL swine influenza virus (SIV) vaccines currently available in the U.S. consist 
of inactivated viruses containing different virus subtypes. These inactivated vaccines 
primarily produce serum antibodies against the hemagglutinin (HA) and neuraminidase (NA) 
proteins which provide protection against disease in the lungs (Renegar 1992). The HA 
antibodies are known to neutralize virus (Couch 2003). Currently, the protective capacity of 
vaccine-induced antibodies is affected by the rate of antigenic drift resulting in alteration of 
the antigen structures on the viral surface (Fields and others 2001). Since the emergence of a 
H3N2 subtype virus in the U.S. swine population in 1998, the frequency of clinical outbreaks 
of respiratory disease associated with SIV in nursery pigs in the presence of passive 
immunity from vaccinated sows has increased. This increased clinical disease in nursery pigs 
appears to be due to reduced protection by maternally derived antibodies (MDAs) against the 
genetically diverse viruses of the same subtype circulating in the herd (Warren and others 
2004). As a result, novel strategies to improve and enhance SIV vaccine efficacy at all levels 
of swine production systems are needed. 
Recently, researchers have focused on developing subunit vaccines with the potential 
to induce a broader immunity to influenza A viruses by using the conserved matrix 2 (M2) 
protein (De Filette and others 2005). The M2 protein is highly conserved as the M2 gene is 
encoded from spliced mRNA of the matrix gene which encodes the M1 protein, the most 
conserved structural protein of the influenza A viruses (Fields and others 2001). The M2 is a 
transmembrane protein with a nonglycosylated extracellular region (M2e) consisting of 24 
amino acids at the N-terminus (Zebedee and others 1985). Monoclonal antibodies against 
M2e have been shown to reduce viral replication and spread in in vitro by interfering with 
virus budding (Zebedee and Lamb 1988). In addition, several studies have demonstrated that 
a M2 protein-based vaccine was effective in protecting against influenza A infection in mice 
(Frace and others 1999; Mozdzanowska and others 2003) and ferret models (Fan and others 
2004). In contrast, one study reported that pigs immunized with a M2 and nucleoprotein (NP) 
DNA-based vaccine were not protected against clinical disease or infection even though 
detectable M2 antibodies were present  (Heinen and others 2002). This same study found 
enhanced clinical disease in pigs which had been vaccinated with the M2 antigen. Since M2-
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specific antibodies do not neutralize the virus, neutralizing HA antibodies are also required to 
prevent initiation of infection. However, to date no studies have reported on the use of the 
M2 protein to enhance immunity in combination with a conventional SIV vaccine which 
produces antibodies against the HA and NA proteins.  
This study evaluated the impact of the rM2 protein combined with a commercial SIV 
vaccine to protect against either influenza infection and disease in pigs experimentally 
challenged with either a classical swine H1N1, which was closely related to the vaccine 
antigen, or a heterologous H1N2 virus with low serological cross-reactivity to the vaccine 
virus in pigs. We hypothesized that vaccination with both the inactivated virus vaccine and 
rM2 protein would induce neutralizing antibodies against the HA and NA proteins reducing 
infection and preventing virus spread and enhance protection against the antigenically 
diverse SIV isolate through antibodies from the conserved M2.  
MATERIALS AND METHODS
Vaccines 
A commercial bivalent SIV vaccine (End-FLUence®-2, Intervet Inc., Millsboro, DE, USA) 
containing an H1N1 and a clade I H3N2 (Thacker and others 2005) was administered 
according to label directions in the study.  Fifty µg of rM2 protein in the adjuvant used in the 
commercial vaccine (Microsol Diluvac Forte®, Intervet Inc., Millsboro, DE) was 
administered intramuscularly in a different area to pigs in the appropriate groups. The rM2 
protein was prepared as previously described (Kitikoon and others 2007). 
Experimental design 
Thirty-five 8- to 12-day-old crossbred pigs, obtained from a commercial herd serologically 
negative for porcine reproductive and respiratory syndrome virus and SIV, were used in the 
study. Pigs were assigned to 7 groups of 5 pigs each with stratification by arrival weight 
(TABLE 1). Throughout the study, pigs were housed in identical isolation rooms based on 
their challenge status. Pigs were provided feed and water ad libitum throughout the trial. All 
study procedures and animal care activities were conducted in accordance with the guidelines 
and under the supervision of the Iowa State University Institutional Committee on Animal 
Care and Use. Vaccinated pigs (TABLE 1) were immunized intramuscularly with the 
commercial vaccine according to label directions at 3 and 5 weeks of age. Groups that were 
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assigned to receive the rM2 protein at the same time were injected with rM2 protein 
intramuscularly in the neck on the opposite side. Two weeks after the second vaccination(s), 
all pigs except the negative control pigs  were challenged with either the classical swine 
H1N1 strain A/Swine/IA/40776/92 (cH1N1) or the H1N2 strain A/Swine/Indiana/9K035/99 
(H1N2) via the intratracheal route.  
 
TABLE 1: Experimental design 
Group Vaccination with rM2 protien SIV infection 
commercial vaccine   
NEG No No No
VrM2/cH1N1 Yes Yes cH1N1 
V/cH1N1 Yes No cH1N1 
cH1N1 No No cH1N1 
VrM2/H1N2 Yes Yes H1N2 
V/H1N2 Yes No H1N2 
H1N2 No No H1N2 
Clinical monitoring 
Rectal temperatures and clinical signs were recorded daily from one day before infection 
until they were euthanized at 5 days post-infection (dpi). Body temperatures of > 400C were 
considered febrile. Respiratory scores were given a range from 0-3; 0 = normal, 1 = 
tachypnea (respiratory rate above 40 per minute) following physical exertion, 2 = tachypnea 
at rest. If coughing was present at rest or during physical exertion, one point was added to the 
respiratory score. 
Macroscopic and microscopic lesions  
Macroscopic lesions consistent with SIV pneumonia (dark red-to-purple lobular 
consolidation) were sketched onto a standard diagram and assessed for percentage of lung 
surface exhibiting lesions as determined using a Zeiss SEM-IPS image analysis system as 
previously described (Thacker and others 2001). Tissue samples were collected from each 
lung lobe and fixed in 10% neutral buffered formalin for the detection of microscopic lesions 
(Thacker and others 2001) and SIV-specific antigen using immunohistochemistry test 
(Vincent and others 1997). 
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Virus isolation from nasal swabs 
Nasal swabs were collected on days -1, 2, 4, and 5 dpi to evaluate the level of SIV excretion. 
Virus isolation was performed as previously described (Kitikoon and others 2006). The viral 
titer in each nasal swab was expressed as log10 50% tissue culture infective dose (TCID50)
per milliliter as calculated by the method of Reed and Muench (Reed and Muench 1938).     
Serology  
Serum samples were collected prior to each vaccination, prior to challenge and at 5 dpi. The 
antibody response was assessed by hemagglutinin-inhibition (HI) assay utilizing both 
challenge viruses. The HI assay was performed according to the standard protocol routinely 
performed at ISU-Veterinary Diagnostic Laboratory (Yoon and others 2004) using 0.5% 
rooster erythrocytes for hemagglutination and 8 hemagglutination (HA) units per 50 µl of
both challenge viruses. The HI antibody titers were expressed as the mean reciprocal number 
of the highest dilution that was able to completely inhibit agglutination of erythrocytes ±
standard deviation. Serum anti-M2 antibodies were measured and expressed as mean optical 
density (OD) of each treatment groups using an indirect ELISA as previously described 
(Kitikoon and others 2007).  
Flow Cytometry Analysis 
Cell-mediated immune (CMI) responses were assessed at -1dpi using a proliferation assay 
coupled to a phenotypic evaluation of the lymphocyte subsets.  Heparinized peripheral blood 
mononuclear cells (PBMCs) were collected and the responding cells of different T cell 
population to the cH1N1 and H1N2 antigen was performed as described previously (Kitikoon 
and others 2006) with modification in the PBMCs culturing step.  As a slight modification, 
carboxyfluorescein diacetate succinimidyl ester (CFSE;Sigma-Aldrich, St. Louis, MO) dye 
was used at a concentration of 107 PBMC in 1 ml of 5 µM CFSE solution. In brief, cells were 
labeled with CFSE for 5 minutes and the reaction stopped with 0.5 ml fetal bovine serum. 
Ten ml of phosphate buffer saline (PBS) was added to the cell mixture and cells were 
pelleted. CFSE-stained PBMCs were washed with RPMI media (Fisher Scientific, Pittsburg, 
PA)  and then resuspended in complete RPMI (RPMI containing 10% fetal calf serum, 2 mM 
L-glutamine, 100 U/ml penicillin , 100 µg/ml streptomycin, 2.5 M HEPES, 50 mM 2-
mercaptoethanol and 5 ml of 100X nonessential amino acids) and cultured as previously 
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described (Kitikoon and others 2006). The program, Modfit Proliferation Wizard (Verity 
Software House Inc., Topsham, Maine), was used to analyze cell proliferation. Data were 
expressed as mean T cell proliferation in 10,000 PBMC to the antigen stimulus used in the 
test and analyzed as previously described (Waters and others 2002).   
Statistical analysis 
Analysis of variance was performed to ascertain group differences for each measured 
parameter. If the P-value for an ANOVA table was less than or equal to 0.05, the differences 
between treatment groups were evaluated using the Tukey-Kramer Honestly Significant 
Difference multiple comparison test. All data analyses were performed using JMP® statistical 
software (SAS Institute, Cary, NC). 
RESULTS
Clinical signs 
Pigs in all SIV-infected groups except group V/cH1N1 (TABLE 1) were febrile at 24 hours 
post infection Pigs in group H1N2 were febrile for 3 days. Mean respiratory disease scores 
(TABLE 2) were significantly increased in all SIV-challenged groups compared to negative 
control group, but no significant differences were observed between vaccinated and 
unvaccinated groups. One pig in each of groups 2 and 6 died at 1 dpi of apparent bacterial 
infection. At necropsy both pigs were positive for Mycoplasma hyopneumoniae in their 
bronchoalveolar lavage fluid (BAL) by PCR, however no other bacteria were isolated. 
Macroscopic and microscopic lesions and SIV antigen in lungs 
Groups cH1N1 and H1N2,  which were the positive control groups, had significantly more 
SIV-induced pneumonia compared to the vaccinated groups and the negative control pigs 
(TABLE 2), No significant differences were detected in the percentage of pneumonia 
between any of the vaccinated and challenged groups. Pigs in group VrM2/cH1N1 had 
significantly lower microscopic lesion scores (TABLE 2) compared to pigs in the V/cH1N1 
and cH1N1 groups. SIV-antigen was detected in all challenged groups with the exception of 
the NEG and VrM2/cH1N1 groups at 5 dpi (TABLE 3). 
 
120
TABLE 2: Clinical signs observed following challenge with A/Swine/IA/40776/92 (cH1N1) 
strain or A/Swine/Indiana/9K035/99 (H1N2) and mean percentage macroscopic lesion and 
mean microscopic lesion scores at 5 days post-infection (dpi) 
 
Fever† at 1dpi Respiratory  Mean % Mean  
Febrile Mean signs†† mean macroscopic microscopic 
Group days temperature (oC)  score 1-5 dpi  lesion  scores††† 
NEG 0 39.2 0.0 a 0.9 a 0.0 a
VrM2/cH1N1 1 40.0 2.8 c 3.6 a,b 0.6 a
V/cH1N1 1 39.9 2.7 c 1.5 a,b 1.9 b
cH1N1 1 40.3 2.9 c 17.9 b 2.7 b
VrM2/H1N2 1 40.0 1.8 b 0.8 a 0.2 a
V/H1N2 1 40.1 1.6 b 1.9 a,b 0.2 a
H1N2 3 40.4 2.4 b,c 15.0 b 2.8 b
a, b, c Means with a common superscript letter within each column are not significantly   
 different at P < 0.05 
 † Rectal temperatures > 400C
†† Respiratory scores - 0 = normal, 1 = tachypnea (respiratory rate > 40 per minute)  
 following physical exertion, 2 = tachypnea at rest and if coughing was present, 1 point  
 was added to the respiratory scores  
 ††† Microscopic lesion scores are based on the severity of bronchiolar epithelial damage  
 (necrotic bronchiolitis). 0, no bronchiolar damage or inflammation; 1, mild airways  
 affected; 2, 30%-70% (moderate) airways and adjacent alveoli affected; 3, >75%  
 (severe) airways affected with diffuse alveolar involvement 
 
TABLE 3: Number of pigs detected with SIV antigen in the lungs at 5 days post infection, 
(dpi) mean virus titers from nasal swabs and mean OD of serum rM2 antibody at -1 dpi    
pigs/total pigs Mean virus titers in nasal swabs† Mean OD of 
# of SIV (number of +/total pigs) rM2 
Group pigs/total pigs 2 dpi 4 dpi 5 dpi at -1 dpi
NEG 0/5 0.0a 0.0a 0.0 (0/5) 0.083a
VrM2/cH1 0/4 0.0a 0.0a 0.0 (0/4) 0.180b
V/cH1N1 2/5 0.0a 1.2a 0.0 (0/5) 0.148a,b
cH1N1 2/5 2.6b,c 4.6b 1.3 (2/5) 0.086a
VrM2/H1N 2/5 0.5a 0.5a 0.0 (0/5) 0.357b
V/H1N2 1/4 1.5a,b 1.0a 1.0 (2/4) 0.156a.b
H1N2 5/5 3.9c 4.2b 1.7 (2/5) 0.080a
a, b, c Means with a common superscript letter within each column are not significantly 
different at P < 0.05 
 † Virus titers are expressed as log10 TCID50 per 1 ml sample 
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Virus isolation from nasal swabs 
Positive control pigs challenged with either virus shed consistently more virus at both 2 and 4 
dpi compared to all other groups (P < 0.0001) as shown in TABLE 3. Three out of 5 pigs in 
group V/cH1N1 shed virus at 4 dpi while no virus was isolated from the pigs in group 
VrM2/cH1N1. A similar pattern was found with the vaccinated pigs that had been challenged 
with H1N2 at 2 and 5 dpi.  
Serology 
Prior to challenge, the commercial vaccine induced cross-reactive antibodies to both 
challenge antigens as measured by HI assay, but significantly higher levels of antibodies 
were present to the cH1N1 antigen than the H1N2 antigen (P<0.002). At -1dpi all vaccinated 
pigs had mean HI antibody titers of 100±17 and 40±4 to cH1N1 and H1N2 viruses, 
respectively. Following challenge, pigs in the H1N2 group produced no antibodies that cross-
reacted with the cH1N1 virus while pigs in the cH1N1 group produced higher levels of 
antibodies to the H1N2 antigen. The addition of rM2 protein to the commercial vaccine did 
not appear to reduce the ability of the vaccine to induce an antibody response. At 5 dpi, all 
vaccinated pigs had mean antibody titers of > 150 to both the cH1N1 and H1N2 antigen. No 
antibodies were detected in any of the negative control pigs throughout the trial. Prior to 
challenge, pigs vaccinated with both the commercial vaccine and rM2 had higher serum 
antibodies to the rM2 than pigs in any other groups (TABLE 3). 
Flow Cytometry Analysis 
Data from flow cytometric analysis demonstrated a significant difference in the proliferation 
of the CD4+ T cell population at -1 dpi which which was antigen dependent. Only PBMCs 
from rM2 vaccinated groups had a significant increase in CD4+ T cell proliferation when 
stimulated with the cH1N1 antigen. In contrast, CD4+ T cells from both vaccinated groups, 
independent of rM2, showed increased proliferation when stimulated with the H1N2 antigen, 
compared to the nonvaccinated negative control group (FIG. 1). No differences in 









































FIG 1: Mean CD4+ T cells in 10,000 peripheral mononuclear blood cells (PBMCs) that 
proliferated to cH1N1 or H1N2 antigen from pigs unvaccinated (NEG), pigs vaccinated 
twice with biVac alone  and pigs vaccinated twice with biVac and rM2 (biVac+rM2). 
*Significant difference compared within the same antigen stimulation (P ` 0.05).     
 
DISCUSSION
An earlier study investigating vaccination of pigs with a M2 and NP DNA vaccine 
(Heinen and others 2002) detected that antibody and CMI responses to both proteins and 
disease were enhanced following SIV infection. In the study reported here, no disease 
enhancement in SIV-challenged pigs that received the rM2 protein with the conventional 
inactivated vaccine was observed. We demonstrated that administration of the rM2 protein 
with a conventional, SIV inactivated vaccine reduced the severity of microscopic lesions 
associated with SIV and reduced the number of pigs shedding virus after infection. The rM2 
protein appeared to enhance the proliferative response of CD4+ T cells to the vaccine as 
shown by the flow cytometry findings at -1dpi. The study demonstrated that CD4+ T cells in 
pigs vaccinated with rM2 protein proliferated significantly more to the cH1N1 antigen 
compared to cells from vaccinated pigs that did not receive the rM2. In contrast, the cellular 
response to the H1N2 antigen was identical in both vaccinated groups independent of the 
presence of the rM2 protein. This suggests that the N2 NA and presumably the internal 
proteins of the H1N2 virus share a similarity with the vaccine antigens while the internal 
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proteins of the cH1N1 are less similar to the vaccine antigen. As a result, the addition of the 
rM2 protein aids in the CD4+ T cell response to the cH1N1 virus, which may have played a 
role in the reduced viral shedding.   
One important function of CD4+ T cells is to assist in generating antibodies against 
the HA and NA proteins (Scherle and Gerhard 1986). In addition, CD4+ T cells enhances 
CMI responses through the production of T-helper 1 cytokines such as interferon-gamma and 
tumor necrosis factor-alpha (Graham and Braciale 1997; Hogan and others 2001). It has been 
suggested that the internal, conserved proteins of SIV stimulate a CMI response which is 
essential in clearing the primary influenza infection and providing cross-protection against 
secondary infection with heterologous viruses (Bot and others 1998; Heinen and others 
2001a; Van Reeth and others 2003a). Earlier studies have also found that conventional 
inactivated SIV vaccines induce poor CMI responses (Heinen and others 2001b; Van Reeth 
and others 2003b). In this study, the protection induced by a heterologous H1N1 virus in the 
vaccine against the H1N2 challenge may be attributed in part to the induction of a CMI 
response as the level of H1N2 specific antibodies was low at -1dpi.  
 The vaccine used in this study significantly reduced macroscopic lung lesions and 
decreased viral shedding following challenge with both viruses although it was unable to 
prevent clinical respiratory disease. Current commercially licensed SIV vaccines in the U.S., 
including the commercial bivalent vaccine used in this study, contain a H3N2 cluster I virus 
(Hill and others 2003; Thacker and others 2005). Therefore, it is possible that the H3N2 
antigen in the vaccine contributed to protection against disease induced by the H1N2 isolate 
due to genetically related internal genes (Karasin and others 2000). The genetic information 
of the H1N1 vaccine virus is proprietary information and therefore the exact genetic 
composition of the virus is not known by the researchers in this study. However, it is likely 
that the H1 HA protein of the vaccine virus shares a closer genetic similarity to the cH1N1 
than the H1N2 virus as reflected by the serum cross-reactivity of vaccine induced antibodies. 
As a result, the protection provided by the vaccine to the cH1N1 infected pigs could be 
correlated with the level of circulating serum antibodies. Many studies have demonstrated 
that SIV vaccine induced protection is strongly correlated to the serum antibodies detected by 
HI assays especially when the vaccine virus matches the infection strain (de Jong and others 
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2003; Heinen and others 2001b; Kitikoon and others 2003; Van Reeth and others 2003b). A 
study of a European bivalent H1N1and H3N2 vaccine demonstrated that the vaccine induced 
only low levels of antibodies to a genetically distinct H1N2 virus and subsequently failed to 
protect against infection with that virus (Van Reeth and others 2003b).  
 Although pigs vaccinated twice with the rM2 protein produced rM2-specific 
antibodies in the serum, the levels were lower than anticipated. Earlier studies showed that 
M2 antibodies are capable of reducing influenza A virus replication both in vitro (Liu and 
others 2003) and in vivo (Mozdzanowska and others 2003). An in vitro study demonstrated 
that the reduced influenza virus spread in cell cultures in the presence of M2 antibodies was 
dose-dependent (Liu and others 2003). In addition, previous M2-vaccine based strategies 
used a 3 dose vaccination protocol (De Filette and others 2005; Fan and others 2004; Frace 
and others 1999). Thus, future studies should investigate if the rM2 antibody response could 
be enhanced through the administration of more vaccinations as well as potentially exploring 
the use of different antigen doses and/or adjuvants.  
 In this study, the ability of the rM2 protein to increase protection against influenza 
disease when used with a conventional vaccine was difficult to determine as the commercial 
vaccine alone protected against pneumonia and reduced viral shedding following challenge 
with both viruses used in this study. However, vaccination with the rM2 protein reduced the 
severity of the microscopic lesions and the number of pigs shedding virus after infection 
while also enhancing the proliferative response of CD4+ T cells in the cH1N1 groups. The 
findings in this study provide support for a potentially positive role for the rM2 protein 
through the enhancement of a broader immune response against SIV infection. Further 
studies are needed to investigate the possible role of M2 protein with influenza vaccines to 
enhance cross-protection against antigenically diverse viruses.  
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CHAPTER 6. GENERAL CONCLUSION 
SUMMARY 
The investigations described in this thesis were conducted with two main objectives. 
The first objective was to investigate factors that may impact SIV vaccination strategies 
using current, commercial inactivated SIV vaccines. The second objective was to investigate 
potential strategies to improve currently available SIV vaccines. With the first objective we 
focused on two major factors; the impact of PRRSV infection at the time of vaccination and 
SIV-specific maternally derived antibodies (MDA) on vaccine efficacy.  The second 
objective included production of a recombinant full-length matrix 2 protein (rM2) in a 
baculovirus expression system for use in immunizing pigs and a truncated N-terminal 
extracellular region of the M2 protein (M2e) for use in an indirect ELISA. The ELISA was 
developed to characterize the M2 antibody response in pigs with different SIV-exposure 
status. In addition, objective two investigated the ability of a combination of a conventional 
SIV vaccine with the rM2 protein to protect against infection with antigenically different SIV 
isolates.                 
The impact of PRRSV infection on SIV vaccine efficacy was evaluated based on 
clinical symptoms, macroscopic and microscopic lung lesions, virus isolation and 
immunological parameters. A North American high virulent strain of PRRSV (VR-2385) was 
used in the study as previous SIV co-infection studies were based on the use of low virulent 
strains. The PRRSV infection was placed between SIV vaccines based on the earlier studies 
using Mycoplasma hyopneumoniae (MHYO) vaccines where it had been determined that the 
presence of PRRSV at that time significantly diminished vaccine efficacy. In the study 
described here, a number of the measured parameters in pigs vaccinated against SIV in the 
face of PRRSV followed by experimental SIV challenge were reduced compared to pigs 
vaccinated in the absence of PRRSV. SIV vaccinated pigs which had also been exposed to 
PRRSV had significantly increased levels of macroscopic and microscopic lesions at 7 days 
post infection (DPI), shed more virus during the acute stage of infection (2 DPI) and shed 
virus for a longer period of time (7 DPI). In addition, pigs vaccinated in presence of PRRSV 
were positive for SIV antigen in the lungs at 7 DPI while other SIV vaccinated-challenged 
pigs had cleared the virus by that time.  It appeared that PRRSV had no significant effect on 
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the production of either systemic or local SIV-specific antibody production induced by 
vaccination or infection. However, it was noticed that just prior to SIV infection, pigs 
vaccinated in the presence of PRRSV had the lowest mean HI titer which was significantly 
lower than pigs vaccinated in the absence of PRRSV. Previous studies have suggested an 
immunosuppressant effect of antibody production following infection with a classical swine 
influenza virus by PRRSV due to increased IL-10 levels [24,281]. Thus, it is possible that 
pigs infected with PRRSV just prior to the second vaccination were transiently 
immunosuppressed resulting in lower levels of antibodies. However, the mechanism by 
which PRRSV decreases SIV vaccine efficacy is currently unknown and requires further 
investigation. This study was the first to describe the impact PRRSV infection on SIV 
vaccination. These findings provide a possible explanation for some of the SIV vaccine 
failures reported in the field and are a reminder of the importance of PRRSV in timing SIV 
vaccine as a successful intervention strategy in the young pigss. 
The second study was conducted using an experimental challenge model to study the 
interference of SIV-specific MDA on conventional SIV vaccines against a heterologous H1 
virus infection. The use of a heterologous strain challenge was intended to more closely 
simulate field conditions where sows and young pigs may possibly be exposed to different 
strains of virus through infection and/or vaccination. Clinical parameters including 
respiratory signs, rectal temperature, macroscopic and microscopic lesions, virus excretion, 
serum and local antibody responses, and influenza-specific T-cell responses were evaluated. 
It was demonstrated that pigs vaccinated in the absence of MDA were effectively protected 
against the heterologous H1 challenge as macroscopic lesions and viral shedding were 
significantly reduced. The presence of MDA’s alone only reduced clinical disease with no 
impact on the other parameters measured. The results of this study clearly demonstrated a 
negative impact on vaccine efficacy by the presence of MDA at the time of the first SIV 
vaccination. Vaccinated pigs with MDA had prolonged clinical signs and shed higher levels 
of virus at 3 DPI compared to vaccinated pigs lacking MDA. Unexpectedly, vaccinated pigs 
with MDA positive had enhanced macroscopic lesions compared to all other groups. In 
addition, the presence of MDA suppressed the serum antibody response as measured by HI 
assay and the induction of SIV-specific memory T-cells following vaccination. The 
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mechanism for the lung lesion enhancement by vaccination in the presence of MDA’s is 
unclear. However, it has been suggested that a deviation in the immune response might have 
occurred during the time of vaccination while MDA was present. Previous studies have 
shown that the innate immune system can divert a T helper (Th)1 to a Th2 adaptive immune 
response by binding the antigen to the IgG Fc portion of the macrophage (FcdR) [282]. Since 
our findings demonstrated that MDA’s were cross-reactive to both the vaccine and challenge 
virus, their presence at the time of vaccination may have resulted in an increased Th2-type 
response due to the presence of Ab-Ag complexes formed from the MDA and vaccine 
antigen. Typically, activated macrophages acting as antigen presenting cells, induce a Th1-
like response. However, when the antigen is bound to an antibody, the FcdR on the 
macrophage can be targeted resulting in a more Th2-like phenotype. Consequently, when the 
pigs were infected 2 weeks later the Th2 deviation resulted in the vaccinated pigs with 
MDA’s being unable to rapidly mount an effective CMI response to clear the virus from the 
lungs. Our suggestion was supported by the finding at 21 DPI of no memory T-cells, and a 
high HI antibody response in the pigs vaccinated with MDA while memory T cells were 
significantly high in pigs vaccinated with no MDA interference while HI antibody levels 
were significantly lower than pigs vaccinated with MDA. Although the exact mechanism of 
the  enhancement of pneumonia with vaccination in the presence of MDA is unknown, this 
study clearly demonstrated that both MDA and vaccination were important as the vaccinated 
pigs that lacked MDA or the unvaccinated pigs with MDA’s showed no increase in lung 
lesions following challenge. These results make it imperative to know the immune status of 
the young pigs to SIV prior to SIV vaccination. In addition, these findings questions the 
practicality of enhancing SIV-specific MDA in young pigs as a intervention protective 
strategy based on the findings demonstrated here as well as with previous studies that showed 
that passive immunity to SIV is less effective compared to induction of an adaptive immune 
response to SIV [16,33].  
 Another factor that can have a major impact on vaccination efficacy when using 
conventional SIV vaccines is the antigenic differences in the influenza viruses. It has been 
well established that there is a correlation between the antigenicity of the vaccine virus to the 
circulating field strain that is key to a successful vaccination. We proposed to use the rM2 
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which is a highly conserved protein of the influenza A virus as a subunit vaccine candidate. 
However, limited data is available in the literature on the antibody response to the M2 protein 
following SIV infection and/or vaccination in pigs. Therefore, the third study was conducted 
to characterize the antibody response to M2 protein. An indirect ELISA to the extracellular 
domain of the M2 (M2e) protein was developed to test sera from serum bank of pigs that had 
been experimentally exposed to different SIV isolates. The samples included serum from 
pigs experimentally infected with six different SIV isolates from three SIV subtypes, pigs 
vaccinated with SIV inactivated vaccine and MDA positive pigs. To confirm that the 
candidate sera came from infected pigs and were specific to each SIV strain, the antibodies to 
subtype and strain-specific hemagglutinin (HA). It was found that M2e antibodies were 
poorly induced through SIV infection or vaccination. In addition, the M2e antibodies were 
exhibited for only a short duration following infection and appeared to rapidly decline by 28 
DPI. The SIV strain or subtype had no effect on the M2e antibody production. Pigs positive 
for MDA with different levels of HI titers were positive to M2e antibodies but levels were 
not correlated with the levels of antibodies detected by HI assay. A high infectivity dose (108
TCID50) resulted in both faster seroconversion and higher levels of M2e antibodies compared 
to using a lower dose of virus (106 TCID50). The levels of virus used for infection were much 
higher than would occur with a natural intranasal infection based on human studies (~127–
320 TCID50) [283].  Similar results could be anticipated in pigs, indicating that low levels of 
M2e antibodies are induced following natural SIV infection. However, levels may increase 
with multiple infections as our results indicated that an anamnestic response occurred in pigs 
challenged for the second time with a high-dose homologous H1N1 virus. 
 In the fourth study, we evaluated the efficacy of the rM2 protein combined with a 
commercial bivalent SIV vaccine that contained a H1N1 and H3N2 cluster I virus in 
inducing protection against experimental challenge. The hypothesis of this study was that a 
combination of an inactivated virus vaccine and rM2 protein vaccination would induce 
neutralizing antibodies against the HA and the NA proteins to prevent against infection, 
while M2 antibodies would enhance protection against antigenically diverse SIV isolates. 
Pigs were vaccinated with or without rM2 protein at 3 and 5 weeks of age and challenged 
intratracheally with a classical (c) swine H1N1 or a H1N2 virus at 7 weeks of age. Both the 
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cH1N1 and H1N2 had demonstrated minimal cross-reactivity by HI assay in an earlier study 
[82]. Parameters assessed in the study included respiratory signs, rectal temperature, 
macroscopic and microscopic lesions, virus excretion, serum antibody response, and 
influenza-specific T-cell responses to both challenge viruses. It was shown that the H1 HA 
protein of the vaccine virus was similar to the cH1N1 compared to the H1N2 challenge virus 
as the antibody levels induced by the vaccine (with or without rM2 protein) to the cH1N1 
virus were higher than observed with the H1N2 virus at -1 DPI. Following challenge, pigs 
that had received the rM2 protein with vaccine had fewer microscopic lung lesions at 5 DPI 
and fewer pigs shed virus compared to vaccinated pigs that did not receive the rM2 protein or 
the positive control pigs. The rM2 protein enhanced the proliferative response of CD4+ T 
cells to the cH1N1 antigen compared to pigs receiving only the commercial vaccine. 
However, vaccination alone without rM2 protein was able to significantly reduce pneumonia 
and decrease the level of virus excretion in pigs after infection with either virus. Thus, the 
effect of including the rM2 protein with the conventional vaccine could not be conclusively 
determined at this time point. However, the findings of the decreased microscopic lesions 
and reduced numbers of pigs shedding virus support the positive role of rM2 protein in 
enhancing a broad immune response against SIV infection. Further studies are needed using 
vaccines that lack cross-protective capabilities with the challenge viruses to confirm the 
possible role of M2 protein addition to vaccines for the control of SIV-induced disease.  
 In summary, the results from the studies reported here add further information on 
factors that influence SIV vaccine strategies.  Confirmation of the negative role of PRRSV 
infection and the presence of SIV-specific MDA on SIV vaccination in young pigss was 
determined. The reduced protective efficacy of vaccination as measured by the presence of 
increased levels of macroscopic lesions and viral shedding occurred with both factors. 
Moreover, there was further evidence that the presence of MDA at the time of the first SIV 
vaccination could result in a disease enhancement after a subsequent SIV infection. However, 
without both the interfering factors it was demonstrated that conventional, commercial 
inactivated vaccines provided effective protection against the challenge viruses used in each 
study. These findings emphasize the importance of knowing the immunological status of the 
young pigs prior to administrating the SIV vaccines. The results described here also provide 
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evidence that pigs produce suboptimal levels of M2 antibodies following infection and 
undetectable levels with vaccination using conventional SIV vaccines.  M2 antibodies were 
detected inconsistently in pigs positive for MDA. The ability of a rM2 protein to broaden the 
protective efficacy of conventional SIV inactivated vaccines against antigenically different 
SIV is still inconclusive. However, the results were promising and suggest further studies 
should be done to determine the potential role of the rM2 protein in increasing vaccine 
efficacy across isolates and possibly subtypes. 
 
FUTURE RESEARCH  
SIV vaccination both in the sow herd and pigs are a common practice. With a half-life 
of approximately 12 days, SIV-specific MDA may persist in pigs until 2-4 months of age 
[29]. As a result, SIV vaccine efficacy in young pigss is commonly compromised by the the 
presence of MDAs. It is important that the exact mechanism of the disease enhancement by 
MDA at the time of SIV vaccination be investigated for developing successful SIV 
vaccination intervention strategies. The correlation of the level of MDA titers to the disease 
enhancement, or the effect of different strains of virus or adjuvants in the vaccines or the use 
of different challenge strains are areas that need to be investigated. More importantly the type 
and specificity of the antibody involved and the specific cytokines induced at the time should 
be characterized.         
 The down side of the immune response elicited through SIV inactivated vaccine is 
that the antibody produced is specific to the virus in the vaccine and the induction of a 
minimal CMI response limits the cross-protective efficacy of the vaccines. The use of rM2 
protein using a eukaryotic system or a prokaryotic system has the potential to induce a 
broader antibody response when incorporated with the conventional vaccine. The results of 
using a rM2 protein with commercial vaccines to provide protection against SIV infection in 
pigs as reported here was inconclusive. Further studies need to be conducted using larger 
numbers of animals and different SIV isolates and/or subtypes that lack cross-protection by 
the vaccine. In addition, the antigen incorporated and frequency and number of vaccinations 
with the rM2 protein including potential adjuvants should be examined. The route of 
injection is another parameter that should be explored as an earlier study in mice 
135
demonstrated that intranasal inoculation of an H3N2 inactivated influenza vaccine induced 
high levels of mucosal antibodies and provided protection against both the H3N2 and H5N1 
challenged viruses [143]. Thus immunizing the rM2 protein through an intranasal route may 
enhance a broader antibody response at the mucosal level which will contribute even more to 
the heterologous immunity.    
In conclusion, the findings described here provided information of factors that can 
reduce the efficacy of currently available SIV vaccine as well as a potential use of the M2 
protein to help improve current SIV inactivated vaccines. However, additional investigation 
is needed for improving SIV vaccine efficacy and their appropriate use of these vaccines to 
meet the ideal goal of enhancing both the humoral and CMI response as well as mucosal 
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